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Abstract 
The trillions of microbial organisms residing in the gut, microbiota, are now recognized as major 
modulators of physiology and health, quickly becoming one of the most exciting emerging areas 
in neuroscience. Preclinical and clinical research alike suggests that the metabolites produced by 
these gut microbes modulate brain, behavior and disease. Short-chain fatty acids, tryptophan 
metabolites and bile acids are promising targets for new microbiome-based therapies. But, little 
is known about their mechanisms. To this end, the second chapter of the thesis collates 278 
studies relating to the human microbiota-gut brain axis, identifying trends and 
technical/bioinformatics limitations. These studies across different disorders of the brain as well 
as healthy human behavioral functions. Then a 35 of these studies was reanalyzed with an up-to-
date bioinformatics pipeline. New tools, mainly the gut-brain modules provide a predictive 
framework for identifying whether these gut microbial metabolic pathways are dysregulated in 
brain diseases and disorders. We uncovered evidence of disease-related alterations in microbial 
metabolic pathways in Alzheimer’s Disease, schizophrenia, anxiety and depression. Previous 
human studies suggest that astrocyte immunity and metabolism is affected by short-chain fatty 
acids. Thus we grew primary male and female mouse astrocyte cultures, treating them with 
acetate, butyrate and propionate. Butyrate treatment (0 – 25µM) increased gene expression of 
Bdnf and Pgc1-α expression, implicating histone-deacetylase inhibitor pathways only in female 
cells. Acetate (0 – 1500 µM) positively correlated with Ahr and Gfap expression in males, 
suggesting an immune modulatory role. These findings show a novel sex-dependent impact of 
acetate and butyrate, but not propionate on astrocyte gene expression. These studies increase 
understanding of microbial metabolites and how they might impact the brain. It also provides 
guidance to improve and direct future investigations aimed at identifying the mechanisms of 
other metabolites. 
  
Chapter 1: Introduction 
“I then most always saw, with great wonder, that in the said matter there were many very 
little living animalcules, very prettily a-moving.” — Antonie van Leeuwenhoek. 
In the 17th century, Leeuwenhoek first described live bacterial cells, isolated from his own 
mouth (Leidy, 1853). Since then, advances in germ-theory lead to a better understanding of 
the microbial world existing around us. It was even more recently that humans began 
exploiting the metabolic properties of these microbes for medicinal purposes. For almost a 
century, humans have exploited microbial cells for improving our own health. Since the 
discovery of penicillin almost a century ago (Fleming, 1946b), we have discovered many 
other microbial properties that confer humans with medical and functional benefits. Studies 
throughout the 1950s and 1960s emphasized the importance of these symbiotic microbes 
through germ-free animal models (Spichak et al., 2019). 
In recent years, research into these microbial cells has re-emerged, cementing their status as 
important mediators of brain health and function (Cryan et al., 2019). Much of these studies 
have focused on the gut microbes, often measured from faecal samples or caecal biopsies. It 
is now recognized that human cells are outnumbered by bacterial cells (Sender et al., 2016b, 
Sender et al., 2016a), further supporting the importance of these microbes in physiology 
(Cryan et al., 2019). Important recent work even associates the metabolic pathways capable 
of generating neuroactive molecules with depression and quality of life scores (Valles-
Colomer et al., 2019). The emergence of improved bioinformatics tools (Callahan et al., 
2016, Callahan et al., 2017, McIver et al., 2018) allows scientists to dissect large swathes of 
16S and shotgun sequencing. These insights are combined with neurophysiological measures 
across in vitro, in vivo and human models of diseases and disorders. Now it’s becoming 
evident that the microbiota-gut brain axis influences host physiology via bidirectional 
signaling through the vagal nerve, inflammatory molecules, endocrine molecules, and 
microbial metabolites (de Weerth, 2017, Erny et al., 2015, Bravo et al., 2011, König et al., 
2016, Blanke et al., 2021, Kong et al., 2020, Marcondes Avila et al., 2020, Wang et al., 
2020c, Chen et al., 2019a, Cryan et al., 2019, Gheorghe et al., 2019, Clarke et al., 2019). See 
Figure 1 for an overview of the microbiota-gut-brain axis. 
Additionally, many data sets are available for download from online repositories. Insight 
collected from open data informs our mechanistic experimental designs, providing important 
value to the field beyond the initial publication it was used for. 
The Microbiota 
The mammalian gastrointestinal (GI) tract is home to trillions of microbial organisms that 
colonize the gut during the birthing process (Benson et al., 2010, Gaulke et al., 2018). The 
collection of microorganisms serves important core functions including the modification of 
host, xenobiotic and dietary-derived molecules into bioactive metabolites that can impact host 
health and disease (Clarke et al., 2019, Sharon et al., 2014, Spanogiannopoulos et al., 2016, 
Morris et al., 2017, Sun et al., 2017). Many different factors influence microbiome 
composition and microbiota-gut-brain axis function (see Figure 2). 
As a microcosm of the complexity within this field, there are different monikers for these 
microbes depending on genetic, ecological and host paradigms (Berg et al., 2020). Within 
this thesis however, the collective individuals within the gut ecosystem will be referred to as 
the microbiota while the collection of genetic information contained within the community 
will be referred to as the microbiome (Lederberg and McCray, 2001).   
Collectively, there are millions more genes contained within the microbiome (>40 million) 
than within the human genome (~22 000) microbial cells in the GI tract are defined the gut 
microbiota (Tierney et al., 2019). We are only beginning to understand the functionality, 
diversity and interactions within these many members. New methods even allow researchers 
to track the transmission of bacterial strains from mother to child (Segata, 2018, Yassour et 
al., 2018). For the Human Microbiome Project, it was estimated that 500 to 1000 unique 
species of microbes reside in our guts (Human Microbiome Jumpstart Reference Strains et 
al., 2010, Human Microbiome Project, 2012). As our bioinformatics tools improve, we may 
reorganize different genera. This was the case with the Lactobacillus genera was recently 
reclassified as 23 related genera (Zheng et al., 2020a).  
Although the individuals within the gut microbiota be long to different kingdoms of life 
including archaebacteria, bacteria, viruses, protists and fungi, a majority of research has 
focused on the bacterial components of the gut microbiota (Cryan et al., 2019). In recent 
years, both the viral phage components and the fungal components of the gut microbiota have 
been recognized for their potential importance in physiology, brain health and function in 
both preclinical models and humans (Chin et al., 2020, Jiang et al., 2020, Zhang et al., 2019b, 
Seth et al., 2019). 
It’s also clear across converging evidence in the mammalian kingdom that microbiota 
differences associate with many different brain disorders. In this thesis, my chapters aim to 
provide insight specifically into neuropsychiatric, neurodevelopmental and neurodegenerative 
disorders. Differences in microbiome composition/diversity and production of microbial-
derived metabolites such as short-chain fatty acids are seen across multiple human studies of 
depression (Valles-Colomer et al., 2019, Bharwani et al., 2020, Dinan and Cryan, 2019, Jiang 
et al., 2015, Lai et al., 2019, Liskiewicz et al., 2019, Zheng et al., 2020b), anxiety-related 
disorders (Jiang et al., 2018a, Slykerman et al., 2017, Stevens et al., 2018), anorexia nervosa 
(Borgo et al., 2017, Dominique et al., 2019, Hata et al., 2019, Kleiman et al., 2017b, Kleiman 
et al., 2015), autism (Ahmed et al., 2020, Carissimi et al., 2019, Grimaldi et al., 2018, Iovene 
et al., 2017, Kang et al., 2017, Kang et al., 2018a, Kong et al., 2019, Kong et al., 2020, Li et 
al., 2019d, Liu et al., 2019d, Luna et al., 2017), attention-deficit hyperactivity disorder (Aarts 
et al., 2017, Jiang et al., 2018b, Prehn-Kristensen et al., 2018, Stevens et al., 2019, Wan et al., 
2020, Wang et al., 2020b), schizophrenia (Schwarz et al., 2018, Severance et al., 2017, Shen 
et al., 2018, Xu et al., 2019, Yuan et al., 2019, Zhang et al., 2020d, Zheng et al., 2019, Zhu et 
al., 2019, Zhu et al., 2020), Alzheimer’s disease (Haran et al., 2019, Liu et al., 2019b, 
MahmoudianDehkordi et al., 2019, Ticinesi et al., 2018, Vogt et al., 2017, Zhuang et al., 
2018) and Parkinson’s disease (Barichella et al., 2019, Bedarf et al., 2017, Heintz-Buschart et 
al., 2018, Heinzel et al., 2020, Hill-Burns et al., 2017, Keshavarzian et al., 2015, Li et al., 
2019b, Li et al., 2017, Lin et al., 2018, Lin et al., 2019, Petrov et al., 2017, Unger et al., 
2016). These studies are more closely analysed in Chapter 2.     
 
Figure 1. The various communication pathways involved in the microbiota-gut-brain axis. Individual microbes generate 
neurotransmitters and neuroactive metabolites that enter the peripheral circulation. Dietary fibres are fermented by colonic 
bacteria, producing a by-product of short-chain fatty acids (SCFAs) which signal with the gut epithelium, the enteric nervous 
system, enteric immune cells and also reach peripheral circulation. By breaking down dietary tryptophan, bacteria can 
generate tryptophan metabolites which also impact the local gut environment or reach peripheral circulation. These 
microbes play an important role in regulating tryptophan metabolites within the host. In the periphery, these molecules 
may reach the brain impacting it directly. They may impact the brain indirectly through peripheral interactions with 
immune cells and other cells. Many other enteric immune cells release pro- or anti-inflammatory cytokines into peripheral 
circulation, impacting neuroimmunity. Bidirectional signalling through the vagus nerve is also a major carrier of information 
between gut microbes and the brain. At the enteric nerve interface, bioactive molecules produced by microbes may initiate 
signalling with vagal afferents. This  figure is adapted from (Cryan et al., 2019).  
Modes of Communication between the Microbiota and the Brain 
Several mechanistic papers describe the connectivity between the microbiota, the enteric 
nervous system and the brain. Experiments involving microbiota perturbation and vagotomy 
in preclinical models show the importance of microbial-vagal signalling in neurogenesis 
(O'Leary et al., 2018, Cawthon and de La Serre, 2018, McVey Neufeld et al., 2019a, Zhang et 
al., 2020b, Lee et al., 2020b, Marcondes Avila et al., 2020). Intestinal microbiota interactions 
with the enteric or peripheral immune system, brain and microbiome are well-characterized 
in both preclinical models and humans (Xu et al., 2020, Sadler et al., 2020, Kong et al., 2020, 
Barra et al., 2020, Fulling et al., 2020, Dworsky-Fried et al., 2020, van de Wouw et al., 2020, 
Boehme et al., 2020, Gururajan et al., 2019, Murray et al., 2019, Xu et al., 2019). The gut 
microbiota also interacts with the cells of the enteric nervous system (Uhlig et al., 2020, 
Onyszkiewicz et al., 2019, Hyland and Cryan, 2016, McVey Neufeld et al., 2015) and the 
neuroendocrine system/hypothalamic-pituitary adrenal axis (Donoso et al., 2020, O'Mahony 
et al., 2020, Tian et al., 2019, Vodička et al., 2018, Golubeva et al., 2015, Perez-Burgos et al., 
2013, Gur et al., 2015, Sudo et al., 2004). Additionally, microbial-derived metabolites 
including quorum signalling and other bacterial proteins (Uhlig et al., 2020, Breton et al., 
2016, Dominique et al., 2019, Tennoune et al., 2014), various neurotransmitters (Strandwitz, 
2018, Strandwitz et al., 2019, Yunes et al., 2016), tryptophan-associated metabolites 
(Golubeva et al., 2017, Israelyan et al., 2019, Jaglin et al., 2018, Lai et al., 2019, Reigstad et 
al., 2015, Rothhammer et al., 2016, Zhu et al., 2020), bile-acid metabolism (Enright et al., 
2017, Golubeva et al., 2017) and short-chain fatty acids (Dalile et al., 2019, de Theije et al., 
2014, Liu et al., 2019d, Matt et al., 2018, Priyadarshini et al., 2014, Provensi et al., 2019, 
Reigstad et al., 2015, Sadler et al., 2020, Unger et al., 2016, van de Wouw et al., 2018, Zhao 
et al., 2018).  
Major Microbial-Derived Metabolites 
Dietary fibres that cannot be digested through host metabolism are fermented by colonic 
bacteria, forming short-chain fatty acids (SCFAs) (Stilling et al., 2016, Gill et al., 2020). 
While SCFAs enter peripheral circulation, it is unclear exactly how much enters the brain 
(Dalile et al., 2019). Nonetheless, recent studies underlie their importance in microbiota-gut-
brain axis communication. One study found that SCFA supplementation attenuates the 
cortisol stress response in a psychosocial stress setting in a dose-dependent manner (Dalile et 
al., 2020). Another study suggests that acetate reaches the hypothalamus, impacting satiety 
signalling in the host (Frost et al., 2014). Across many preclinical studies, SCFAs modulate 
immunity, brain health and behaviour (Chen et al., 2019b, Erny et al., 2015, Matt et al., 2018, 
Hoffman et al., 2019, Lee et al., 2020a, Wang et al., 2020e, van de Wouw et al., 2018). 
Tryptophan metabolites are produced from breaking down dietary proteins, playing important 
roles locally in the gut and throughout the host (Gheorghe et al., 2019, Kennedy et al., 2017, 
O'Mahony et al., 2015). Tryptophan metabolism is perturbed in psychiatric disorders like 
depression (Lai et al., 2019, Maes et al., 2011a, Rudzki et al., 2019, Maes et al., 2011b). This 
is further explored in animal models where perturbations in this metabolic pathway are 
associated with social impairments and anxiety-like or depressive-like behaviours (Golubeva 
et al., 2017, Clarke et al., 2013, Desbonnet et al., 2015, Hiroi et al., 2016, Jaglin et al., 2018, 
Tian et al., 2020).  
Bile-acids form another intriguing class of metabolites, which undergo biotransformation by 
the gut bacteria and are also altered in some human brain disorders (Kiriyama and Nochi, 
2019, MahmoudianDehkordi et al., 2019). Emerging preclinical studies suggest that bile-acid 
modulating bacteria are important for regulating brain health and behaviour (Golubeva et al., 
2017, Hoffman et al., 2019, Jena et al., 2018, McMillin et al., 2015, Nizamutdinov et al., 
2017, Yanguas-Casas et al., 2017, Quinn et al., 2020).  
These metabolites are discussed in more detail in Chapter 2. See Figure 2 for an overview of 
these metabolites within the microbiota-gut-brain axis. 
 
 
Figure 2. Potential pathways for microbiota-gut-brain axis communication. While it’s is unclear exactly how microbial-
derived metabolites impact the brain, there are several potential pathways. Non-digestible fibres are broken down into 
SCFAs which act as histone deacetylase inhibitors on FOXP3+ TReg cells in the gut, leading to clonal expansion. SCFAs many 
also influence the enteric dendritic and marcrophage cell population by increasing acetylation at specific gene targets 
impacting cytokine expression. SCFAs may also affect enterochromaffin cells in the gut, stimulating the release of serotonin 
into the lumen. Travelling through the blood, the SCFA butyrate may increase occludin expression at the blood-brain barrier 
as well as decrease its permeability to different molecules. If present in a sufficient concentration, SCFAs may impact 
microglial maturation through free-fatty acid receptor-mediated mechanisms. Bile acids used to aid in lipid digestion are 
deconjugated and biotransformed into secondary bile acids. These act on myenteric neurons to inhibit gut motility. In the 
brain, there is evidence that the secondary bile acid, deoxycholic acid (DCA) is associated with cognition. Tryptophan 
derived from dietary protein sources impacts both the enteric and central nervous system environments. Briefly, bacteria 
may generate indole molecules which can act on myenteric neurons to increase gut motility. Tryptophan (TRP) or 5-
Hydroxytryptophan (5-HTP) are also generated from dietary protein sources. TRP and 5-HTP can be converted into 5-HT in 
enterochromaffin cells. In the brain, indoles impact immunity through activation of the Aryl-Hydrocarbon receptor in 
astrocytes. Alternatively, TRP or 5-HTP can be transported across the blood-brain barrier and converted into the 
neurotransmitters 5-HT, quinolinic acid or kynurenic acid. It is unclear what role the vagal nerve pathway plays in mediating 
microbial-derived metabolite signalling.    
Early Life Factors: Delivery Mode, Breastfeeding, Antibiotics  
There are now a large number of studies showing a marked effect of mode of delivery on the 
gut microbiome (Jakobsson et al., 2014, Dominguez-Bello et al., 2010, Mueller et al., 2015, 
Biasucci et al., 2008, Bäckhed et al., 2015, Madan et al., 2016, Biasucci et al., 2010, Azad et 
al., 2013b, Salminen et al., 2004, Brumbaugh et al., 2016, Dogra et al., 2015, Grześkowiak et 
al., 2015, Martin et al., 2016, Hill et al., 2017, Tun et al., 2018, Reyman et al., 2019, Shao et 
al., 2019, Begum et al., 2019), although some studies have found less of an influence than 
others (Chu et al., 2017).  Infants born via Caesarean-section (C-section) had a gut microbiota 
more similar to the maternal skin microbiota than the vagina (Jakobsson et al., 2014, 
Dominguez-Bello et al., 2010, Mueller et al., 2015, Biasucci et al., 2008), delayed 
Bacteroides colonization (Mueller et al., 2015, Biasucci et al., 2008), delayed Lactobacillus 
colonization (Dominguez-Bello et al., 2010),  lower circulating chemokines (Jakobsson et al., 
2014) and a higher risk of vertical obesity transmission from their mother (Tun et al., 2018).  
Thus, the immune changes during the birthing process are key determinants of the early 
microbiota and later neurodevelopment (Gur and Bailey, 2016) 
Similar to humans, C-section mice initially had a significantly different gut microbiota from 
their mother (Hansen et al., 2014). In addition, they had significant differences in the 
abundance of bacteria in the orders Clostrodiales and Bacteroidales as well as lower systemic 
interleukin-10 expression (Hansen et al., 2014). (Morais et al., 2020) showed altered 
Bifidobacterium spp. abundance in C-section born mice as well as social, cognitive and 
anxiety deficits throughout life. These alterations were rescued by co-housing with vaginally-
born mice or via B. breve administration, further strengthening the connection between C-
section, Bifidobacterium spp. and the brain (Morais et al., 2020). 
Although the restoration of the microbiota in Caesarean born infants using a vaginal swab has 
been piloted, the long term consequences of such an intervention have yet to be studied 
(Dominguez-Bello et al., 2016). Alterations in the microbiota induced by C-section may play 
a functional role in predisposing such infants to a greater relative risk of allergy, asthma, 
obesity and Type 1 Diabetes (Bager et al., 2008, Tun et al., 2018, Cardwell et al., 2008, 
Stokholm et al., 2020). The relative contribution of such disturbances to brain health is less 
clear although epidemiology and animal studies are beginning to unlock some clear links 
(O'Neill et al., 2016, Fond et al., 2016, Moya-Perez et al., 2017, Martinez et al., 2017, Curran 
et al., 2017, Calatayud et al., 2019, Butler et al., 2020). 
In addition to delivery mode, breastfeeding and early antibiotic use also shape the early 
microbiome and may impact later host behavior (Azad et al., 2014, Azad et al., 2013b, Hill et 
al., 2017, Slykerman et al., 2019). While it remains somewhat controversial, there is potential 
for mode of delivery, antibiotic use and breastfeeding in early life, to shape 
neurodevelopmental and neuropsychiatric trajectories. 
Host Genetics and the Microbiota 
There is some conflicting evidence regarding the role of host genetics in human and mouse 
gut microbiota colonization and composition (Goodrich et al., 2017, Rothschild et al., 2018, 
Chung et al., 2012, Zmora et al., 2018). Recently, a study using mice found that differences 
in host background amongst mouse strains, as well as gut microbiota composition impacted 
fructose metabolism (Ahn et al., 2020). Baseline difference in Akkermansia, shown to be a 
putative mediator of fructose metabolism, may be related to the differences in host genetics 
between strains (Ahn et al., 2020). Another study identified deleterious genetic variants in 
families with a genetic predisposition of Irritable Bowel Disease (Park et al., 2020). They 
found 22 disease-associated microbial taxa that associated with 17 deleterious host genetic 
variants (Park et al., 2020). Interestingly, there is evidence of the ability of certain microbiota 
traits to predict phenotypic traits across large populations (Rothschild et al., 2020).   
Drugs and the Microbiota 
Over a quarter of pharmaceutical drugs have been shown to impact the composition of the 
microbiota (Le Bastard et al., 2018, Degroote et al., 2016, de Theije et al., 2014, Davey et al., 
2013, Cussotto et al., 2018b, Panee et al., 2018, Flowers et al., 2019, Clarke et al., 2019, 
Zimmermann et al., 2019, Ma et al., 2020, Vidal-Martinez et al., 2020, Vich Vila et al., 
2020), which has been implicated in both the efficacy and side effects of these drugs (Maier 
et al., 2018). Researchers hope that screening individuals for specific microbiota 
characteristics would help predict pharmaceutical treatment outcomes. 
Different classes of antidepressant drugs including tricyclic antidepressants (Csiszar and 
Molnar, 1992) and selective serotonin inhibitors (Munoz-Bellido et al., 2000), as well as 
ketamine (Yang et al., 2017) which may be used in the future as a new treatment, impact the 
growth of bacteria. It is unclear if their bacteriocidal/bacteriostatic actions impact their 
efficacy. Prenatal exposure to selective serotonin reuptake inhibitors induces anxiety-like and 
depressive-like behavior in adulthood (Homberg et al., 2010) in rodents, though the 
implications of these results for humans are still being discussed (Gur et al., 2013). In 
addition, evidence suggests that these drugs  may impact birth weight and motor development 
in humans, as well as in animal models (Hutchison et al., 2018); however  potential 
mechanisms are unknown.  
Antidepressants, including fluoxetine, are known to alter the microbiota and behavior in 
rodents (Yu et al., 2019, Yang et al., 2017, Sun et al., 2019b, Ramsteijn et al., 2020, Cussotto 
et al., 2019). In humans, antidepressants have been shown to transfer through breast milk and 
some can reach a clinically significant concentration in the infant’s serum (Sachs and Drugs, 
2013), though their effects on the infant have not yet been established (Glover and Clinton, 
2016). While there are many other patient factors to consider, antidepressants do alter the 
microbiota of patients themselves (Zhang et al., 2019a, Valles-Colomer et al., 2019, 
Bharwani et al., 2020). (Bharwani et al., 2020) shows promise that the microbiota can even 
distinguish antidepressant-responders from non-responders.  
Antipsychotics have been shown to impact the microbiota in rats and adolescent children, 
leading to weight gain (Davey et al., 2013, Morgan et al., 2014, Bahr et al., 2015). There is 
also evidence that microbiota profiles are influenced by antipsychotics in adult humans (Ma 
et al., 2020, Gorbovskaya et al., 2019, Flowers et al., 2019). It’s unclear if there are 
similarities in the metabolic changes in adults and adolescents prescribed these medications.  
Several recent human studies show the impact of nicotine, marijuana, alcohol and other 
recreational drugs on the human microbiome (Panee et al., 2018, Bjorkhaug et al., 2020, Seo 
et al., 2020, Hefner et al., 2019, Bajaj et al., 2019, Stadlbauer et al., 2019, Barengolts et al., 
2018, Fulcher et al., 2018). Considering the different chemical and orexigenic properties of 
these drugs, its unsurprising that they impact the gut microbiota in distinct ways. In rodents, 
ethanol (Yan et al., 2011, Mutlu et al., 2009, Peterson et al., 2017, Frost et al., 2019, Jadhav 
et al., 2018) and cocaine exposure (Kiraly et al., 2016) have shown effects on the gut 
microbiota composition.  
Exposure to antibiotics within the first three years of life in humans decreased microbiome 
stability and diversity while it transiently increased transcription of antibiotic resistant genes 
(Yassour et al., 2016) and increased adiposity in males during childhood (Azad et al., 2014). 
Moreover, neonatal exposure in rodents to antibiotics have been shown to alter the 
microbiota, brain inflammation and behavior (Leclercq et al., 2017), contribute to obesity 
(Cho et al., 2012), increase visceral pain receptors and sensitivity (O'Mahony et al., 2014) 
and even alter the editing of a serotonin receptor 2C isoform (van de Wouw et al., 2019). 
Diet 
Unhealthy diet in humans leads to obesity and poor cardiovascular health but recent research 
has also shown its impact on neurocognitive development in both humans and rodents (Monk 
et al., 2013). Common rodent models of unhealthy diet include high-fat diet (36-60 % kcal 
from fat), Western diet (high fat and high sugar) as well as diets focusing on specific types of 
fats. Some of these studies have been criticized because improper controls are often selected 
and may introduce confounds that complicate the interpretation of admittedly intriguing 
results (Almeida-Suhett et al., 2017, Pellizzon and Ricci, 2018, Morrison et al., 2020).  
Recent research indicates that fiber plays a more important role than fat in determining 
microbiome composition in these dietary paradigms (Morrison et al., 2020). In addition, both 
prenatal and adolescent exposure to a high fat diet changed the gut metabolome and 
microbiota composition in mouse, rat and macaques (Gohir et al., 2015, Oberbach et al., 
2017, Buffington et al., 2016, Ma et al., 2014). Unhealthy prenatal diets lead to sex-specific 
differences in gene expression (Edlow et al., 2016, Graf et al., 2016), social deficits 
(Buffington et al., 2016, Graf et al., 2016), altered hypothalamic stress response (Grissom et 
al., 2017) and inflammation (Grissom et al., 2017, Du et al., 2012) in the offspring (see Table 
2). This suggests that a greater emphasis should be placed on nutrition during pregnancy, 
though it is unclear if these changes in maternal microbiota directly impact the stress 
response in human infants. 
Several nutrients may play a positive role in neurodevelopment and microbiota maturation. A 
high-fat diet supplemented with omega-3 polyunsaturated fatty acids increased the diversity 
of microbiota and enriched Bifidobacterium at a species level (Patterson et al., 2014). Omega-
3 intake during pregnancy regulated the hypothalamic-pituitary-adrenal (HPA) axis activity, 
shifted the maternal stress-induced gut microbiota composition to be more similar to an 
unstressed composition and conferred resilience to stress later in life; in contrast, a deficit in 
omega-3 polyunsaturated fatty acids affected the metabolome, impaired communication and 
social behavior, worsened immune function, while increasing depressive-like behavior 
(Robertson et al., 2017a, Weiser et al., 2015, Robertson et al., 2017b, Pusceddu et al., 2015, 
Leyrolle et al., 2020).  
Prebiotics promote the growth of beneficial bacteria and include indigestible fibers that are 
fermented by colonic bacteria to produce short-chain fatty acids and provide a health benefit, 
though their effects on neurodevelopment have not been well studied (Gibson et al., 2017). 
Administration of the prebiotics galactooligosaccharide and inulin in mice reduced immune 
activation and intestinal permeability in offspring through gut microbiota modulation 
(Bouchaud et al., 2016). The prenatal administration of caprine milk oligosaccharide in mice 
has been shown to increase Bifidobacteria and butyric acid in the offspring colon (Thum et 
al., 2016). Interestingly, the addition of inulin to a mouse maternal high-fat diet abrogated the 
negative metabolic effects of the high-fat diet on offspring (Zou et al., 2018).  
Probiotics are beneficial strains of bacteria that confer a health benefit to the host. 
Administration during pregnancy in humans can reduce the risk of atopy but not other 
immunity-related diseases like asthma (Elazab et al., 2013, Azad et al., 2013a), however, 
many current supplements lack proof of effectiveness (Reid and Kirjaivanen, 2005). More 
recent work shows promise for prenatal administration of L. reuteri LR92 DSM 2686 in the 
last four weeks of pregnancy to reduce the incidence and severity of colic, consistent with 
evidence from previous trials (Pourmirzaiee et al., 2020, Chau et al., 2015). It is unclear if 
prenatal probiotic intervention may also reduce the incidence of mental health and brain 
disorders later in the offspring. 
 
An unhealthy diet commencing in early postnatal life also alters the microbiota composition 
(Turnbaugh et al., 2008) and results in different behavioral and inflammatory phenotypes 
across rodents and humans. High-fat diet after weaning and during adolescence altered the 
HPA-axis in female rats and impaired hippocampal memory and increased hippocampal 
lipopolysaccharide-induced cytokine response in the males (Boukouvalas et al., 2008, Boitard 
et al., 2014). Meanwhile high-fat diet bingeing during adolescence in mice increased anxiety 
and cocaine self-administration in adulthood (Blanco-Gandía et al., 2017). Meanwhile 
cafeteria diet during adolescence alters systemic inflammation in rats, and neuroinflammation 
in male mice (Fulling et al., 2020, Nicolas et al., 2020).  
Studies in humans indicate the presence of acute effects in response to daily dietary intake 
(Johnson et al., 2019). Meanwhile, another study unveiled individual level differences in 
dietary responses to the exact same meal, attributed to host genetics and microbiome (Berry 
et al., 2020).  
In rodents, Lactobacillus administration had similar effects to inulin, reducing anxiety 
through the HPA axis (Barrera-Bugueño et al., 2017). Interestingly, when combined with 
inulin, it did not affect the corticosterone levels and increased 5-HT1A receptor mRNA in the 
hippocampus, a receptor associated with anxiety and depression (Barrera-Bugueño et al., 
2017). Notably, Lactobacillus rhamnosus and L. helveticus administration in stressed infant 
rats (postnatal day 2 to 14) had a protective effect on fear conditioning memory and relapse 
after extinction in early life (Cowan et al., 2016). Some strains, such as Bifidobacteria 
longum and Bifidobacteria breve, can mediate anti-anxiety and anti-depressive behaviors in 
preclinical rodent models (Savignac et al., 2014). In mice, Bifidobacterium breve combined 
with prebiotics in early life exerted protection from the negative metabolic effects of a 
Western diet (Mischke et al., 2018), showing promise for co-administration of prebiotics and 
probiotics.  
A combination of Lactobacillus rhamnosus GG on its own or along with polydextrose and 
galactooligosaccharide protected maternally-separated (MS) male rats from MS-induced 
anxiety, while also rescuing hippocampal mRNA gene expression (McVey Neufeld et al., 
2019b). Administration of the prebiotic inulin in young mice reduced the immunological 
changes associated with ageing while also reducing the infiltration of Ly-6hi monocytes into 
the brain (Boehme et al., 2019). Taken together, these studies suggest targeting the 
gastrointestinal microbiota with prebiotics and probiotics is a promising strategy for 
attenuating the immune and behavioral effects of stress and ageing. 
In humans, probiotics may reduce the risk of depression (Huang et al., 2016) and autism 
(Pärtty et al., 2015, Gilbert et al., 2013). While many studies have been conducted, their 
results thus far are confounded by differences in strains used and a lack of metadata. Thus far, 
various strains of Lactobacillus and Bifidobacterium were tested in student-stress conditions 
providing evidence that these probiotics may modulate stress or sleep  (Nishida et al., 2017, 
Nishida et al., 2019, Kato-Kataoka et al., 2016, Rao et al., 2009, Takada et al., 2017, Takada 
et al., 2016, Tanida et al., 2016, Moloney et al., 2020). Lactobacillus gasseri CP2305 
administration exerted protective effects against chronic stress on the microbiota, while also 
improving self-reported measures of anxiety and sleep disturbances (Nishida et al., 2019). 
While some probiotic strains characterized in rodents translated some neurophysiological 
effects in humans (Allen et al., 2016) many other strains do not (Kelly et al., 2017). 
These findings further generate interest for psychobiotic research, looking to identify live 
bacterial strains that confer mental health benefits (Bambury et al., 2018, Butler et al., 2019, 
Dinan and Cryan, 2019). Nonetheless, there have been few randomized clinical trials 
conducted in depressed or anxious populations, and even fewer studies finding strong 
benefits for these psychobiotics (Smith et al., 2019a). Even fewer studies have looked at the 
impact of administering prebiotics as an adjuvant treatment for depression or anxiety (Smith 
et al., 2019a). Another meta-analysis of randomized clinical trials did not find strong support 
for the administration of fermented food, prebiotics or probiotics for enhancing cognitive 
outcomes (Marx et al., 2020b). Looking across seven studies, a meta-analysis reported 
significant mood improvements for those taking pre or probiotics, noting that they may 
especially benefit individuals with irritable bowel syndrome co-morbidity (Noonan et al., 
2020). 
Maternal Stress 
Maternal stress is modulated by the HPA axis and has been shown to impact this axis in the 
offspring. In offspring, maternal stress has increased serum levels of corticosterone, increased 
anxiety, social impairment and altered the resilience of different strains of rodents (Lee et al., 
2016, Rana et al., 2015, Bale, 2015, Hiroi et al., 2016, Golubeva et al., 2015, Egerton et al., 
2020, Donoso et al., 2020, Strzelewicz et al., 2019, Rincel et al., 2019). Maternal stress can 
also alter the gut and vaginal microbiota during pregnancy, decreasing diversity of maternal 
gut microbiota as well as dysregulating glucose metabolism in mice (Jašarević et al., 2017). 
(Golubeva et al., 2017) reported that specific gut microbes (Bifidobacterium and Blautia) in a 
strain of mice with social deficits, BTBR T+Itpr3tf/J, were associated with bile acid and 
tryptophan metabolism. Reductions in bile acid and alterations in tryptophan metabolism also 
associated with gastrointestinal dysfunction and social deficits in these mice (Golubeva et al., 
2017). Varied prenatal stress interrupted normal pregnancy-related compositional changes in 
the mouse vaginal microbiota and also altered the protein content in the vaginal mucosa, 
which may have contributed to altered abundance of Firmicutes and Bacteroidetes in their 
offspring’s gut microbiota (Jasarevic et al., 2015). After pregnant mice experienced restraint 
stress specifically, female offspring showed more anxiety-like behaviors as well as decreases 
in brain-derived neurotrophic factor in the placenta concurrent with later decreases of its 
expression in the adult amygdala (Gur et al., 2017).  Further investigation found MS-induced 
microbiome alterations (decreases in Bacteroides and Parabacteroides) persisting into 
adulthood, resulting in a decrease in sociability and serotonin metabolism.  
In humans, ongoing maternal stress (inclusive of prenatal and postnatal stress) has been 
associated with altered microbiota mental health problems in adult offspring (Betts et al., 
2015), as well as with influencing the development of the offspring microbiota over the first 
110 days after birth (Zijlmans et al., 2015). Stress-induced alterations within the microbiome 
could contribute to neurodevelopment and impact future offspring behavior (Gur et al., 2015, 
Codagnone et al., 2019a). However, the mechanism by which the negative impact of maternal 
stress is transmitted to the offspring’s microbiota is unknown, though IgA mediated 
immunity could be implicated (Kang et al., 2018b). Interestingly, exposure to intimate partner 
violence in pregnant women altered the infant microbiota, increasing Weisella and 
Citrobacter abundance (Naude et al., 2020). It’s likely that these stressors also hold long-term 
consequences on brain development in humans, as they do in animals. It’s unclear however, 
whether these microbiota alterations induced by the stress also play an important function. 
Maternal Immune Activation 
The maternal immune activation model is based around the controversial idea that maternal 
infections during pregnancy can impact psychiatric outcomes in the children (Estes and 
McAllister, 2016). A rodent model of maternal immune activation commonly administers 
viral mimetic poly(I:C) or bacterial lipopolysaccharide to produce psychiatric 
endophenotypes in offspring. Specifically, the viral mimetic poly(I:C) administered at E12.5 
in mice altered the gut microbiota composition and increased gut leakiness by decreasing 
claudin expression, while also elevating intestinal cytokine levels, including interleukin-6 in 
offspring (Hsiao et al., 2013). This model also elevated the bacterial production of, 4-
ethylphenylsulfate, which induced anxiety-like symptoms in wild-type mice (Hsiao et al., 
2013).  However, there is heterogeneity in the time of administration of the viral mimetic 
poly(I:C) which can lead to the development of different biomarkers or behaviors common to 
different disorders including schizophrenia (Juckel et al., 2011, Li et al., 2009) or autism-
spectrum disorder-like behaviors in mice (Malkova et al., 2012), and inconsistent depression-
like endophenotypes in rats and mice (Ronovsky et al., 2016).  
Though there exists no current research of its impact on the microbiota, the bacterial mimetic 
lipopolysaccharide can also induce behavioral phenotypes for anxiety, depression, or autism 
spectrum disorder in offspring (Depino, 2015, Oskvig et al., 2012); impairments in 
hippocampal development and neurogenesis (Escobar et al., 2011, Romero et al., 2007); and 
increased postnatal inflammation (Oskvig et al., 2012). In mice, lipopolysaccharide-induced 
maternal inflammation caused placental damage and fetal intestinal injuries that persisted in 
adulthood (Fricke et al., 2018).  
Intriguingly, researchers discovered that this phenotype requires the influence of the gut 
microbiota in initiating the immune cascade (Kim et al., 2017). Segmented filamentous or 
human-microbiome commensal bacteria were required to initiate the intestinal found that 
segmented filamentous bacteria or human-microbiome commensals were required to initiate 
the TH17 response (Kim et al., 2017). This cascade initiates a neuroinflammatory response 
which is required for developing MIA-induced behavioural abnormalities (Kim et al., 2017). 
While there are few studies in humans, maternal immune activation could potentially impact 
the offspring, associated with brain connectivity, function and even retrospectively with 
schizophrenia (Guma et al., 2019).  
Postnatal Stress and the Microbiota 
Early postnatal stress impacts the HPA-axis and contributes to the programming of brain 
health in later life (Heim and Nemeroff, 2001). Different types of early postnatal stress 
(social isolation, maternal separation) alter the gut microbiota composition and metabolism in 
rats (Farshim et al., 2016, Doherty et al., 2018, O'Mahony et al., 2009, Vodička et al., 2018, 
van de Wouw et al., 2018) and their inflammatory profiles (Doherty et al., 2018, O'Mahony 
et al., 2009). Social isolation also impaired memory and learning in rats (Doherty et al., 
2018).  Finally, germ free mice were more vulnerable to restraint stress – resulting in higher 
adrenocorticotropic hormone and corticosterone in plasma (Sudo et al., 2004, Clarke et al., 
2013), a reduction in glucocorticoid receptor mRNA and an increased stress response (Sudo 
et al., 2004). Remarkably, these effects were rescued with microbiota transplantation during 
adolescence but not adulthood (Sudo et al., 2004).  
While few studies focused on the microbiota and stress in the early postnatal period, it’s clear 
that many stress-related psychiatric disorders have marked alterations in the gut microbiome 
and metabolome (Cryan et al., 2019, Bastiaanssen et al., 2020, Bastiaanssen et al., 2019). 
Figure 3. Factors affecting the microbiota-gut-brain axis. Many dietary, pharmacological, stress and infection-
related factors influence the microbiota-gut-brain axis. These disruptions impact microbiota composition, the 
hypothalamic-pituitary-adrenal axis and microglial inflammation. Adapted from (Codagnone et al., 2019b). 
 
Sex-Specific Programming of Psychiatric Disorders Later in Life 
Many psychiatric disorders differ among the sexes in terms of prevalence or onset – including 
autism (Yeargin-Allsopp et al., 2003), mood disorders (Merikangas et al., 2010), anxiety 
disorders (Merikangas et al., 2010) and schizophrenia (Aleman et al., 2003). The underlying 
biological basis of these sex differences is still unknown. Since microbiota-related alterations 
have shown sex-specific effects after exposure to prenatal or postnatal environmental stimuli 
(Steegenga et al., 2017, Bahr et al., 2015, de Theije et al., 2014, Gur et al., 2017), they may 
play a role in the sex-specific programming of health later in life (Jaggar et al., 2020). See 
Figure 3 for the overlap between sex hormone levels, microbiota and brain dimorphism over 
time. 
Figure 3 Factors affecting the microbiota-gut-brain axis. Many dietary, pharmacological, stress and infection-related factors influence the 
microbiota-gut-brain axis. These disruptions impact microbiota composition, the hypothalamic-pituitary-adrenal axis and microglial 
inflammation. Adapted from Codagnone & Spichak et al., (2019).  
 
The gut microbiota and its metabolites influence the development of the microglia, and in its 
absence, development is disrupted in a sex-specific manner (Erny et al., 2015, Desbonnet et 
al., 2014, Thion et al., 2018). Abnormal microglial phenotypes were rescued with short-chain 
fatty acids, produced by certain members of the microbiota (Erny et al., 2015). The microglia 
are involved in synaptic pruning and maturation during neurodevelopment (see review by 
Salter (Salter and Beggs, 2014)).   
 
Figure 4 Variations between sex hormones, microbiota and brain dimorphism over the lifespan. Early sex 
differences in synaptic pruning correspond with sex differences in the gut microbiota of infants. Later in 
adulthood, females show increased alpha-diversity differences in gut microbiota and vast differences across 
neuropsychiatric disease and disorders. It is suggested that changes in microbiota may correspond to microbial 
androgen metabolism as well as brain function and disease.  (Jaggar et al., 2020). 
Importance of the Microbiota: Observations from the Germ-Free Model  
The idea that microbes are essential for proper host development and function is not new. In 
1885, Louis Pasteur posited the necessity of microbes for the existence of life (Pasteur, 
1885). The first GF animal was the guinea pig, which followed only 10 years after Pasteur’s 
publication (Nuttall and Thierfelder, 1895, Williams, 2014). Only decades later was the 
importance of this model truly recognized (Gordon and Pesti, 1971) and the concept of GF 
became more popular in the media. Interestingly, David Vetter, known as “the boy in the 
bubble” was also born in the year Gordon and Pesti published their seminal article. Vetter 
suffered from a disorder known as severe compromised immune deficiency and had to live in 
a sterile environment.  
Over the last few decades, several vertebrate models (rodent, bird, fish, pig) and invertebrate 
models (Drospohila) have provided insights on the impact and necessity of the gut 
microbiota for gut, immune and brain development (Rawls et al., 2004, Bates et al., 2006, 
Gordon et al., 1966, Savage et al., 1981, Erny et al., 2015, Hoban et al., 2016); anxiety, 
depression mood and social behavior (Hoban et al., 2017, Kraimi et al., 2018, Davis et al., 
2016b, Neufeld et al., 2011, Desbonnet et al., 2014, Buffington et al., 2016); locomotion and 
feeding (Leitao-Goncalves et al., 2017, Davis et al., 2016a, Diaz Heijtz et al., 2011, Schretter 
et al., 2018); learning, memory and transcriptional/molecular changes (Clarke et al., 2013, 
Hoban et al., 2018, Stilling et al., 2018, Rawls et al., 2004, Gareau et al., 2011). The scope of 
this review will primarily include the GF rodent model and its contributions to our 
understanding of host microbiome-neuroimmune interactions.  
Generation of the GF Rodent 
The first GF rodent models involved the aseptic Caesarean section of pups from the mother, 
who were then hand-reared in a sterile isolator or cross-fostered by a germ-free mother. In the 
late 1950s (Gustafsson, 1959, Reyniers and Sacksteder, 1958), a technique for generating 
successive generations of GF rodents was developed, and similar techniques and equipment 
are still most frequently used today (Williams, 2014). Alternatively, embryos at the 2-cell 
stage can be implanted into pseudopregnant GF mothers, thus ensuring a sterile vaginal birth 
(Inzunza et al., 2005, Okamoto and Matsumoto, 1999).  
Physiological and Anatomical Differences in the GF Rodent 
GF animals show marked alterations in their gross anatomy, indicating the essential role that 
microbes have in host development. When compared to conventionally raised counterparts, 
GF rodents have alterations in bone health (Sjogren et al., 2012, Quach et al., 2018), 
decreased weight of spleen, submandibular lymph nodes, liver as well as significantly larger 
colon (Reveley et al., 1983, Jeppsson et al., 1979, Gordon et al., 1966), liver metabolism (Li 
et al., 2018, Dempsey et al., 2018, Kindt et al., 2018) white blood cell count and distribution 
(Gordon et al., 1966), and even eye lipids (Oresic et al., 2009), in addition to various reported 
alterations in intestinal and brain measures (see (Spichak et al., 2019) for a thorough review). 
Their immune system is  also profoundly immature (see Fig. 5). 
 
Figure 5. Profound immaturity in peripheral and CNS immunity in the GF rodent. Immune cell immaturity, transcription and 
distribution of these cells is altered. The blood-brain barrier is more permeable while microglia in the brain are immature. 
Adapted from (Spichak et al., 2019). 
The behaviour, brain and immunity of the GF rodent is  also markedly affected by the lack of 
a microbiota (see Fig. 6). 
 
Figure 6 Phenotype of the GF rodent. This figure summarizes the most common findings across species and strain of GF 
rodent. GF rodents typically weigh less, have a significantly larger cecum and more cecal contents, possess altered liver 
metabolism, reduced gut motility, differences in bone density as well as striking changes to the structure of the gut. These 
GF rodents have learning and memory impairments, social impairments, altered anxiety-like behavior as well as an increase 
in self-grooming. Gut and peripheral immunity is severely compromised from the GF status of these rodents. As such, the 
lymphocyte immunoglobulin repertoire is attenuated, there is altered methylation in natural killer cells, and these rodents 
also possess resistance to some autoimmune diseases. In addition, their blood-brain barrier possesses increased 
permeability while the microglia in the brain have an immature phenotype. This microglia phenotype confers resistance 
against neurodegenerative disease. Finally, these GF rodents have many transcriptional changes in the amygdala and 
hippocampus contributing to an immature neuronal morphology, prefrontal cortex hypermyelination, and a hyperactive 
hypothalamic-pituitary adrenal axis. 
Microbiota-Gut Brain Axis Metabolite-Mediated Modulation of Glia 
Astrocytes 
In the 1850s, Rudolf Virchow coined the term neuroglia referring to the glue-like substance 
that holds neurons in place (Parpura and Verkhratsky, 2012, Barres, 2008). Further research 
found different types of neuroglia, with much of it focused on describing the supporting cells 
of the brain, called the astrocytes (Barres, 2008). While widely recognized as modulators of 
brain metabolism and immunity, recent work suggests these cells are genetically 
heterogenous and may even be involved in cognition, memory and behaviour (Khakh and 
Sofroniew, 2015, Khakh and Deneen, 2019, Alberini et al., 2018, Cao et al., 2013, Martin-
Fernandez et al., 2017). It’s also evident that astrocytes are involved in synaptic pruning 
during neurodevelopment (Chung et al., 2015).  Until very recently, astrocytes were used as 
proxy-measurements of CNS inflammation during microbiota-gut-brain axis studies. 
However, striking evidence suggests that they directly interact with microbial metabolites to 
regulate aspects of the brain’s immune response (Rothhammer et al., 2016).  
Dietary-derived tryptophan-indole metabolites were shown to reduce inflammation in the 
experimental autoimmune encephalitis model of multiple sclerosis (Rothhammer et al., 
2016). Indole metabolites activated the aryl-hydrocarbon receptor in astrocytes, leading to a 
downstream cascade activating the Interferon-I transcriptional pathway that reduced 
inflammation (Rothhammer et al., 2016). The indole metabolite indoxyl-3-sulfate is not 
produced in germ-free mice and is indeed shown to cross the blood-brain barrier to activate 
the aryl hydrocarbon receptor in astrocytes (Rothhammer et al., 2016). Humans with multiple 
sclerosis also showed a reduction in circulating indole metabolites that could act as agonists 
of the aryl-hydrocarbon receptor (Rothhammer et al., 2016). In adult mice, this pathway 
attenuates inflammation after stroke and reduces neurogenesis, perhaps preserving the 
neurogenic niche for more favourable conditions (Chen et al., 2019c) 
Another study found sex differences in responses to a high-fat, high sucrose diet in both the 
microbiome and astrocytes (Daly et al., 2020). Interestingly, while female mice showed an 
increase in the GFAP+ hypothalamic expression in the high fat, high sucrose condition 
compared to controls, this difference was absent in males (Daly et al., 2020). This suggested 
a reduction in astrogliosis only in females (Daly et al., 2020). 
Even fewer studies focused on these interactions in humans. In autistic children, the astrocyte 
inflammation mark S100β is found increased in the bloodstream (Tomova et al., 2019). 
S100β is often used as a marker for brain inflammation or injury (Michetti et al., 2019), and 
in study negatively correlated with the abundance of gut Bilophila and Carboxydothermus 
(Tomova et al., 2019). Another study indicates that the gut-derived SCFA acetate reaches 
astrocytes in the hypothalamus, modulating satiety and appetite (Frost et al., 2014).  
Microglia 
Microglia, the brain’s resident macrophages, mediate both immunity and synaptic pruning in 
the brain (Tremblay et al., 2011). Due to their importance in disease and neurodevelopment, 
impairments may contribute to different neurodevelopmental and neuropsychiatric disorders. 
In accordance with observations of peripheral immunity, microglia in GF animals are 
immature and cannot properly react to harmful stimuli (Erny et al., 2015, Castillo-Ruiz et al., 
2018). In addition to global transcriptional differences with conventional mice (Erny et al., 
2015), the microglia of GF rodents even have a different pattern of regional infiltration into 
the brain during development (Castillo-Ruiz et al., 2018). Further, altered cytokine and 
chemokine pathways in GF animals prevent the development of appropriate innate immune 
responses (Erny et al., 2015), which could impact synaptic pruning. 
Another study found temporal and sex-dependent differences in microglia gene expression 
and function. RNA sequencing of microglia revealed differentially expressed genes during 
embryonic development, with more differences in between GF males and their conventional 
counterparts, than in GF females and their conventional controls (Thion et al., 2018). 
Interestingly, the magnitude of these differences is reversed in adulthood, with more 
differentially expressed genes between GF and conventional females, than between the males 
(Thion et al., 2018). In addition, while conventional mice had an increase in differentially 
accessible regions in their genetic material as the embryo matured, but not in the GF mice 
(Thion et al., 2018). These results were shown to be translatable to humans, as there were 
transcriptomic similarities between microglia in both organisms during mid-gestation (Thion 
et al., 2018)). 
Using an antibiotic depletion model, evidence for the necessity of the microbiota for proper 
microglia development has been strengthened (Erny et al., 2015, Thion et al., 2018). 
Impairments in the GF model were rescued with the introduction of a complex microbiota or 
through short-chain fatty acid-mediated activation of the Free Fatty Acid Receptor 2 (Erny et 
al., 2015). Short-chain fatty acids can be produced by the human and rodent gut microbiota 
through the fermentation of indigestible fibres (Stilling et al., 2016). The immature GF 
microglia also show impaired responses to ischemia (Singh et al., 2018) and bacterial 
lipopolysaccharide (Campos et al., 2016). 
In mouse models of Alzheimer’s disease, the microbiota is often targeted to influence 
microglial inflammation. One study supplemented the diet of a transgenic model of 
Alzheimer’s disease, with a prebiotic soybean finding that it reduced microglial inflammation 
in the brain, attenuated the cognitive decline of the mice, reduced fecal lipopolysaccharide 
and increased the populations of Lactobacilli and Bifidobacteria in the gut (Lee et al., 2018). 
In other rodent models of Alzheimer’s disease, antibiotic administration reduced microglial-
related inflammation only in males (Mezo et al., 2020, Dodiya et al., 2019), mediated by 
changes in the levels of the ‘M0’ homeostatic microglial state (Dodiya et al., 2019). 
Additionally, administration of the butyrate producing probiotic Clostridium butyricum 
attenuated microglial inflammation and cognitive impairment in this transgenic model (Sun et 
al., 2020). Using the Amyloid-β induced BV2 microglial cell line, (Sun et al., 2020) found 
that butyrate administration reduced the expression of CD11b, COX-2 and reduced the 
phosphorylation of the transcription factor  NF-κβ p65. There is a plethora of evidence 
showing the functional involvement of short-chain fatty acids in the microglial pathogenesis 
across different mouse models of Alzheimer’s disease. 
These anti-inflammatory mechanisms may act in other disease states. The gut microbiota was 
necessary for activation of the neuroprotective microglial TLR4 response against viral-
induced neurologic signalling  (Brown et al., 2019). Other work indicates that microglia 
derived TGFα and VEGF-B mediated the astrocytic aryl-hydrocarbon receptor response in 
experimental autoimmune encephalitis; it was found that microglial activation was also 
dependent on dietary tryptophan metabolites (Rothhammer et al., 2018). 
Interestingly the microbiota and microglia may also mediate behaviour. The tetracycline 
antibiotic minocycline inhibited microglial activation, attenuating anxiety and depressive-like 
behaviours in a high-anxiety breed of rats (Schmidtner et al., 2019). Minocycline treatment 
also reduced the caecal abundances of butyrate-producing families of bacteria 
Lachnospiraceae and Clostridiales Family XIII (Schmidtner et al., 2019). The abundance of 
these families, as well as the amount of 3-OH-butyrate in the serum were positively 
correlated with reductions in anxiety behaviours (Schmidtner et al., 2019).   
Oligodendrocytes  
The myelinating cells of the CNS, oligodendrocytes, also require a gut microbiota for proper 
maturation and function. Converging lines of evidence implicate the microbiota and its 
metabolites in oligodendrocyte function and gene expression.  
Sex specific differences in myelination have been found in the prefrontal cortex GF mice 
(Gacias et al., 2016, Hoban et al., 2016, Radulescu et al., 2019, Lu et al., 2018). One study 
which used diffusion tensor imaging, showed that male C57BL/6 mice had hypomyelination 
in the corpus callosum, at 4 weeks of age, and internal capsule at 12 weeks of age, while 
females did not (Lu et al., 2018). In addition, differences in myelination between males and 
females were significant in each investigated region (Lu et al., 2018).  In contrast, Swiss 
Webster GF males displayed an upregulation in myelination genes in the prefrontal cortex, 
suggestive of  hypermyelination – which was absent in females (Hoban et al., 2016). This 
was verified with electron microscopy and Western blot (Hoban et al., 2016).  
 
One study administered a probiotic consisting of Lactobacillus acidophilus and 
Bifidobacterium infantis to pregnant C57BL/6 dams during pregnancy and weaning (Lu et al., 
2020). Compared to controls, offspring from these dams showed increased protein expression 
of neuroglia-2, a marker of oligodendrocyte progenitor cells (Lu et al., 2020). In a model of 
maternal stress in rats, coadministration of a prebiotic with the milk-fat globule membrane 
prebiotic attenuated the negative impact of maternal stress-mediated increases on the 
expression of myelin-associated glycoprotein in the prefrontal cortex (O'Mahony et al., 
2020). 
 
The role of microbiota-mediated myelination was investigated in a genetic FVB mouse model 
of Huntington’s disease. A reduction in myelin-related proteins was measured in the 
prefrontal cortex of these mice, suggesting hypomyelination (Radulescu et al., 2019). Much 
like the immature microglial phenotype, profound oligodendrocyte immaturity in the 
prefrontal cortex was also observed and measured using immunohistochemistry in the GF 
mice (Radulescu et al., 2019). In the corpus callosum of GF Huntington’s mice, 
immunohistochemistry and electron microscopy uncovered hypermyelination (Radulescu et 
al., 2019). Interestingly, GF mice with genetically-induced Huntington’s disease also had an 
increase in the proportion of small diameter axons as well as a decreased proportion of 
medium diameter axons (Radulescu et al., 2019). However, the results of this study were not 
stratified by sex. 
A model of cuprizone-induced demyelination found that administration of the SCFA butyrate 
attenuated demyelination and enhanced remyelination, via its direct impact on 
oligodendrocytes (Chen et al., 2019b). Butyrate exerted its effects on remyelination by 
modulating the differentiation of immature oligodendrocytes (Chen et al., 2019b).  
Research of multiple sclerosis in humans and corresponding rodent models finds that the 
microbiota mediates the autoantigen peripheral immune response during disease progression 
(Berer et al., 2017, Berer et al., 2011, Zeraati et al., 2019, McMurran et al., 2019, Miller et 
al., 2015) but little impact on subsequent remyelination (McMurran et al., 2019). Indeed, 
modulating the gut microbiota through diet in rodents modified disease severity in 
experimental autoimmune encephalitis (Libbey et al., 2018, Escribano et al., 2017). Microbial 
taxa reduced during the pathogenesis of multiple sclerosis produce SCFAs; accordingly, 
administration of SCFAs also attenuated the severity of disease in a rodent model of 
experimental autoimmune encephalitis indirectly via T-cell mediated effects (Mizuno et al., 
2017a). Faecal microbiota transplants from healthy naïve mice, reduced the severity of 
experimental autoimmune encephalitis (Li et al., 2020a).  
It’s clear that there is both direct and indirect influences of the gut microbiota and its 
metabolites on oligodendrocytes maturation, myelination and function.  
 
Sequencing the Gut Microbiota 
Reductions in the cost of RNA-sequencing as well as the innovations and improvements 
across these platforms enables the study of the gut microbiota (Claesson et al., 2017). 
Commonly, faecal samples are collected and stores at -80° C until the RNA is extracted and 
cDNA is synthesized (Bastiaanssen et al., 2019, Chen et al., 2020a, Cardona et al., 2012). 
This genetic material is amplified using the PCR reaction, either targeting multiple microbial 
genes for whole-genome shotgun sequencing or only the hypervariable 16S rRNA gene for 
16S sequencing (Bastiaanssen et al., 2019, Fouhy et al., 2016, Clooney et al., 2016). While 
16S sequencing is less cost-intensive, it does not provide as much strain-level resolution as 
whole-genome sequencing (Bastiaanssen et al., 2019, Fouhy et al., 2016, Clooney et al., 
2016). Next-generation sequencing platforms then provide readouts of RNA sequences 
(Bastiaanssen et al., 2019). These readouts are pre-processed and assigned to microbial taxa, 
functional pathways or potential neuroactive modules (Bastiaanssen et al., 2019, Valles-
Colomer et al., 2019, Iwai et al., 2016, McIver et al., 2018). A recent study identified the 
importance of neuroactive gut-brain modules in mood disorders (Valles-Colomer et al., 
2019). These gut-brain modules are inferred from microbiome composition and are validated 
on a large human dataset (Valles-Colomer et al., 2019). This tool is important for further 
investigations of the microbiome, adding on more functional input and insight. 
The data analysis approach must account for the compositional nature of the microbiota to 
reduce spurious findings (Gloor et al., 2017, Quinn et al., 2018). Most microbiome studies 
measure the α-diversity of samples to determine the amount, evenness and distribution of 
difference species within each sample (Bastiaanssen et al., 2019). β-diversity metrics quantify 
the differences between two different groups, often displayed using Principal Component 
Analysis (or Principal Coordinate Analysis, when compositional methods are not used) 
(Gloor et al., 2017). Identifying differentially-abundant taxa is a common method for 
explaining the potential relationship between certain elements of the microbiota and host 
physiology (Gloor et al., 2017).  
 
Figure 7. Pipeline of microbiota analysis, from faecal sample to final output. After fecal samples are collected, microbial 
genetic material is extracted. Microbial genes are amplified through PCR and the microbial genes are sequenced. Following 
this step, the microbiome information is digitized. Various bioinformatics tools are then used to identify the individual taxa 
within the sample. After generating a table containing the amount of different microbes found in each sample, 
bioinformatics analysis can determine whether one group expresses more of a specific taxa. Additionally, the amount of 
different bacteria and their distribution is compared between groups to assess different types of alpha diversity. The counts 
table can also be used to predict functional characteristics of the microbiota. Finally, a principal component analysis allows 
for the visualization of all samples, to determine whether groups cluster away from each other. This provides a measure of 
beta-diversity. Adapted from (Cryan et al., 2019). 
  
  
Overall goal and Specific Aims 
Given the importance of both the microbiota metabolites and glia in health and disease, my 
overall goal is to use two approaches to increase our knowledge of microbial metabolites and 
in particular SCFAs in brain health and disease  
Aims Addressed in Chapter 2 
While many studies analyse the microbiota in association with disorders or other aspects of 
the brain, they often find different results. Additionally, identifying differentially expressed 
microbes does not provide any functional information. A few studies also measure fecal 
short-chain fatty acids but other key metabolites, notably bile acids and tryptophan 
metabolites are rarely assessed. Since the development and validation of bioinformatics tools 
to identify neuroactive microbial pathways, these studies can be reanalyzed (Valles-Colomer 
et al., 2019). This chapter looks for differences or similarities in gut-brain module abundance 
across >200 human microbiome studies can be assessed. To our knowledge, this is the first 
such attempt at comparing and reconciling differences within these studies. With the addition 
of updated bioinformatics pipelines and taxonomic classifiers, a consistent pipeline is applied 
to analyse the data. 
1. Although there is many studies on the microbiome in psychiatric disorders there is a 
lack of knowledge on the functionality of such changes in disease. Thus one of the 
major goals of this thesis is to synthesize,  summarize and reanalysis of all existing 
human-microbiome-brain studies to probe for evidence of predicted microbial-
metabolites associating with brain function, behaviour or disease in humans. 
2. Use a standardized bioinformatics pipeline to determine if common microbiota-gut 
brain axis trends persist across existing human studies. 
Aims Addressed in Chapter 3 
A plethora of supporting studies suggest that SCFAs, especially butyrate, impact the glial 
components of the brain. While much of the focus has been on microglia, it is important to 
assess the specific roles of astrocytes within a homeostatic setting. (Frost et al., 2014) found 
that acetate impacts the glutamate-glutamine cycle in hypothalamic astrocytes, regulating 
appetite. SCFAs are also involved in the Krebs’ cycle and thus may play a regulatory role in 
the brain. However, studies have not assessed whether there are sex-specific differences in 
cortical astrocyte function at physiologically-relevant levels of SCFAs.  Thus the effects of 
SCFAs on gene expression of astrocytes may underpin some of the changes seen at a 
population level. 
3. Determine whether physiologically relevant concentrations of microbially-derived 
SCFAs alter gene expression in vitro using primary cortical murine astrocyte cultures. 
4. Determine if these effects in vitro are dependent upon sex. 
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There is increasing knowledge regarding the role of the microbiome in modulating brain and 
behaviour. Indeed, the actions of microbial metabolites are key for appropriate gut-brain 
communication in humans. Among these metabolites short-chain fatty acids, tryptophan, and 
bile acid metabolites/pathways show strong preclinical evidence for involvement in various 
aspects of brain function and behaviour. With the identification of neuroactive gut-brain 
modules, new predictive tools can potentially be applied to existing datasets.  
We identified 278 studies relating to the human microbiota-gut-brain axis which included 
sequencing data. This spanned across psychiatric and neurological disorders with a small 
number also focused on normal behavioural development. With a consistent bioinformatics 
pipeline, thirty-five of these datasets were reanalyzed from publicly available raw sequencing 
files and the remainder summarized and collated. Among the reanalyzed studies, we 
uncovered evidence of disease-related alterations in microbial metabolic pathways in 
Alzheimer’s Disease, schizophrenia, anxiety and depression. Amongst studies that could not 
be reanalyzed, many sequencing and technical limitations hindered the discovery of specific 
biomarkers of microbes or metabolites conserved across studies. Future studies are warranted 
to confirm our findings. We also propose guidelines for future human microbiome analysis to 
increase reproducibility and consistency within the field.  
Keywords: Microbiota; brain; enteric-nervous system; short-chain fatty acids; bile acid; 
tryptophan; indole; psychiatry; neurodegenerative disease; diet 
  
Highlights 
• Microbially-derived metabolites are implicated in human brain health and disease 
• Evidence is lacking for consistent microbial changes across studies  
• Evidence suggests metabolites are involved in schizophrenia, anxiety/depression and 
Alzheimer’s disease 
• Technical sequencing and bioinformatics limitations hinder cross-study comparison 
• Improved methods and data reporting are key to find robust associations  
Introduction  
1.1 Role of Metabolites in the Microbiota-Gut-Brain Axis 
Since the serendipitous discovery of the antibacterial properties of penicillin in 1928, 
microbial metabolites have been harnessed for their various antimicrobial properties and are 
emerging as mediators of mammalian health and behaviour (Fleming, 1946b, Fleming, 
1946a, O'Mahony et al., 2015, Blacher et al., 2017, Levy et al., 2017, McCarville et al., 
2020). The mammalian gastrointestinal tract is colonized at birth by a diverse collection of 
microorganisms, collectively called the microbiota (Codagnone et al., 2019a, Theis et al., 
2019). One of the core functions of the gut microbiota is the modification of host, xenobiotic 
and dietary-derived molecules into bioactive metabolites that can impact host health and 
disease (Clarke et al., 2019, Sharon et al., 2014, Spanogiannopoulos et al., 2016, Morris et al., 
2017, Sun et al., 2017).  The ecological community coexisting within a shared space is 
defined as the microbiome (Lederberg and McCray, 2001). One of the most surprising 
findings over the past decades is the cornucopia of genes within the microbiome that enable 
the production and modification of neuroactive metabolites which may modify gut-brain axis 
function (Zimmermann et al., 2019, Strandwitz et al., 2019, Lyte, 2014, Clarke et al., 2014, 
Tennoune et al., 2014, Lee et al., 2015). Most studies in this field characterize the 
predominant bacterial and archaeal components of the gut microbiota.  
Microbial metabolites communicate through dynamic bi-directional pathways within the 
microbiota-gut-brain axis to mediate host brain immunity and physiology (Spichak et al., 
2019, Erny et al., 2017, Pott and Hornef, 2012, Blacher et al., 2017, Levy et al., 2017, 
McCarville et al., 2020). They exert effects directly after being transported across the blood-
brain barrier or indirectly through immune, neuroendocrine or vagal mechanisms (Alenghat, 
2015, McCarville et al., 2020, Roager and Licht, 2018, Stilling et al., 2016, Fulling et al., 
2019). Advances in sequencing technologies over the past decade enable the relatively rapid 
and comprehensive illumination of the composition of the microbiome in the gut (Song et al., 
2018, Bailey et al., 2019, Shakya et al., 2019). For the most part, sequencing of faecal 
samples is used as a surrogate of the gut microbiota composition of individuals. However, 
since most studies differ in methods, developing a consensus from this data is difficult 
(Pollock et al., 2018).  Nonetheless, these studies are invaluable for assessing the role of the 
bacterial metabolites within the human host’s central nervous system (CNS).  
Three of the most-studied metabolic pathways within the gut microbiota are the short chain 
fatty acids (SCFAs), tryptophan metabolism and bile acid metabolism and will form the focus 
of our paper. 
1.2 Aims and Scope  
Knowledge on the role of the main microbial metabolic pathways influencing brain and 
behaviour is emerging. It is important to collate all the currently available datasets in order to 
identify gaps and point to novel areas of discovery. Thus, the aim of this paper is to assess 
metabolic signatures of different human brain health and disease states. All publicly available 
datasets will be reanalyzed and all existing data from the remaining studies will be collated. 
This study focuses on SCFAs, tryptophan pathway metabolites and bile acids.  To the best of 
our knowledge, this is the first extensive analysis of the MGBA involving all publicly available 
data to determine whether any clear microbial composition and metabolic signatures emerge 
for psychological and psychiatric diseases. Briefly this will involve the following steps: 
1. An extensive literature review (PubMed) on all studies involving sequencing the 
faecal microbiota in humans to compare with a functional or clinical brain measure, or 
disease status. Significant findings at the genera level related to the metabolites 
involved in the scope of this study will be recorded, along with significance and effect 
size, if available. Differentially abundant microbes known to be involved in metabolic 
pathways (tryptophan, SCFA and bile acid) will be identified from the existing 
literature (Molinero et al., 2019, Roager and Licht, 2018, Valles-Colomer et al., 2019, 
O'Mahony et al., 2015).  
2. A reanalysis of all publicly available datasets with a common, updated pipeline to 
identify differentially abundant microbes and gut-brain modules (GBMs). Recently 
the concept of GBMs has emerged, providing an additional predictive index for 
bacterial 16S rRNA gene sequencing studies (Valles-Colomer et al., 2019). Briefly, 
the authors performed an extensive literature review to inform the assembly of 
pathways with neuroactive potential in bacteria. Existing databases don't curate all 
these pathways or predict their ability to bypass the blood-brain barrier (Valles-
Colomer et al., 2019). After construction and validation from genomes of human-
associated microbes, GBMs were validated on a large cohort of human 16S rRNA 
gene sequencing data (Valles-Colomer et al., 2019). This revealed novel insight into 
the gut metabolic signatures of depression (Valles-Colomer et al., 2019). To fulfil a 
GBM, the microbe must possess each enzyme within the pathway (Valles-Colomer et 
al., 2019). Though this method does not directly measure the abundance of these 
metabolites, it provides stringent associations validated on large independent cohorts.   
In addition to changes in microbial composition and GBMs, effect sizes and 95% 
confidence intervals will also be reported.  
3. Assess if common disease signatures exist across studies. If there is a specific host-
microbe-metabolite interaction within a disease, we would expect a common unique 
signature of differentially-abundant taxa and GBMs across all studies of that disease.  
2.0 Methods 
2.1 Study Selection 
PubMed database searches were conducted by searching for disease or health-related terms 
along with ‘microbiome’. These terms were: obesity brain, anorexia, ADHD, ASD, 
PANDAS, schizophrenia, Alzheimer’s Disease, amyotrophic lateral sclerosis, neurovascular, 
ischemia, temperament, personality trait, multiple sclerosis, IBS anxiety depression, 
fibromyalgia, migraine, stress AND human, posttraumatic, anxiety OR depression human 
faecal, alcohol-dependence, bipolar disorder, epilepsy, opioid use, smoking human faecal, 
human drug addiction faecal, sleep human faecal, human ‘psychological stress’, Rett 
syndrome. An example of one search would be: microbiome AND obesity brain. This search 
yielded a total of 3552 results on June 10th, 2020. The abstracts were manually searched and 
any studies not involving humans, the colonic microbiota or any brain or behaviour-related 
measures were excluded leaving 249 studies. 35 of these datasets were reanalyzed. 39 more 
studies published after June 10th 2020 were also included. 
In the studies where the raw microbiome data was not reanalyzed the sequencing strategy, 
relevant results relating to differential abundance of microbes involved in neuroactive 
pathways and limitations were summarized.  
2.2 Downloading datasets 
Raw sequencing files (.fastq or .fastq.gz format) were downloaded from the European 
Nucletotide Archive or the Sequence Research Archive by generating a bash script to 
download the dataset (https://sra-explorer.info). For data deposited on the China National 
GeneBank Database Sequence Archive or Qiita sequencing files were downloaded by writing 
bash scripts to download each individual dataset (Gonzalez et al., 2018). Some data was also 
downloaded from the Metagenomic Rapid Annotations using Subsystems Technology (MG-
RAST) using scripts from https://github.com/MG-RAST/MG-RAST-Tools (Meyer et al., 
2008, Wilke et al., 2015).  Two studies were excluded from reanalysis because one could not 
be demultiplexed and another was sequenced using the SOLiD platform and could not be 
processed through the same pipeline.  
2.3 Generating counts tables for 16S rRNA gene sequencing platforms 
Raw sequencing files for each dataset were processed through the DADA2 pipeline (Callahan 
et al., 2016). Briefly, files were first filtered and trimmed to 200 base pairs (where possible 
with the following settings: trimLeft = 37, truncLen=237, maxEE=2, truncQ=2, maxN=0, 
rm.phix=TRUE) (Callahan et al., 2016). Next, sequence quality reports were generated using 
FastQC, using a threshold score of 28 (Andrews, 2010). If necessary, samples were filtered 
again and trimmed. Forward and reverse error rates (settings: nbases=1e8) were generated for 
each dataset, followed by merging of individual files into a sequence table and the removal of 
de novo bimeras (Callahan et al., 2016). The SILVA v132 training set was input into the RDP 
classifier in DADA2 to assign taxonomy to the sequence table (Glockner et al., 2017, Pruesse 
et al., 2019, Quast et al., 2013, Yilmaz et al., 2013, Wang et al., 2007).  
Scripts used for bioinformatics analysis are found here: https://github.com/simon-sp/Mining-
Metabolites. 
2.4 Bioinformatics Analysis: Differentially Abundant Microbes  
R version 3.6.3 was used in R Studio v1.2.5 for Ubuntu 18.04. Any amplicon-sequence 
variants (ASVs) with fewer than 2 raw counts were filtered out, and data was transformed 
using the centred-log-ratio (CLR) in ALDEx2 with 1000 Monte-Carlo sampling permutations 
(Fernandes et al., 2014, Quinn et al., 2018). Three studies were excluded where the majority 
of ASVs were filtered out, leaving a counts table with only 2-10 microbial taxa.  
An overall PCA was generated by principal component analysis for visualisation and quality 
check purposes using the ggplot2 package (Wickham, 2016). 
A list of differentially abundant microbes was generated with the Tjazi 
pairwise_DA_wrapper by incorporating the Wilcoxon Rank-Sum test for comparing the 
abundance of each individual microbe across groups, followed by a Benjamini-Hochberg 
post-hoc test (Bastiaanssen, 2019, Pounds and Cheng, 2004) . Microbes were reported if they 
had a Padj < 0.1 and an effect size > 0.65 to increase the robustness of these findings. The 
95% confidence intervals are also reported.  
2.5 Bioinformatics Analysis: Differentially Abundant Gut Brain Modules 
Raw sequencing data was transformed to be input into Piphillin for predicted functional 
analysis of the sequencing data (Iwai et al., 2016). The output of Piphillin produced a counts 
table of the Kyoto Encyclopdia of Genes and Genomes (KEGG) orthologs, which could then 
be used to assess the abundance of GBMs via omixerRpm, using the GBM_v1.0 dataset  
(Kanehisa et al., 2019, Kanehisa and Goto, 2000, Kanehisa, 2019, Valles-Colomer et al., 
2019). Differential abundance of GBMs was determined using the Tjazi pairwise_DA-
wrapper. GBMs were reported if they had a Padj < 0.1 and an effect size > 0.4 to increase the 
robustness of these findings. The 95% confidence intervals are also reported. 
2.6 Generating Counts Tables for WGS Shotgun Analysis  
First, adapter sequences were trimmed using bbduk (ktrim=r, mink=6, hdist=1, qtrim=rl, 
trimq=20, minlength=70, tpe, tbo, rcomp = T) followed by decontamination using bbmap     
(-Xmx16g, minid=0.95, qtrim=rl, trimq=10, untrim) against the masked human genome 
(Hg38) and merging using bbmerge (bbmerge-auto.sh, -Xmx24g, rem, k = 62, extend2=50, 
ecct) (Bushnell, 2020, Bushnell et al., 2017). The fastq.gz files were then processed through 
‘biobakery_workflows wmgx’ run within a separate Miniconda environment (Python v2.7) 
with the following parameters: --bypass-strain-profiling --bypass-quality-control using the 
UniRef default databases for MetaPhlAn2 and HUMAnN2 (Truong et al., 2015, McIver et 
al., 2018, Franzosa et al., 2018). The rest of bioinformatics analysis of the count tables for 
genes and gene pathways is described in Section 2.3 with two differences. Piphillin is not 
used because HUMAnN2 provides counts tables of gene pathways/proteins as outputs and 
thus do not need to be inferred. Counts tables for bacterial genes as well as gene 
pathways/proteins were first run through the guess_counts function within the Tjazi R library, 
before CLR transformation (Bastiaanssen, 2019). Two whole genome shotgun (WGS) studies 
were excluded from re-analysis because the publicly available dataset did not contain all 
sequenced samples or the fastq.gz files were not labelled. 
3.0 Results and Discussion 
3.1 Short-Chain Fatty Acids (SCFAs) in Brain Health and Disease 
3.1.1 Biochemistry and Function 
SCFAs are molecules consisting of a 1-6 carbon chain with a carboxylic acid group (Dalile et 
al., 2019). Colonic bacterial fermentation of non-digestible, non-absorbable fibres (inulin, 
cellulose, wheat bran and resistant starches) produces SCFAs as a by-product (Cummings, 
1981). The following genera commonly found in the gut are known to produce SCFAs: 
Akkermansia, Bifidobacterium, Lactobacillus, Lactocaseibacillus, Ligilactobacillus, 
Ruminococcus, Ruminoclustridium, Blautia, Bacteroides, Roseburia, Prevotella, 
Eubacterium, Fusicatenibacter, Faecalibacterium, Enterococcus, Clostridium and 
Coprococcus (Takada et al., 2013, Dalile et al., 2019, Joseph et al., 2017, Valles-Colomer et 
al., 2019, Basson et al., 2016, Zheng et al., 2020a). It is unclear how these genera impact the 
absorption of SCFAs in the colon (Ruppin et al., 1980) nor how GI absorption may differ 
between individuals independent of these microbes (Dalile et al., 2019). Other factors that 
may impact differences in SCFA circulating concentrations include host genetics, dietary 
intake and colonic absorption of SCFAs (Dalile et al., 2019). 
SCFA production involves overlap with pyruvate metabolism and other molecules involved 
in the Krebs Cycle (see Figure 1). The most abundant SCFAs in humans are acetate, butyrate 
and propionate (Dalile et al., 2019). They differ in their aliphatic tail length and the position 
of their carboxylic acid group (Dalile et al., 2019). These minor differences affect affinity and 
specificity to G-protein coupled receptors (GPCRs; (FFAR1, FFAR2, FFAR3, GPR109A, 
GPR164 and OR51E2)) (Dalile et al., 2019). SCFAs also act as histone deacetylase inhibitors 
in enteric neurons, enterochromaffin cells, and microglial cells (Stilling et al., 2016, Erny et 
al., 2015, Dalile et al., 2019, Woo and Alenghat, 2017, Yang et al., 2019). Through these 
mechanisms, SCFAs impact host physiology by driving the expansion of FOXP3+ Treg cells 
(Woo and Alenghat, 2017),  or mediating the release of IL-6, IL-10 and IL-12, dendritic cells 
and macrophages, in turn driving T cell maturation (Woo and Alenghat, 2017).   
Many SCFA-sensing GPCRs are located on enteric immune and neuronal cells  (Nohr et al., 
2013, De Vadder et al., 2014). In the millimolar concentration range butyrate depolarizes 
enteric neurons (Neunlist et al., 1999), and reduces monocyte activation and mast cell 
degranulation (Digby et al., 2012, Diakos et al., 2006). Though a growing body of pre-
clinical evidence suggests SCFAs are neuroactive metabolites influencing the brain and 
behaviour (Liu et al., 2020b, Sadler et al., 2020, van de Wouw et al., 2018, Lee et al., 2020a), 
few clinical studies thus far have reported on these effects in humans. Some promising 
evidence shows that SCFA production correlates with health outcomes in humans. For 
example, increasing dietary-fibre intake from an average of 12.12g  daily to 37.10g  over the 
course of 84 days modulated clinically-relevant host outcomes in Type 2 Diabetes, including 
reducing the levels of haemoglobin A1C (Zhao et al., 2018).   
3.1.2 Potential of SCFAs to Cross the Blood-Brain Barrier 
To reach the brain, SCFAs must cross the intestinal epithelium through passive diffusion 
or via monocarboxylate transporters (MCT1, SMCT1) (Bergersen, 2015, Chiry et al., 2006), 
before  passing through the hepatic circulation without being completely depleted by hepatic 
enzymes (Stilling et al., 2016). In recently-deceased or fasting individuals, researchers found 
SCFAs in peripheral circulation were depleted to ~20% after passing through hepatic 
circulation (Stilling et al., 2016, Cummings and Macfarlane, 1997, Peters et al., 1992, Hamer 
et al., 2008).  
SCFAs are transported across the blood-brain barrier by MCT1 or SMCT1, but it is unclear if 
they reach a relevant physiological concentration in the brain (Bergersen, 2015, Chiry et al., 
2006). One human study used PET in vivo imaging to microbially-produced acetate from the 
colon reached the hypothalamus to regulate satiety signalling (Frost et al., 2014). In addition, 
butyrate is involved in mediating the integrity and permeability of the blood-brain barrier by 
increasing occludin expression in preclinical models (Braniste et al., 2014, Li et al., 2016, 
Sun et al., 2016a, Sun et al., 2016b). Meanwhile, in vitro studies show that propionate can act 
on GPCR receptors at 1µM  to promote neuroprotective pathways (Hoyles et al., 2018).  The 
human metabolomic database assessed concentrations of SCFAs in the cerebrospinal fluid, 
finding ranges of 0-171µM  for acetate, 0-6µM  for propionate and 0-2.8µM  for butyrate 
(Wishart et al., 2018). An older study performed gas chromatography on human brains, 
finding higher SCFA concentrations than the metabolomics study found in the cerebrospinal 
fluid (Bachmann et al., 1979). These studies are not conclusive but suggest that SCFAs do 
enter the brain. It is unknown if these SCFA levels induce effects on circumventricular 
organs such as the hypothalamus.   
3.2 Tryptophan Pathway Metabolites 
3.2.1 Biochemistry and Function of Bacterially-Produced Indoles 
The gut microbiota can generate and modify neurotransmitters as well as their precursors, 
including serotonin and tryptophan (see Gheorghe et al. (2019), (Lee et al., 2015) for review).  
The potential for gastrointestinal microbes to metabolize tryptophan and its various 
metabolites was first characterized in the 1970s (Allison et al., 1974, Whitt and Demoss, 
1975). In the decades since, metabolites exclusively produced by microbial enzymes yet 
communicate with the host, called indoles were functionally characterized (Lee et al., 2015, 
O'Mahony et al., 2015). While indoles are commonly produced by pathogenic strains of 
bacteria to improve their survival, they are also present in a symbiotic ecosystem (Lee et al., 
2015). While the neurotransmitter serotonin is produced from the dietary-derived essential 
amino acid tryptophan (Reigstad et al., 2015), indoles are produced by the breakdown of 
tryptophan using the bacterial enzyme tryptophanase (Lee et al., 2015). 
Many of the bacterial strains capable of expressing tryptophanase are also involved in the 
other tryptophan metabolic pathways described below. These genera include Bacteroides, 
Butyrivibrio, Clostridium, Enterococcus, Escherichia, Eubacterium, Haemophilus, 
Fusobacterium, Peptostreptococcus, Bifidobacterium, Parabacteroides, Megamonas, 
Anaerostipes, Ruminococcus (Roager and Licht, 2018, Valles-Colomer et al., 2019, 
O'Mahony et al., 2015).    
Indoles are present in the high nanomolar to low millimolar range in the colon (Bansal et al., 
2010, Karlin et al., 1985). These metabolites, produced by the enzyme tryptophanase, signal 
with human intestinal epithelial cells in the millimolar concentration range, increasing tight 
junction resistance and mucin production (Bansal et al., 2010, Karlin et al., 1985). Indole 
metabolites also regulate enteric neuronal signalling and motility in the myenteric plexus 
through the aryl-hydrocarbon receptor (Obata et al., 2020). In the brain, indoles act on this 
same receptor in the central nervous system (CNS) astrocytes to regulate inflammation and 
immunity (Rothhammer et al., 2016, Rothhammer et al., 2018).  
3.2.2 Biochemistry and Function of Serotonin 
Microbial tryptophan metabolism regulates bioavailability of precursors required for host 
serotonin (5-HT) production (Kennedy et al., 2017, Yano et al., 2015).  To produce 5-HT, 
tryptophan hydroxylase converts tryptophan into 5-hydroxytryptophan, which then requires 
an enzymatic decarboxylation reaction to form 5-HT (Gheorghe et al., 2019, Kennedy et al., 
2017). 5-HT is important for gastrointestinal motility, absorption and secretion tract 
(Kennedy et al., 2017). ~95% of 5-HT is produced by the enterochromaffin cells in the gut 
and secreted into the lumen in response to different stimuli (Kuo et al., 2002, Gershon and 
Tack, 2007). The enterochromaffin cells can uptake tryptophan or 5-hydroxytryptophan and 
generate serotonin via tryptophan hydroxylase (Kuo et al., 2002, Gershon and Tack, 2007). In 
disorders such as ulcerative colitis or irritable bowel syndrome, tryptophan hydroxylase 1 
mRNA, serotonin transporter mRNA and serotonin transporter expression were markedly 
reduced (Coates et al., 2004). There is also cross-talk with SCFAs which modulate the 
expression of serotonin production within enterochromaffin cells by promoting tryptophan 
hydroxylase 1 gene expression (Reigstad et al., 2015).   
The serotonergic system within the brain is involved in regulating cognition, mood and 
behaviour, and is dysfunctional in depression, anxiety and other neuropsychiatric disorders 
(Jacobs and Azmitia, 1992, Gheorghe et al., 2019). 
3.2.3 Biochemistry and Function of Other Tryptophan Catabolites 
Tryptophan is degraded in the colon and throughout the rest of the body by the ubiquitously 
expressed indoleamine-2,3-dioxygenase (IDO1) or tryptophan-2,3-dioxygenase in the liver 
(TDO2)  (Seifert, 1993, Ruddick et al., 2006). The expression of these enzymes is increased 
past homeostatic levels by stress-released cytokines and elevated levels of glucocorticoids, 
toll-like-receptor activation or aryl hydrocarbon receptor activation (Morris et al., 2017, Maes 
et al., 2011b, Schrocksnadel et al., 2006, Kennedy et al., 2017). This increases the presence of 
downstream catabolites including quinolinic acid and kynurenic acid which act within the 
CNS or the enteric nervous system (ENS) (Morris et al., 2017, Maes et al., 2011b, 
Schrocksnadel et al., 2006, Kennedy et al., 2017).  
Kynurenic acid is a GPR35 agonist in the gastrointestinal tract and in mononuclear immune 
cells in the ENS (Wang et al., 2006) and provides neuroprotection in the CNS as an 
antagonist of the N-methyl-D-aspartate (NMDA) receptor and the α-7-nicotinic receptor 
(Foster et al., 1984, Hilmas et al., 2001). Quinolinic acid on the other hand exerts agonistic 
excitotoxic activity in the CNS through activation of the NMDA receptor  (Foster et al., 
1984). 
Interestingly, in a recent a double-blind randomized placebo-controlled trial in humans it was 
found that probiotic supplementation with L. plantarum 299v altered kynurenine metabolites 
and improved cognition measures in individuals with major depressive disorder. However, 
the microbiota compositional changes were not characterized in this trial (Rudzki et al., 
2019). It could be hypothesized that the changes introduced into the gut microbial ecosystem 
sufficiently altered the expression of hepatic TDO2, indirectly influencing peripheral 
tryptophan metabolism.  
3.2.4 Transport into the Brain 
Tryptophan is absorbed in the small intestine and transported into peripheral circulation and 
can be catabolized by IDO1 throughout the body or TDO2 in the liver (Seifert, 1993, 
Kennedy et al., 2017). Remaining tryptophan is transported across the blood-brain barrier via 
the large neutral amino acid transporter, where it can be converted to 5-HT or kynurenine 
catabolites (Ruddick et al., 2006). Kynurenic acid and quinolinic acid cannot cross the blood-
brain barrier but other catabolites such as indoles and kynurenine have been detected in the 
brain (Morris et al., 2017, Maes et al., 2011b, Schrocksnadel et al., 2006, Kennedy et al., 
2017, Gheorghe et al., 2019). Serotonin transporters in the brain can mediate the reuptake of 
excess 5-HT at the synaptic cleft, and is a common target of pharmaceutical interventions for 
depression and anxiety (Schwarcz et al., 2012).   
3.3.1 Bile Acids and the Brain 
Bile acids are molecules synthesized from cholesterol in the liver, characterized by 
amphipathic steroidal functional groups (Mertens et al., 2017, Kiriyama and Nochi, 2019). 
They play crucial roles facilitating the digestion and absorption of dietary lipids and fat-
soluble vitamins (Mertens et al., 2017, Kiriyama and Nochi, 2019, Enright et al., 2018). Most 
bile acids are generated through the hydroxylation reaction by CYP7A1, while the rest are 
synthesized via the alternative pathway involving the liver enzymes CYP271 and CYPB1 
(Enright et al., 2018). In the mouse, the expression of these three enzymes is mediated by the 
host microbiota (Sayin et al., 2013). Shortly after they are generated in the liver, the bile acids 
are conjugated with taurine or glycine before being transported for storage in the gall bladder 
(Dawson and Karpen, 2015, Long et al., 2017). Once released to aid in the digestion and 
absorption of lipids, they travel through the gastrointestinal tract and can be deconjugated and 
bio transformed by gut microbes where they can be absorbed into peripheral circulation 
(Enright et al., 2017). These bile acids are also involved in cellular signalling, particularly as 
ligands for nuclear receptors and various transmembrane surface receptors (Mertens et al., 
2017, Kiriyama and Nochi, 2019).  
Bile salt hydrolases, enzymes produced by members of the mammalian gut microbiota, 
deconjugate bile acids  (Long et al., 2017) (Fig. 1). Currently, these genera are known to 
produce this enzyme: Bacteroides, Clostridium cluster VIA, Lactobacillus, Bifidobacterium, 
Eubacterium (Molinero et al., 2019).  In the gut, the primary bile acid deoxycholic acid, can 
inhibit colonic motility through the GpBAR1 (TGR5) receptor on enteric neurons (Sun et al., 
2004a, Sun et al., 2004b, Poole et al., 2010). Disruptions and alterations in the gut microbiota 
contribute to bile acid dysregulation in the BTBR mouse model of autism-like behaviour 
(Golubeva et al., 2017). It is unclear how these gut microbial and bile acid changes relate to 
the behaviour in this model.  
Conjugated and unconjugated bile acids, as well as taurine or glycine alone are potential 
neuroactive ligands in humans (Mertens et al., 2017, MahmoudianDehkordi et al., 2019). 
Taurine is thought to be neuroprotective as it functions as an agonist of glycine, GABAA and 
GABAB receptors in the brain (Albrecht and Schousboe, 2005, Boldyrev et al., 1999, Choe et 
al., 2012, Hilgier et al., 2005, El Idrissi and Trenkner, 1999, Beetsch and Olson, 1998). It is 
unknown how much taurine is transported into the brain and if it is sufficient for signalling 
(Albrecht and Schousboe, 2005). Recently (Sharon et al., 2019a) showed that offspring of 
mice colonized with a human autism faecal microbiota produced less taurine than offspring 
of controls colonized with a neurotypical faecal microbiota. These mice were impaired in 
their social behaviours, suggesting a gut-brain connection is involved in these behaviours 
(Sharon et al., 2019a). Indeed, when they supplemented BTBR mice with taurine, 
characterized as socially-impaired, researchers could rescue these deficits (Sharon et al., 
2019b)  
Recently, a large multicentre metabolomics study of 1464 total participants found that the 
bacterially produced deoxycholic acid, as well as its glycine and taurine conjugated forms 
were increased in the serum metabolome of individuals with Alzheimer’s Disease 
(MahmoudianDehkordi et al., 2019), suggesting increased 7α-dehydroxylation of cholic acid 
by the gut microbiota, as these metabolites cannot be produced by the host. Importantly, 
deoxycholic acid was also associated with cognitive decline, providing human evidence of a 
link between microbial bile acid metabolism and mental health (MahmoudianDehkordi et al., 
2019).   
3.4 Sequencing and Software 
3.4.1 Sample Preparation and Sequencing Technology 
There is great heterogeneity in sequencing preparation, sequencing strategy and downstream 
bioinformatics analysis despite multiple studies identifying a clear need and multiple efforts 
for standardization of these protocols (Fouhy et al., 2016, Clooney et al., 2016, Pollock et al., 
2018, Aigrain et al., 2016, McLaren et al., 2019, Hogue et al., 2019, Santiago et al., 2014, 
Cardona et al., 2012).  
Even before a sample is sequenced many factors influence the microbial community within it. 
Many studies reported a bias in different DNA extraction protocols biasing towards gram-
positive or gram-negative bacteria (Watson et al., 2019), delivery-conditions and speed of the 
faecal sample and library preparation (Yeoh et al., 2019), fractional subsampling of faecal 
material (Yeoh et al., 2019), and storage (Panek et al., 2018, Chen et al., 2020a, Neuberger-
Castillo et al., 2020, Carruthers et al., 2019).   
Early microbiome studies used real time quantitative PCR (RT-qPCR) based techniques to 
amplify bacterial specific sequences from stool samples for species and genera-level 
identification. Other techniques hybridized fluorescent primers to these sequences for 
quantification or used terminal-restriction fragment length polymorphism analysis. These 
preliminary methods did not produce high-throughput, high coverage outputs and only 
describe the abundance of a few specific genera. There are indeed considerations in terms of 
bacterial load that could not have been addressed in these studies, making it difficult to draw 
robust conclusions about overall abundance without a clear picture of the entire microbiome 
(Vandeputte et al., 2017). With the decline in cost of sequencing, most high-throughput 
microarray-based technologies were replaced with next-generation sequencing, also known 
as high-throughput sequencing (NGS). NGS emerged as a method that provided untargeted 
information about the community as well as more reads and coverage (Bonk et al., 2018). 
One method of sequencing the faecal microbiota involves the amplification of the 
hypervariable regions of bacterial 16S rRNA gene, found within the DNA of all bacteria. 
However, there is no universal consensus for selecting a hypervariable region to amplify 
despite substantial evidence showing its impact on the abundances of different detected taxa 
within a sample (Clooney et al., 2016, Kumar et al., 2011). The metagenomic GC content 
also biases the amplification process resulting in a decreased abundance of microbial taxa 
with higher GC content (Laursen et al., 2017). In addition, there is no consensus for 
determining when single-end sequencing preparation is adequate and when paired-end 
sequencing methods must be used. While single-end reads often provide more coverage, 
paired-end reads provide more phylogenetic resolution (Werner et al., 2012, Chen et al., 
2018). 
When using a 16S rRNA gene based sequencing platform, there is great variation between 
different technological platforms such as 454 Roche Pyrosequencing, Illumina HiSeq and 
Illumina MiSeq (Clooney et al., 2016, Fouhy et al., 2016, Degnan and Ochman, 2012). 
Newer Illumina-based platforms improve coverage while reducing costs, predominantly 
replacing the use of 454 Roche Pyrosequencing (Degnan and Ochman, 2012). While 16S 
rRNA gene-base sequencing methods can accurately-identify taxa with genus-level 
resolution, WGS is required for quality species, strain and substrain identification in faecal 
samples. In addition, they identify previously uncultured bacteria and their genes. Since WGS 
amplifies all metagenomic information within a sample, it provides a more accurate view of 
the community composition and diversity while also providing functional information; 
however preferably amplified fragments however lead to overestimation in abundance of 
certain microbes (Clooney et al., 2016, Ranjan et al., 2016, Tessler et al., 2017). The 
currently most commonly-used platforms involve the use of Illumina sequencers however 
studies have not compared different WGS methods with each other. 
3.4.2 Taxonomic Databases and Classifiers 
Differences in taxonomic classification databases and taxonomic assignment likely 
contributed to inconsistent classification of microbial sequences across studies. In addition, 
researchers which conducted studies >3 years ago did not have access to more extensive 
taxonomic databases  (Glockner et al., 2017, Pruesse et al., 2019, Quast et al., 2013, Yilmaz 
et al., 2013). Many existing studies have used the Greengenes database for assigning 
microbial taxonomy, but this database is problematic because it has not been curated/updated 
since 2013 and thus cannot identify novel sequences (DeSantis et al., 2006).  Greengenes has 
a significant overrepresentation of certain taxa; for example, at the species level ~15% of all 
sequences are assigned to Faecalibacterium prausnitzii (Allard et al., 2015). This is in 
contrast to other databases such as SILVA, which do not have a single species level 
assignment allocated to even 5% of all sequences within the database (Allard et al., 2015). 
This means that studies which used Greengenes to assign taxonomy were also a lot more 
likely to find an enrichment in Faecalibacterium prausnitzii and an underrepresentation of 
other taxa. In studies using untransformed relative abundance metrics, a non-specific 
assignment of Faecalibacteirum prausnitzii would affect the relative abundance of other 
identified genera.  
One reason that different databases would assign a different classification to the same 
sequence is the size of the database (Balvociute and Huson, 2017). Having a larger taxonomic 
database can improve the specificity of these classifications since there will be more 
sequences with similarity to the read (Balvociute and Huson, 2017). Since taxonomic classes 
above the genus-level are very diverse, these differences were not reported in this analysis 
because they do not provide adequate resolution to infer the production of bacterial 
metabolites. Even bacterial members within the same family can differ in their enzymatic and 
metabolic capabilities. 
In addition, the use of amplicon sequencing variants (ASVs) rather than operational 
taxonomic units (OTUs) provide more replicable and meaningful identification of taxa across 
studies (Callahan et al., 2017). However, many past studies have used and many still use 
OTUs, hindering comparison across datasets. Often, studies may even identify some OTUs 
belonging to one microbial genus increased in one group while also finding other OTUs 
belonging to the same genus reduced in that same group. This confounds interpretation and 
replicability. 
The gut microbiota functions as an ecological community with keystone species and genera 
necessary for its function. Identifying individual ASVs that are altered in a disease could help 
identify these keystone members. Thus, if an important keystone genus is disrupted, the 
metabolic output of the community is altered which may impact host health (Chng et al., 
2020, Banerjee et al., 2018, Berg et al., 2020, Fisher and Mehta, 2014).  
3.4.3 Compositional Data Analysis 
Widely used relative abundance and general logarithmic transformations are inappropriate for 
microbiome data. Microbiome data is, by definition, compositional and thus using relative 
abundance, or rarefaction during processing is inappropriate and would skew study results 
(Gloor et al., 2017). In addition, issues within correlational analysis of compositional data 
have long been noted and are another challenge when analysing microbiome data (Gloor et 
al., 2017, Lovell et al., 2015, Friedman and Alm, 2012, Kurtz et al., 2015, Pearson, 1897). 
There is a known bias for spurious and negative correlations within microbiome datasets 
(Gloor et al., 2017). Additionally, we found many studies where rarefaction is used when 
processing reads. This involves subsampling of each sample’s read counts to a common 
sequencing depth but results in a loss of information and precision (McMurdie and Holmes, 
2014). Finally, it is also possible to mathematically model the bias within metagenomic 
experiments (McLaren et al., 2019). This would allow for reference calibration to correct 
these biases, but only if the data has already been compositionally transformed (McLaren et 
al., 2019). 
3.4.4 Use of Outdated Tools and Software 
Additionally, we also found that bioinformatics tools are often used after they are deprecated; 
a few studies described in Table 1 used Quantitative Insights into Microbial Ecology 
(QIIME) Version 1 past the date that it was still supported by its developers, while many 
studies did not specify the version used.   
3.5 Healthy Humans 
3.5.1 Infant Temperament and Behaviour 
3.5.1.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
The only WGS study found multiple associations between Bifidobacterium, Clostridium and 
Bacteroides species associated with brain connectivity and temperament. However, four 16S 
sequencing studies did not find any genus-level associations between infant temperament and 
microbiota composition (Carlson et al., 2018, Gao et al., 2019, Christian et al., 2015, Rosin et 
al., 2020). Two studies showed positive associations of increased Bifidobacterium abundance 
in infants with positive behaviours (soothability and emotional regulation) (Wang et al., 
2020d, Aatsinki et al., 2019). Though Loughman et al. (2020) did not find associations with 
Bifidobacterium, Prevotella abundance was associated with behavioural problems. These 
studies rely on correlational analysis but since the microbiota is compositional by nature, 
these datasets are prone towards spurious correlations (see 3.4.3) (Gloor et al., 2017). Though 
Bifidobacterium and Prevotella participate in tryptophan and SCFA metabolic pathways 
(Valles-Colomer et al., 2019), it is still unclear whether these specific pathways are 
implicated in these behaviours. See Table 1 for more detail. 
3.5.2 Adult Personality and Behaviour 
3.5.2.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Many descriptive studies have associated individual genera of bacteria with personality traits. 
In healthy participants, Taylor et al. (2019) found a negative correlation of Blautia abundance 
with anxiety. Tillisch et al. (2017) did not assess anxiety but found a negative correlation of 
Prevotella abundance with negative affect. Interestingly, Kim et al. (2018) found associations 
between increased Roseburia abundance and conscientiousness while Johnson (2020) instead 
found Oscillispira associated positively with sociability. There were no consistent findings at 
the genus-level within these studies, resultant from limitations described in Table 1. Without 
additional metadata and strain level resolution, it is difficult to associate personality traits 
with microbial genera. While many studies identified associations with bacteria involved in 
SCFA and tryptophan metabolic pathways, the current state of the evidence for robust 
microbial associations with personality traits is weak.  
3.5.2 Sleep Characteristics and Quality 
3.5.2.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Liu et al. (2019a) collected faecal samples from ten individuals who reported insomnia and 
another ten who served as healthy controls. Though no GBMs were differentially abundant, 
Alloprevotella abundance was significantly reduced in individuals with insomnia (padj < 0.1, 
effect = -1.16; 95% CI: [-14.97; 0.17]).  No other microbes or GBMs relating to SCFA, 
tryptophan or bile acid pathways were differentially abundant within this dataset.  
3.5.2.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Few studies focused on associating sleep-quality and microbiota composition (see Table 1). 
Among these, two showed no genera-level associations between microbes and sleep (Liu et 
al., 2020c, Anderson et al., 2017). One 16S sequencing study found disruptions in across 
different sleep stages in individuals with a Prevotella enterotype (Ko et al., 2019). Smith et 
al. (2019) collected extensive metadata, allowing for the correlation of specific microbes to 
sleep parameters. While Holdemania and Corynebacterium abundance negatively associated 
with number of awakenings, Coprococcus and Neisseria were associated with increased 
awakenings (Smith et al., 2019b). Blautia also negatively associated with sleep efficiency and 
total sleep time (Smith et al., 2019b). Though these findings are interesting, participants used 
faecal swabs to collect microbiota samples (Smith et al., 2019).  
An additional three studies compared the gut microbiome of individuals with sleep disorders 
such as insomnia and narcolepsy type 1 to controls (Lecomte et al., 2020, Li et al., 2020c, 
Valentini et al., 2020). These compelling pilot studies point to possible associations of 
different microbial genera and healthy sleep. 
While the interactions between circadian rhythm, sleep and the microbiome are compelling 
and gaining more traction (Godinho-Silva et al., 2019, Govindarajan et al., 2016, Li and Cui, 
2018, Weger et al., 2018, Teichman et al., 2020), more human studies are necessary to 
investigate this interaction.   
3.5.3 Ageing and Cognition 
3.5.3.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
No common genus-level differences associated with healthy cognitive ageing across existing 
studies (see Table 1). However, these studies all compared different subsets of unhealthy 
cognitive aging. One study compared healthy ageing to mild-cognitive impairment, another 
with Cirrhotic individuals, another with dementia and finally one was a 12 week crossover-
double blind trial (Nagpal et al., 2019, Kim et al., 2020, Bajaj et al., 2016, Saji et al., 2019). 
While compelling large-cohort studies associated microbial populations with frailty and diet 
in aging (Ghosh et al., 2020, Meehan et al., 2015, O'Toole and Jeffery, 2018, Ticinesi et al., 
2017, Verdi et al., 2018) they do not overtly focus on the cognitive aspects of ageing per se. 
3.6 Neurodevelopmental Disorders 
3.6.1 Attention-Deficit Hyperactivity Disorder  
3.6.1.1 Studies Where Raw Microbiome Data Was Reanalyzed 
One 16S sequencing study was reanalyzed, involving 19 individuals with Attention-Deficit 
Hyperactivity Disorder (ADHD) and 77 control participants, including a wide age-range for 
their participants (Aarts et al., 2017). Upon reanalysis, no significant differences within the 
microbial composition or GBM abundance were found (Aarts et al., 2017) (see Table 2). 
The study is notable because 28 of these participants underwent a further fMRI analysis and 
found associations between microbial compositions with responses to reward anticipation 
(Aarts et al., 2017). Since fMRI data was not provided, this aspect of the study was not 
reanalyzed. 
3.6.1.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Wan et al. (2020) used a WGS strategy to identify a reduction in KEGG Orthologs for 
dopaminergic pathways in individuals with ADHD. Consistent with Jiang et al. (2018b), 
ADHD individuals showed a reduction in the abundance of Faecalibacterium (Wan et al., 
2020). In fact, Faecalibacterium abundance negatively associated with the total Conners 
Parent Rating Scales score, which assesses children’s behavioural difficulties, as well as the 
hyperactivity index (Jiang et al., 2018b). No other common differences in microbial genera 
between ADHD and controls were reported across a set of five other studies (Stevens et al., 
2019, Prehn-Kristensen et al., 2018, Szopinska-Tokov et al., 2020, Pärtty et al., 2015, Wang 
et al., 2020b). However, one of these studies used a compositional approach for their data 
analysis (Szopinska-Tokov et al., 2020). They found an increased relative abundance of 
Ruminoclostridium 9 and Ruminococcus 2 in ADHD individuals, and were able to correlate 
Ruminococcus 2 with inattention scores (B = 1.525, p = 0.001) (Szopinska-Tokov et al., 
2020). Nonetheless, there is weak evidence for specific SCFA or tryptophan associated 
microbial pathway alterations in ADHD (see Table 2). 
3.6.2 Autism Spectrum Disorder (ASD) 
3.6.2.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Across seven reanalyzed studies (see Table 2), only two showed a robust effect of Autism 
Spectrum Disorder (ASD) on microbiota composition (Averina et al., 2020, Son et al., 2015, 
Pulikkan et al., 2018, Kang et al., 2019, Kong et al., 2019, Liu et al., 2019d, Strati et al., 
2017). In the data collected by (Pulikkan et al., 2018), Roseburia abundance was increased in 
ASD (padj < 0.001, effect = 0.9; 95% CI: [-1.9, 10.38]). When stratifying individuals with 
ASD by the median Autism Treatment Evaluation Checklist score, those below the median of 
62 showed a reduction in Ruminoclostridium 9 (padj < 0.1, effect = -0.78; 95% CI: [-7.28, 
1.80]) (Kong et al., 2019). However, none of these studies found any differentially abundant 
GBM pathways. Interestingly, in the dataset collected by Son et al. (2015), twins discordant 
for ASD showed no overall differences in microbiota composition. This may indicate that 
environmental factors such as diet as well as other factors are largely responsible for 
microbiota changes in these studies. 
3.6.2.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Over 30 other studies assessed differences between the ASD microbiota and controls, or 
differences within ASD subgroups (see Table 2). Across the WGS studies, only one found 
changes in GBM abundance (Wang et al., 2019a). They reported decreased gut 
glutamate/glutamine metabolism in ASD individuals (Wang et al., 2019a).  
Bacteroides abundance was increased in ASD groups amongst four datasets (Zhai et al., 
2019b, Zurita et al., 2019, Coretti et al., 2018, Ahmed et al., 2020) and reduced in four (Dan 
et al., 2020, Niu et al., 2019, Ding et al., 2020, Zhang et al., 2020c). Similarly the relative 
abundance of Bifidobacterium was increased in two datasets (Dan et al., 2020, Plaza-Diaz et 
al., 2019), and decreased in three others (Niu et al., 2019, Wang et al., 2020b, Zhang et al., 
2020c). Another compelling argument from the use of ASVs over OTUs is identifying 
whether a specific genus is increased or decreased. For example, in Zurita et al, (2019), one 
Ruminoccocus OTU is increased in ASD while another is reduced. Until recently, the 
important Lactobacillus genera encompassed many distinct strains; with updated 
nomenclature it might be possible to differentiate amongst the genera and find other potential 
signatures (Zheng et al., 2020a). Overall, there is great heterogeneity in the methods, 
reporting and results.  
Though they did not find correlations between ASD symptoms and faecal SCFAs, Berding 
and Donovan (2019) found that the SCFAs correlated strongly with diet. A separate study 
reported increased valerate and decreased butyrate in ASD faecal samples (Liu et al., 2019d).    
 As many as 90% of individuals with ASD display picky and repetitive eating behaviours, 
which can further impact their nutrient intake and microbiota (Kral et al., 2013). It’s unclear 
whether SCFA dysregulation is a result of the microbial production or dysregulation in gut 
absorption. Along with host genetics, this is an important consideration for future studies. 
3.6.3 Schizophrenia 
3.6.3.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Four studies were reanalyzed (see Table 2), but we found differentially abundant genera in 
only two of these studies (Xu et al., 2020, Shen et al., 2018, Flowers et al., 2019, Nguyen et 
al., 2019). In these two studies, individuals with schizophrenia had higher abundances of the 
acetate-producing Fusicatenibacter (padj < 0.001, effect: 0.67; 95% CI:[-1.48; 7.56]; padj < 
0.001 and effect =1.06; 95% CI: [-1.05; 7.60]) (Shen et al., 2018, Xu et al., 2020). In the 
samples collected by Xu et al. 2020, individuals with schizophrenia also showed an increase 
in the following GBMs: Butyrate synthesis II (padj < 0.001, effect: 0.61; 95% CI:[-1.83; 
5.41]), Kynurenine synthesis (padj < 0.001, effect: 0.68; 95% CI:[-2.10; 6.12]), and Inositol 
degradation (padj < 0.001, effect: 0.83; 95% CI:[-1.58; 6.96]). In addition, Lactobacillus 
abundance was reduced (padj < 0.001, effect: - 1.28; 95% CI:[-12.85; 0.11]) (Xu et al., 2020).     
Perhaps Fusicatenibacter was only differentially abundant in the Chinese cohorts, compared 
to the North American cohorts due to dietary and environmental differences. 
3.6.2.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Across three WGS studies, various Lactobacillus OTUs are increased in schizophrenia 
compared to controls (Zhu et al., 2020, Xu et al., 2020, Schwarz et al., 2018), however some 
OTUs were also reduced in one of the studies (Zhu et al., 2020). In two studies, 
Bifidobacterium adolescentis was increased in patients, while Clostridium perfingens was 
increased in one dataset (Xu et al., 2020) but reduced in the other (Zhu et al., 2020). 
Interestingly, this contrasts with the reduction found when reanalyzing the 16S dataset from 
(Xu et al., 2020). This discrepancy is resultant from the different sequencing and 
bioinformatics pipelines used. The majority of 16S sequencing studies assessed different 
subpopulations of schizophrenia and thus are difficult to compare with each other. Combined 
with reanalyzed results, there is evidence supporting Lactobacillus and Bifidobacterium 
dysregulation in schizophrenia, as well as potential changes in tryptophan and SCFA-related 
GBMs (see Table 2).   
3.6.4 Pediatric Acute-onset Neuropsychiatric Syndrome and Pediatric 
Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection 
3.6.4.1 Studies Where Raw Microbiome Data Was Reanalyzed 
One 16S sequencing study was reanalyzed but no relevant bacterial genera or differences in 
GBMs were found (Quagliariello et al., 2018). 
3.6.5 Rett’s Syndrome 
3.6.5.1 Studies Where Raw Microbiome Data Was Reanalyzed 
A small descriptive study was reanalyzed (Borghi and Vignoli, 2019) but no genus-level 
differences were found between Rett’s Syndrome and age-matched controls. However, both 
faecal isobutyrate and isovalerate were increased in Rett’s syndrome (see Table 2). 
3.6.5.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Strati et al. (2016) found an increased abundance in faecal isobutyrate, isovalerate and 
propionate (see Table 2). However, after controlling for constipation and disease severity, no 
bacteria were differentially abundant within the disease group. There may be host-genotype 
microbiota associations involved in influencing SCFA production or absorption. 
3.7 Epilepsy 
3.7.1 Studies Where Raw Microbiome Data Was Reanalyzed 
In the dataset from Lindefeldt et al. (2019), twelve children with epilepsy provided two faecal 
samples, one before commencing the ketogenic diet and three months afterwards (see Table 
3). While no age-matched controls were included within the study, the children’s parents 
served as a healthy control (Lindefeldt et al., 2019). The dataset was reanalyzed through the 
WGS pipeline described in Section 2.6. We found that the ketogenic diet increased 
abundance in L-Tryptophan biosynthesis pathways (padj < 0.1, effect = 0.9; 95% CI: [-1.07; 
10.67]) and S-Adenosyl Methionine biosynthesis (padj < 0.1, effect = 0.63; 95% CI: [-1.89; 
8.86]) (Lindefeldt et al., 2019). Though the study’s authors found a reduction in relative 
abundance of Bifidobacterium their data was not treated compositionally (see 3.4.3 for 
limitations of non-compositional data approaches) (Lindefeldt et al., 2019).  
Another reanalyzed study looked at individuals co-morbid with cerebral palsy and epilepsy 
(Huang et al., 2019a). While over 20 differentially abundant bacteria had an absolute effect 
size >0.65, there were no differences across GBM abundance (Huang et al., 2019a). From a 
bioinformatics perspective, this indicates that large genus-level differences do not always 
change the overall abundance of GBMs. 
3.7.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Four 16S studies used different types of cohorts and comparisons (see Table 3). (Xie et al., 
2017) assessed microbiome differences between epileptic infants and healthy controls. Two 
studies compared individuals with drug-responsive epilepsy, to drug-resistant epilepsy and 
controls from the same family (Peng et al., 2018, Zhang et al., 2018b). Peng et al. (2018) 
looked at the efficacy of dietary intervention while Safak et al. (2020) focused on idiopathic 
focal epilepsy. Another study compared same-family controls to epileptic individuals finding 
many genera-level differences (Liu et al., 2020a). As a result, we cannot make any definitive 
conclusions about GBM-related bacteria or signatures within epilepsy and epilepsy-responses 
to dietary or pharmacologic treatment. Interactions between diet, epilepsy, epileptic 
medication and the microbiome remain unclear. 
3.8 Neurodegenerative Disease 
3.8.1 Alzheimer’s Disease 
3.8.1.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Most of the raw sequences from one 16S study could not be aligned to ASVs (Liu et al., 
2019b). In the other 16S sequencing study (Li et al., 2019a), a reduction was detected in the 
SCFA-producing Ruminoclostridium 5 (padj< 0.01, effect = -0.67; 95% CI: [-8.52, 1.59] 
while the following SCFA-specific GBMs were upregulated when comparing Alzheimer’s 
Disease (AD) to healthy controls: isovaleric acid synthesis II ( padj < 0.1, effect = 0.42; 95% 
CI: [-2.11; 5.62]),  butyrate synthesis I ( padj < 0.1, effect = 0.44; 95% CI: [-2.33; 6.25]), 
butyrate synthesis II ( padj < 0.1, effect = 0.52; 95% CI: [-3.60; 4.79]), and acetate synthesis 
III ( padj < 0.1, effect = 0.50; 95% CI: [-2.04; 5.92]) (Li et al., 2019a). 
Though no differentially abundant microbes were identified when comparing individuals with 
mild cognitive impairment (MCI) to healthy controls, several SCFA and tryptophan related 
GBMs were increased: isovaleric acid synthesis II ( padj < 0.01, effect = 0.43; 95% CI: [-2.48; 
5.98]),  butyrate synthesis I ( padj < 0.1, effect = 0.44; 95% CI: [-2.33; 6.25]), acetate 
synthesis I ( padj < 0.01, effect = 0.58; 95% CI: [-1.93; 5.86]), acetate synthesis II ( padj < 0.1, 
effect = 0.47; 95% CI: [-1.81; 5.33]), acetate synthesis III (padj < 0.01, effect = 0.64; 95% CI: 
[-1.52; 6.26]), tryptophan synthesis ( padj < 0.1, effect = 0.48; 95% CI: [-1.94; 6.71]), 
quinolinic acid synthesis ( padj < 0.01, effect = 0.49; 95% CI: [-1.93; 6.43]), quinolinic acid 
degradation (padj < 0.01, effect = 0.56; 95% CI: [-1.93; 6.43]) (Li et al., 2019a). 
Additionally, several other GBMs were differentially abundant in the MCI and AD groups 
compared to the controls, indicating an increase in overall pathways promoting excitatory 
neuronal signalling (Li et al., 2019a) (see Table 4). 
3.8.1.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Bacteroides is found differentially abundant across the two 16S and one WGS study 
comparing AD to controls. However, it is found to be increased in two of these studies – one 
of which involves WGS (Haran et al., 2019, Vogt et al., 2017), and decreased in the third 
study (Zhuang et al., 2018). Additionally, Alistipes abundance was increased in the AD 
individuals in two of these studies (Haran et al., 2019, Vogt et al., 2017). Though findings 
from one reanalyzed dataset are strong (Li et al., 2019a), additional measures of metadata are 
needed to disentangle GBM differences in AD or mild-cognitive impairment from sex, diet 
and age. 
3.8.2 Multiple Systems Atrophy 
3.8.2.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Three studies analyzing the gut microbial composition of individuals with Multiple Systems 
Atrophy (MSA) have been conducted (see Table 4), with two of these studies finding genus-
level differences in bacterial abundance (Du et al., 2019, Engen et al., 2017, Tan et al., 2018). 
However, none of the genera are found differentially abundant across these two studies (Tan 
et al., 2018, Du et al., 2019). Interestingly, Tan et al. (2018) also found a reduction in faecal 
acetate, propionate and butyrate in their disease cohort. This data together suggests that MSA 
may alter the production or absorption of SCFAs, though it is unclear if individual microbial 
genera are involved. 
3.8.3 Amyotrophic Lateral Sclerosis 
3.8.3.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
There were no consistent findings across three studies (Zhai et al., 2019a, Brenner et al., 
2018, Mazzini et al., 2018, Zeng et al., 2020, Nicholson et al., 2020, Ngo et al., 2020) (see 
Table 4). (Blacher et al., 2019) did not find any significant microbes using a WGS approach 
but found an overall reduction in tryptophan metabolism-related genes in ALS compared with 
controls. Two other WGS studies did however find differentially abundant microbes, 
involved in SCFA and tryptophan metabolism (2020, Zeng et al., 2020). Indeed, there were 
alterations in serum tryptophan and nicotinamide metabolites suggesting the serum 
metabolome may have been altered by the gut microbiota (Blacher et al., 2019). 
3.8.4 Parkinson’s Disease 
3.8.4.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Surprisingly, across six studies (one WGS, five 16S) only 1 ASV was found differentially 
abundant (Bedarf et al., 2017, Heintz-Buschart et al., 2018, Aho et al., 2019, Pietrucci et al., 
2019, Qian et al., 2018, Weis et al., 2019) (see Table 4). When stratifying 16S sequencing 
data from Weis et al. (2019) by gastrointestinal symptoms and L-DOPA dosage, there was 
one differentially abundant genus. Parkinson’s disease (PD) individuals taking a L-DOPA 
dose of <300mg/day had a lower abundance of Lactobacillus than controls (effect = 0.83; 
95% CI: [-2.10, 8.07]) (Weis et al., 2019). No GBMs related to SCFAs, tryptophan or bile-
acid modifying bacteria were identified.  
3.8.4.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Hill-Burns et al. (2017) found significant differences in bacterial abundance between PD and 
controls after controlling for covariates. They reported an increased abundance of 
Bifidobacterium, Lactobacillus, Akkermansia and Roseburia (Hill-Burns et al., 2017). Ren et 
al. (2020) used a generalized linear model to control for sex, age, body mass index and 
education and did not find any changes in these four genera in their cohort. Instead, they 
reported a reduction in Ruminococcus and Blautia in their PD group which had not 
experienced MCI (Ren et al., 2020). However, three other studies did find an increased 
abundance of Lactobacillus in PD (Petrov et al., 2017, Barichella et al., 2019, Cirstea et al., 
2020). Additionally, three other 16S studies reported a reduction in Roseburia compared to 
their control cohorts (Barichella et al., 2019, Keshavarzian et al., 2015, Cristea et al., 2020). 
Four other 16S studies also found an increased abundance of Akkermansia (Keshavarzian et 
al., 2015, Vidal-Martinez et al., 2020, Li et al., 2019b, Zhang et al., 2020a) and 
Bifidobacterium (Petrov et al., 2017, Cirstea et al., 2020, Barichella et al., 2019, Tan et al., 
2020). Interestingly, Lin et al. (2019) found Akkermansia was increased in the tremor PD 
subtype when accounting for age, sex and diet. Finally, Unger et al. (2016) reported 
reductions in faecal acetate, butyrate and propionate. However, many of these studies used 
Greengenes, rarefaction and relative abundance. It is nonetheless fascinating that differences 
in microbial abundance at the genus-level were found in almost every PD study, especially 
those comparing different subtypes. It is unclear if the effect sizes in these studies are robust 
when data is analyzed in a compositional manner (see Table 4). If effect sizes are small, there 
is a higher probability that the effect sizes will not replicate in other studies. This may either 
obscure real differences in the PD microbiota or provide false positives.   
3.9 Addiction and Substance Use 
3.9.1 Alcohol 
3.9.1.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Stadlbauer et al. (2019) collected faecal samples from participants before an acute 2mL  
alcohol binge, and one day afterwards in 15 healthy participants. We did not find any 
significant effects on the microbiota composition or GBMs in this dataset (Stadlbauer et al., 
2019).  The alcohol binge was likely too mild to exert any robust effects. 
Another dataset focused on the long-term effects of alcohol-dependence on the gut 
microbiota (Bjorkhaug et al., 2019). Bacteria involved in SCFA and tryptophan metabolism 
were altered in the alcohol-dependent cohort (Bjorkhaug et al., 2019). Specifically, 
Ruminococcus 2 abundance was increased (padj < 0.1, effect = 0.72, 95% CI: [-2.91; 6.75]) 
and a reduction in Ruminoclostridium 9 (padj < 0.001, effect = - 0.99, 95% CI: [-7.99; 1.00]) 
(Bjorkhaug et al., 2019). Though SCFA-related GBMs were not altered, the tryptophan 
degradation module was reduced in alcohol-dependent subjects (padj < 0.1, effect = - 0.46, 
95% CI: [-5.78; 2.47]) (Bjorkhaug et al., 2019). In addition, other GBMs suggested increased 
GABA synthesis as well as a reduction in g-hydroxybutyrate and dopamine degradation 
(Bjorkhaug et al., 2019). 
3.9.1.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Due to differences in cohorts, it is challenging to draw conclusions from other alcohol-related 
studies (see Table 5). Briefly, a WGS investigation using the SOLiD sequencing platform 
compared the microbiota of individuals with alcoholic dependence syndrome, alcoholic liver 
cirrhosis and control (Dubinkina et al., 2017). Dubinkina et al. (2017) reported an increased 
abundance of Lactobacillus salivarius in alcohol-dependent subjects. These results are not 
easily reconciled, with findings from Leclercq et al. 2014, where a three-week detoxification 
increased Lactobacillus spp. in alcohol-dependent subjects. Two other studies involving 
alcohol-dependence and alcohol overconsumption did not find any changes in Lactobacillus 
abundance (Tsuruya et al., 2016, Bjorkhaug et al., 2020). Meanwhile, a study of the 
microbiota and drinking habits of 212 twin pairs only found a reduction in Roseburia 
abundance associated with alcohol consumption, after correcting for heritability (Seo et al., 
2020). Interestingly, one study found that Haemophilia abundance was associated with 
drinking only (Lin et al., 2020) while other genera associated with both drinking and smoking 
(Bacteroides, Phascolarctobacteirum, Ruminococcus UCG-002, Ruminococcus UCG-003, 
Ruminoclostridium-9). Many of these genera are associated with SCFA/tryptophan 
metabolism. 
Future studies must account for factors such as diet, heritability and drinking frequency to 
demystify the effects of alcohol on gut microbiota composition and metabolism. 
3.9.2 Smoking and Tobacco Use 
3.9.2.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Stewart et al. (2018) collected faecal samples from tobacco smokers, electronic cigarette 
users and controls (see Table 5). Though we did not uncover genus-level differences in 
microbial abundance, we found an increase in the tryptophan degradation module (padj < 0.1, 
effect = 0.84,, 95% CI: [-0.97; 8.52]) and the propionate synthesis III module (padj < 0.1, 
effect = - 0.80, 95% CI: [-9.86; 1.45])(Stewart et al., 2018). 
3.9.2.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Among other studies assessing the microbiota composition of smokers, only a qPCR study 
identified microbial changes (Ishaq et al., 2017). Combined with results in 3.5.1.1, tobacco 
smoking may alter the overall metabolism of the gut microbiota. 
3.9.3 Addiction and Recreational Drug Use 
3.9.3.1 Studies Where Raw Microbiome Data Was Reanalyzed 
There were no differentially abundant microbial or GBM-related associations within the 
(Barengolts et al., 2018) dataset of men characterized with a high-disease burden and opioid 
use. 
3.9.3.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
While Fulcher et al. (2018) reported specific changes in microbial abundance with many 
recreational drugs, Xu et al. (2017) did not find any differences between users and non-users 
when controlling for age and sex (see Table 5). Panee et al. (2018) recently found that 
Prevotella abundance in marijuana users was positively associated with cognitive functions. 
More studies investigating recreational drug use, controlling for age, sex and type of drug, 
must be conducted to deconvolute any potential changes. 
3.10 Multiple Sclerosis and Demyelinating Diseases 
3.10.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Across two 16S sequencing datasets, no differences in microbial abundance or GBMs related 
to SCFA, tryptophan or bile acid metabolism were identified (Miyake et al., 2015, Jangi et 
al., 2016) (see Table 6). When comparing individuals with neuromyelitis optica spectrum 
disorder (NMOSD) to control samples in the (Gong et al., 2019) dataset, there was a reduced 
abundance of Streptococcus in diseased individuals (padj < 0.001, effect = - 0.74, 95% CI: [ - 
6.40; 1.53]). The researchers also reported an overall reduction of faecal SCFAs and 
associations between acetate, butyrate and disease severity (Gong et al., 2019). 
3.10.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
There were no consistent effects across Multiple Sclerosis (MS) studies. Using WGS Ventura 
et al. (2019) found Clostridium increased across individuals with MS with Caucasian, 
Hispanic and African American ethnicities. Interestingly, (2017) compared faecal samples 
from 34 discordant twin pairs and did not find-any genus-level compositional changes when 
accounting for heritability. Other recent studies found a few dysregulated genera but did not 
take ethnicity into account (Ling et al., 2020b, Kishikawa et al., 2020).   
A recent investigation by Reynders et al. (2020) found associations between multiple 
bacterial genera and clinical subtypes of MS. Another study also found differences in SCFA-
producing genera between different subtypes of multiple sclerosis and controls (Saresella et 
al., 2020). Zeng et al. (2019) compared microbial and faecal SCFA abundance between MS, 
NMOSD and controls finding a reduction in acetate, butyrate and propionate when 
comparing either MS or NMOSD to controls. Interestingly, they also reported that faecal 
acetate and propionate are reduced in NMOSD individuals compared to those with MS (Zeng 
et al., 2019).  
 Together, these results suggest that measurements of faecal SCFAs and stratification by 
clinical subtype are crucial for uncovering any potential robust changes in bacterial 
abundance or GBMs.  
3.11 Pain-Related Disorders 
3.11.1 Fibromyalgia 
3.11.1.1 Studies Where Raw Microbiome Data Was Reanalyzed 
In the 16S dataset collected by Minerbi et al. (2019), only one bacterial genus was associated 
with the disease state (see Table 7). The abundance of Sutterella was increased in 
fibromylagia compared to controls living in the same address as the patient (padj <0.1, effect = 
0.66; 95% CI: [-0.43; 0.92]) (Minerbi et al., 2019). However, no differences were found when 
comparing to overall controls in both this 16S dataset as well as in the samples from (Clos-
Garcia et al., 2019). 
3.11.1.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
One study found several SCFA-associated bacteria differentially abundant between 
individuals with fibromyalgia and unrelated controls, corresponding to changes in serum 
SCFA concentrations (Minerbi et al., 2019). Compared to the 16S data produced from this 
cohort (discussed in 3.7.1.1), WGS provides species level resolution and identifies many 
more differentially abundant microbes (Minerbi et al., 2019).   
3.11.2 Irritable-Bowel Syndromes 
3.11.2.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Ten 16S sequencing studies to date, investigated the associations between psychological well-
being, IBS and the microbiota (see Table 7). While one study found Bacteroides abundance 
positively associated with perceived stress (Peter et al., 2018b), while Jeffery et al. (2012) 
reported that it was reduced in Irritable-Bowel Syndromes (IBS) individuals compared with 
controls. Since no controls were included in the study by (Peter et al., 2018b), these results 
are not necessarily contradictory. Since many of these studies involved different probiotic, 
prebiotic and faecal microbiota transplant interventions and a lack of controls, the results of 
these studies could not be compared. Several studies do report changes in SCFA and 
tryptophan associated bacteria, with Labus et al. (2019) finding that Clostridium XIVa and 
Coprococcus associated with differences in brain connectivity between IBS and controls. 
While the overall changes in microbiota composition are unclear, there is some evidence that 
manipulating its composition may improve various psychological aspects of IBS pathology. 
3.11.3 Other Pain-Related Disorders 
3.11.3.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
A recent WGS study (see Table 7) reported the increased abundance of the kynurenine 
synthesis GBM and a reduction in quinolinic acid degradation in elderly women with 
migraines compared to healthy age-matched control (Chen et al., 2019). In addition, 
Faecalibacterium prausnitzii and Bifidobacterium adolescentis were reduced in the women 
who experienced migraines (Chen et al., 2019). However, this was the only microbiota study 
assessing migraines to date. Another conducted on a cohort with myalgic 
encephalomyelitis/chronic fatigue syndrome found negative correlations between 
Faecalibacterium and total sleep awakening (Kitami et al., 2020). Meanwhile, a study of 
chronic widespread pain patients found a decrease in Coprococcus comes abundance (Freidin 
et al., 2020) 
3.12 Eating Disorders 
3.12.1 Obesity 
3.12.1.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Across studies of obesity where psychological or other brain measures were recorded, no 
genus-level associations were reported (see Table 8). However, one study used a 
commercially available dysbiosis test (GA-Map Dysbiosis) to compare the morbidly obese 
microbiomes to controls (Farup and Valeur, 2018). Bacteroides, Prevotella and faecal SCFAs 
were negatively associated with the WHO-5 Wellbeing Index Score within the obese group 
(Farup and Valeur, 2018). In addition, other SCFA and tryptophan modulating microbes, 
Faecalibacterium prausnitzii and Dorea were positively associated with this measure (Farup 
and Valeur, 2018). Recent studies associate microbiome, brain connectivity and structure as 
well as food craving (Dong et al., 2020b, Dong et al., 2020a). Another study finds alterations 
in aromatic amino acid metabolism in obesity impairing short-term memory (Arnoriaga-
Rodríguez et al., 2020). There is insufficient evidence to conclude microbial-derived 
metabolites associate with psychological measures in obesity. 
3.12.2 Anorexia Nervosa 
3.12.2.1 Studies Where Raw Microbiome Data Was Reanalyzed 
Using the raw dataset from (Borgo et al., 2017), we were unable to find any significant 
differences in microbial abundance or GBMs between anorexic individuals and controls. 
Another dataset (see Table 8) with a higher sample size however, found increased abundance 
in isovaleric acid synthesis I (padj < 0.1; effect = 0.44, 95% CI: [-2.80, 5.07]), quinolinic acid 
synthesis (padj < 0.1; effect = 0.48, 95% CI: [-2.13, 5.35]), and quinolinic acid degradation 
(padj < 0.01; effect = 0.42, 95% CI: [-2.33, 4.80]) (Mack et al., 2016). After gaining weight 
and subsequent release from the hospital, individuals with anorexia had a reduction in 
butyrate synthesis II compared to controls (padj < 0.01; effect = -0.43, 95% CI: [-4.88, 2.55]) 
(Mack et al., 2016).  Importantly, ClpB was also elevated at baseline admission, compared to 
controls (padj < 0.1; effect = 0.43, 95% CI: [-2.30, 4.98]) (Mack et al., 2016). This 
Escherichia coli produced protein is an alpha-melanocortinin stimulating hormone mimetic, 
known to reduce appetite in mice (Tennoune et al., 2014). 
3.12.2.2 Studies Where Raw Microbiome Data Was Not Reanalyzed 
There were no consistent findings across microbial genera in six other studies (Morkl et al., 
2017, Morita et al., 2015, Kleiman et al., 2015, Armougom et al., 2009, Schulz et al., 2020, 
Monteleone et al., 2020) (see Table 8). With the release of new tools interrogating GBM 
abundance may be important for identifying potential changes within the anorexic 
microbiota, especially ClpB production. All evidence considered, there is strong evidence for 
the involvement of microbially-derived ClpB but it’s unclear if the microbes involved in its 
production also impact SCFA, tryptophan and bile-acid metabolism. 
3.13 Neurovascular Disease 
3.13.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Many preclinical studies identified butyrate as a potential neuroprotective agent for ischemia 
(Akhoundzadeh et al., 2018, Lee et al., 2020a, Sadler et al., 2020, Singh et al., 2018, Sun et 
al., 2016a). There are fewer studies assessing changes in the gut microbial composition 
responses to stroke in humans. One study compared the gut microbiota of infants who 
received hypothermia treatment for hypoxic ischemic encephalopathy (Watkins et al., 2017). 
Indeed compared to control infants, those undergoing treatment for ischemia showed a 
reduction of Bacteroides abundance (Watkins et al., 2017). Wang et al. (2018) assessed gut 
microbial composition in individuals after cerebral infarction but did not find any genus-level 
abundance changes compared to controls. The butyrate and tryptophan metabolism associated 
bacterial genera Bacteroides, Parabacteroides, Akkermansia, Prevotella and 
Faecalibacterium were reduced after cerebral infarction when compared to controls (Ji et al., 
2017). 
Studies where participants were stratified by type of stroke and stroke severity uncovered 
more compositional differences that may impact SCFA, bile acid and tryptophan metabolism. 
Liu et al. (2020a) found many such genera which were altered when comparing participants 
who suffered post-stroke cognitive impairment with controls. Another study compared 
individuals post-stroke with no cognitive impairment along with those co-morbid with 
depression and cognitive impairment, finding few differences (Ling et al., 2020a).  Another 
study stratified individuals with ischemic stroke by severity and found Enterobacter was 
reduced in severe ischemic stroke compared to mild stroke. Across two different studies 
comparing ischemic stroke to controls, Akkermansia was differentially abundant (Ji et al., 
2017, Li et al., 2019c). However, in one study it was more abundant in the ischemic stroke 
(Li et al., 2019c) while it was reduced in the other study, though it only two individuals in the 
ischemic stroke cohort (Ji et al., 2017). 
Polster at al. (2020) found robust differences and correlations within a large sample (N = 122) 
of individuals with cavernous angioma using a combination of 16S and WGS techniques. 
Compared with controls from the human microbiome project, individuals in the disease group 
showed an increased abundance of Bacteroides thetaomicron and Odoribacter sphlancus 
along with a reduction in Bifidobacterium adolescentis and Faecalibacterium prausnitzii 
(Polster et al., 2020). They found evidence that these changes in abundance promoted gut 
inflammation and increased lipopolysaccharide (LPS) synthesis pathways (Polster, 2020). 
Indeed, this robust methodology even identified differentially abundant species by cavernous 
angioma subtype and severity (Polster et al., 2020).  
Exciting findings from (Polster et al., 2020) warrant more investigation into gut-brain 
communication after other neurovascular insults such as stroke. See Table 9 for more detail. 
3.14 Stress and Psychiatric Disorders 
3.14.1 Stress  
3.14.1.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
The effect of stress on the human microbiota is difficult to study, often involving associating 
lifetime stress metrics with microbiota composition (see Table 10). One 16S sequencing study 
identified that pregnant women that experienced more than 2 adverse childhood events had 
an increased abundance of Prevotella (Hantsoo et al., 2019).  Another study of 75 women 
with pregnancy-related anxiety was unable to find genus-level associations between maternal 
anxiety and the infant meconium (Hu et al., 2019a). Interestingly, Naude et al. (2020) found 
infants born to mothers exposed to intimate partner violence has an increased abundance of 
Citrobacter and Weisella. (Carson et al., 2018) showed that Fusobacterium abundance was 
increased with stress in participants that identified as Black but not amongst other 
demographics, indicating host-mediated contributions to the microbiome stress responses. 
Even though there are clear links between stress and the microbiome (see for reviews 
(Cussotto et al., 2018a, Dinan and Cryan, 2012, Foster and McVey Neufeld, 2013, Liu, 2017) 
for extensive reviews of the subject), these studies indicate how much metadata is needed to 
properly stratify participants and identify some of these changes. 
Another strategy focused on providing probiotic interventions, later comparing microbiome 
and stress metrics between individuals receiving controls or a placebo. Of three such 
randomized control trials, two found genus-level associations with psychological stress 
measures (Nishida et al., 2017, Nishida et al., 2019, Soldi et al., 2019). One study 
administered Lactobacillus gasseri CP2305 which reduced the magnitude of Bifidobacterial 
reduction after the stressor and increased faecal valerate concentrations (Nishida et al., 2019). 
Another study using the same probiotic intervention found different magnitudes of changes in 
the abundances of Corynebacterium in addition to improved sleep quality and a reduction in 
stress symptoms in female participants (Nishida et al., 2017). 
3.14.2 Posttraumatic Stress Disorder  
3.14.2.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Two studies have assessed the impact of post-traumatic stress disorder on the gut microbiota. 
(Hemmings et al., 2017) did not find any differentially abundant genera when using a trauma-
exposed comparison group (does not meet threshold for posttraumatic stress disorder). Bajaj 
et al. (2019) used a conventional control cohort, finding differences even after accounting for 
hepatic encephalopathy. In individuals without hepatic encephalopthay, the posttraumatic 
stress disorder individuals showed an increased abundance of Streptococcus and a reduction 
in Acidaminococcus, Ruminococcus, Roseburia, Anaerostipes, Clostridium XIVAa and 
Pseudoflavonicbacter compared to controls (Bajaj et al., 2019). In the subset of individuals 
with hepatic encephalopathy, posttraumatic stress disorder individuals only showed a 
reduction in Subdoligranulum (Bajaj et al., 2019). 
3.14.3 Bipolar Disorder 
3.14.3.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
There were no consistent microbial changes observed across eleven 16S and WGS studies of 
bipolar disorder (see Table 10). In the two WGS studies, the SCFAs and tryptophan 
associated genera Streptococcus, Clostridium, Oscillibacter and Bifidobacterum were 
increased in bipolar individuals compared with controls (Rong et al., 2019, Lai et al., 2021). 
Due to differences in methodology and data analysis, other studies did not see these same 
differences in abundance. Evans et al. (2017) only reported reductions in Facealibacterium in 
bipolar individuals but did associate its abundance with sleep and depressive symptoms. 
Contrary to these findings, Painold et al. (2019) reported increased Faecalibacterium 
abundance in bipolar disorder. Two other studies noted increased abundance of Bacteroides in 
bipolar disorder but their other findings differed (Hu et al., 2019b, Zheng et al., 2020b). 
Interestingly some of the studies did not find any genus-level differences in microbial 
composition (Coello et al., 2019, Vinberg et al., 2019, McIntyre et al., 2019). Coello et al. 
(2019) found that all the differences in abundance that they observed were explained by sex 
effects, heritability and smoking. 
3.14.4 Depression and Anxiety  
3.14.4.1 Studies Where Raw Microbiome Data Was Not Reanalyzed 
Multiple studies have investigated the explanatory power of the gut microbiota in anxiety and 
depression (see Table 10). Only three 16S or WGS sequencing studies did not find any 
significant  differences in major depressive disorder (MDD) compared to controls at the 
genus-level (Paulsen et al., 2017, Bharwani et al., 2020, Naseribafrouei et al., 2014). (Jiang et 
al., 2020) compared the gut microbiota of individuals currently undergoing a depressive 
episode to controls, finding increased abundance of Akkermansia, Veillonella, Ruminococcus 
gnavus and reductions in Fusicatenibacter, Sutterella, Dialister. A previous study (Jiang et 
al., 2015), reported a reduction in Dialister during active MDD. Other studies did not find 
any similarities with Jiang et al. (2020), thus it is unclear if the gut microbiota changes 
throughout depression or if these differences are a result of different methodologies.  
Few other similarities in gut microbial signatures were reported across other studies. Two 
studies did report an increased abundance of the SCFA and tryptophan metabolism-
associated microbe Collinsella in their respective depressed cohorts (Stevens et al., 2018, 
Zheng et al., 2016). Three studies also reported an increased abundance of Blautia in MDD 
(Huang et al., 2018, Jiang et al., 2015, Yang et al., 2020). When predicting clinical outcomes 
from baseline microbiome data, researchers did not find that the microbiota in MDD 
predicted clinical response (Liśkiewicz et al., 2021). Nonetheless, they did find 
Paraprevotella strongly correlated with the Hamilton Depression Rating Scale-24 Item 
metric (Liśkiewicz et al., 2021) 
Madan et al. (2020) compared rates of remission in psychiatric inpatients and aimed to 
identify microbial genera that predicted readmission or remission from severe depression or 
anxiety. Coprococcus catus was associated with moderate anxiety at admission and was 
reduced in individuals that had lower rates of remission from anxiety or depression (Madan et 
al., 2020). Interestingly, the Coprococcus genera was found increased in the depressed cohort 
by Huang et al. (2018).  Other studies did report however, a reduction in Coprococcus 
abundance in depression (Valles-Colomer et al., 2019, Liu et al., 2016). 
Valles-Colomer et al. (2019) used compositional data methods as well as large cohorts in 
their study, where they found Coprococcus as well as Faecalibacterium associated with a 
higher quality of life and that Dialister and Coprococcus were depleted in depression.  
Interestingly, the Dialister finding is consistent with other studies (Jiang et al., 2015, Jiang et 
al., 2020). Indeed, other studies also found negative correlations between Facalibacterium 
and anxiety or depression (Jiang et al., 2015, Jiang et al., 2018a, Stevens et al., 2018). The 
findings involving Dialister and Faecalibacterium are striking because they persisted despite 
non-compositional data analysis in other studies. A recent systematic-review also found a 
reduction in short-chain fatty acid producing bacteria such as Faecalibacterium across studies 
of anxiety and depression (Simpson et al., 2020).  
3.15 Limitations of Existing Studies 
There are many challenges that prevent researchers from drawing causal conclusions from 
their datasets beyond the technical and bioinformatics limitations discussed in Section 3.4, 
especially in observational human studies (Ma et al., 2019c, Lynch et al., 2020, Koh and 
Bäckhed, 2020, Walter et al., 2020, Ma, 2020). See Table 11 for a description of these 
common limitations and available tools to address them. In addition to those limitations, even 
functional analysis of WGS data does not provide direct information about the proteomics or 
metabolomics within the gut community.  
3.15.1 Sources of Inter-Individual Variance 
One of the greatest challenges with human microbiota studies is making inferences about the 
composition of the colonic microbiota from faeces. There are known differences between the 
faecal and caecal microbiota composition in humans along with spatial variation across the 
gastrointestinal tract (Gevers et al., 2014, Lavelle et al., 2015). Finding healthy volunteers 
willing to provide one or multiple biopsies for a microbiota study is challenging. In addition, 
it’s difficult to determine whether certain microbes are overrepresented in the faeces 
compared to others. The overall microbial load, though seldom measured, is an important 
determinant of microbiota composition (Vandeputte et al., 2017).  It is also recognized that 
microbiota composition changes day-to-day in response to diet, circadian rhythms and sex 
hormones among other confounds (Jaggar et al., 2020, Johnson et al., 2019, Nobs et al., 2019, 
Markle et al., 2013).  
In addition to long-term dietary patterns (Wu et al., 2011), food alters the microbiota on a 
smaller timescale as well. (Johnson et al., 2019) assessed day-to-day variations within 
microbiota composition by collecting detailed daily food diaries and daily faecal samples for 
seventeen days. While the microbiota composition was correlated with food preferences, it 
was not associated with individual nutrients (Johnson et al., 2019). Subject had different 
responses to the same types of foods, which could affect the microbiome for up to two days 
after consumption (Johnson et al., 2019). Meanwhile (Berry et al., 2020) reported that even 
twins had different metabolic responses. Interestingly, the microbial composition of 
individuals explained more variation in postprandial lipemia than meal macronutrients (Berry 
et al., 2020).  Metabolic disease and obesity is common amongst sufferers of anxiety and 
depression (Rajan and Menon, 2017) while food pickiness is common in ASD (Kral et al., 
2013). In addition, microbiota correlates with both the diet and other peripheral health 
measures in elderly individuals (Claesson et al., 2012). Many neuropsychiatric disorders 
involve alterations in food preference (Greenwood et al., 2005, Yau and Potenza, 2013, 
Folley and Park, 2010).  To detangle interindividual differences in dietary responses from 
microbial-brain-disease associations, multi-timepoint sampling and dietary records must be 
incorporated. Other considerations when collecting dietary-related data or integrating dietary 
interventions include study design, control selection, measuring subject compliance, diet-
measurement error, participant bias and method of collecting dietary information (Swann et 
al., 2020, Willett, 2012). 
Another large confound in many of these studies is the medication that individuals may take 
for their disease or disorder, as well as recreational alcohol and drug use (Maier et al., 2018, 
Fulcher et al., 2018, Cussotto et al., 2018b, Vich Vila et al., 2020, Forslund et al., 2015, 
Vieira-Silva et al., 2020, Barengolts et al., 2018, Peterfreund et al., 2012, Zhernakova et al., 
2016, Falony et al., 2016, Panee et al., 2018, Bjorkhaug et al., 2019, Dubinkina et al., 2017, 
Seo et al., 2020, Tsuruya et al., 2016, Coello et al., 2019, Ishaq et al., 2017, Stewart et al., 
2018). 
In addition to diet, and drugs, sex hormones plays an important component in many of these 
neuropsychiatric disorders, the microbiota is also able to participate in 17-β-estradiol 
degradation (Valles-Colomer et al., 2019), and potentially other pathways (Fuhrman et al., 
2014, Shin et al., 2019). (Shin et al., 2019) reported that the faecal abundance of multiple 
bacterial genera was associated with serum levels of testosterone and oestrogen in humans.  
There are also limitations in diagnosing and subtyping different types of diseases and 
disorders. There are a wide spectrum of symptoms and conditions associated with the 
disorders mentioned within the study. The heterogenous nature of many disorders and 
conditions such as ASD, anxiety, depression and stress serve as large confounders (Feczko et 
al., 2019). Much of the metadata does not detail specific symptoms or subtypes of a diagnosis 
or a disorder. Having this information would allow for a higher resolution analysis of gut-
brain interactions. 
Even when accounting for host-genotype effects with larger cohorts, accounting for sex, body 
mass index and genotype, it is difficult to interpret microbiome-host associations without 
identifying the driving influence in such an interaction (Hughes et al., 2020). A preprint by 
(Rothschild et al., 2020) suggests that large cohort studies may require thousands of 
participants on order to reach 20% explanatory power for a certain host-trait with specific 
microbiota-associated metrics (Shannon diversity, relative microbial abundance). The 
collection of metadata is important to allow for a better comparison between studies and to 
identify differentially abundant microbes arising from confounding variables. 
3.15.2 Reporting of Effect Sizes and Confidence Intervals  
The magnitude of the effect size is also important to consider, as the microbiome is a 
dynamic system, and effect size measurements prove more informative than p-values alone 
though they are seldom reported (Sullivan and Feinn, 2012). In addition, tools involving 
linear discriminant analysis for identifying differentially expressed microbes and their effect 
sizes do not consider the compositional nature of microbiome data. Unfortunately, most 
studies did not report effect sizes.  
4.0 Conclusion 
Though the evidence for the involvement of individual microbial genera or GBMs related to 
SCFA, tryptophan or bile acid metabolism within humans is weak, we found several salient 
findings and features within these datasets. GBMs allow us to search metagenomic data for 
specific neuroactive metabolic pathways leading to mechanistic insights. Within a very short 
time after their release, several human (Butler et al., 2020; Chen et al., 2019; Tomizawa et al., 
2019; Zhu et al., 2020) and preclinical studies have taken advantage of their descriptive 
properties (O’Connor et al., 2020; Van de Wuow et al. 2020).    
Many studies involving healthy humans are currently investigating associations between 
temperament, cognition and personality across the lifespan. While these studies may continue 
to find various associations, without proper compositional data analysis these associations are 
likely spurious and biased towards negative correlations (Gloor et al., 2017). Even with 
compositional data methods, finding explanatory genera or ASVs may require thousands of 
participants to power the study (Hughes et al., 2020). 
Neurodevelopmental disorders accounted for many of the human-microbiome-brain studies. 
While a WGS study suggests reductions in the KO abundance of dopamine pathways in 
ADHD (Wang et al., 2020b), it is hindered by a lack of compositional analysis. Other studies 
suggested correlations between Faecalibacterium, Ruminococcus and Ruminoclostridium 9 
with symptoms of ADHD (Jiang et al., 2018b, Szopinska-Tokov et al., 2020). These 
microbial genera may alter SCFA or tryptophan related pathways but must be further 
validated through metabolomic methods. Across dozens of ASD studies, very few 
consistencies were found across these studies. When reanalyzing raw microbiome data, very 
few differentially regulated microbes or GBMs reached the significance and effect size 
thresholds. In the dataset from Son et al. (2015), there were no differences in microbial 
composition within a sample of twins discordant for ASD. However, some of these studies 
suggested the important interplay between diet and faecal SCFAs within ASD (Berding and 
Donovan, 2019, Liu et al., 2019d, Wang et al., 2020e). Meanwhile there is moderate level of 
evidence that Lactobacillus and Bifidobacteria are dysregulated amongst multiple 
schizophrenia studies, as well as dysregulation within SCFA and tryptophan-related GBMs 
(Zhu et al., 2020, Xu et al., 2020, Schwarz et al., 2018, Shen et al., 2018). While there are 
difficulties in determining strong associations because of the diversity and new nomenclature 
of Lactobacillus genera (Zheng et al., 2020a), we found evidence of broad dysregulation 
across most existing schizophrenia studies.  
In one longitudinal study assessing the impact of ketogenic diet on the microbiota of young 
epileptic children, we found increased abundance of the Tryptophan Biosynthesis and S-
Adenosyl Methionine Biosynthesis GBMs (Lindefeldt et al., 2019). This would imply 
different mechanisms for the efficacy ketogenic diet on epilepsy than seen in mice (Olson et 
al., 2018). In studies assessing the overall microbial differences found in epilepsy, we found 
that most studies assessed different cohorts making them difficult to compare with each other. 
These results are not consistent with the findings in mice by Olson et al. (2018). In mice, the 
gut microbiota is required for mediating the anti-epileptic effects of the ketogenic diet; 
specifically, Akkermansia and Parabacteroides were implicated as mediators (Olson et al., 
2018). In healthy adult humans, there is evidence that the ketogenic diet alters the gut 
microbiota and intestinal immunity, but more studies are needed to determine the 
mechanisms of anti-epileptic effects in humans (Ang et al., 2020).  
Across neurodegenerative disorders, there is evidence of changes in SCFA and tryptophan-
related GBM abundance in AD and MCI (Li et al., 2019a). However, most of this evidence is 
emergent from one reanalyzed study. Though the microbiota is an intriguing target for 
amytotrophic lateral sclerosis and multiple systems atrophy, we did not find enough studies 
investigating this link to warrant a consensus. Preclinical evidence suggests PD pathogenesis 
can be initiated through α-Synuclein overexpression in the myenteric plexus, reaching the 
brain through the vagus nerve (O'Donovan et al., 2019, Holmqvist et al., 2014, Ulusoy et al., 
2013, Uemura et al., 2018, Manfredsson et al., 2018). However, when reanalyzing raw data 
and accounting for recorded metadata we did not find evidence of consistent gut microbiota 
alterations. While PD is progressive and features many different subtypes, it may be 
necessary to stratify participants by medication and subtype. Nonetheless, this was a 
somewhat surprising finding. 
A lack of dietary metadata may have hindered cross-comparison across alcohol-dependence 
studies. Though various genera involved in SCFA and tryptophan metabolism were identified 
across many of these datasets (Bjorkhaug et al., 2019, Seo et al., 2020, Dubinkina et al., 
2017, Leclercq et al., 2014). Even with a small sample size consisting of 10 tobacco smokers 
and 10 controls, we found an increased abundance of the tryptophan degradation module and 
a reduction of the propionate synthesis III (Stewart et al., 2018). In addition, studies 
investigating the impact of recreational drug-use also reported differences in tryptophan and 
SCFA-associated genera (Fulcher et al., 2018, Panee et al., 2018). This must be taken into 
consideration when collecting metadata, as some of the strong microbiota-related changes 
between two groups may be explained by alcohol and drug use. 
Reductions in faecal SCFA concentrations were reported in two studies investigating 
demyelinating diseases (Gong et al., 2019, Zeng et al., 2019). It is unclear if this is a result of 
subtle microbiota changes or gastrointestinal physiology within the disease group. 
There are too few fibromyalgia and migraine microbiome-related studies to make definitive 
conclusions. However, one fibromyalgia study found altered microbial species associated 
with SCFA and tryptophan metabolism, as well as changes in serum levels of SCFAs 
(Minerbi et al., 2019). Similarly the sole migraine-microbiota study reported an increased 
abundance of the kynurenine synthesis GBM (Chen et al., 2019). While few taxa were 
consistently associated with psychological metrics within IBS, interventions involving faecal 
matter transplantation of material high in Bifidobacterium (Mizuno et al., 2017b) or probiotic 
Bifidobacterium strains (Ma et al., 2019b, Pinto-Sanchez et al., 2017a) may improve the 
psychological dimensions of this disease. 
Across studies of obesity involving 16S and WGS methods, we did not find differentially 
abundant microbes and microbial metabolic pathways consistently associated with 
psychological aspects of obesity. When reanalyzing studies of anorexia, we found an 
increased abundance in isovaleric acid synthesis I, quinolinic acid synthesis, quinolinic acid 
degradation when comparing anorexia to control individuals (Mack et al., 2016).  While the 
ClpB GBM, produced by Escherichia coli (Tennoune et al., 2014), was elevated at admission 
compared to controls, after weight gain it was ameliorated (Mack et al., 2016). It is unclear 
whether microbial-host pathways involving ClpB and hunger also interact with SCFA and 
tryptophan metabolism.  
Due to the heterogeneity of stroke and vascular disease conditions, it is difficult to make 
substantial comparisons between studies. However, (Polster et al., 2020) report convincing 
evidence for the involvement of specific microbial genera/species and a neurovascular 
condition in humans. However, rather these taxa were linked to LPS biosynthesis rather than 
SCFA production (Polster et al., 2020). 
Several studies suggest lasting microbial changes in response to prenatal or postnatal stress 
(Naude et al., 2019, Hantsoo et al., 2019, Carlson et al., 2018) though these do not provide 
evidence for the involvement of SCFA, tryptophan or bile-acid modifying bacteria. Similar to 
stress, there are very few studies assessing the impact of posttraumatic stress disorder on the 
microbiota. Though multiple studies have assessed the microbiota composition in bipolar 
disorder, there were no consistent signatures across studies. In fact, one study found sex 
effect, heritability and smoking explained all observed changes in the gut microbiota between 
bipolar disorder and controls (Coello et al., 2019). Meanwhile, across studies of anxiety and 
depression there is moderate evidence for Dialister and Faecalibacterium reductions in 
depression and anxiety (Valles-Colomer et al., 2019, Jiang et al., 2015, Jiang et al., 2020, 
Jiang et al., 2018a, Stevens et al., 2018). It is unclear if the metabolic pathways that these 
microbes contribute to, mainly SCFA and tryptophan-related pathways, impact the host 
phenotype. 
5.0 Future Directions 
In part due to the many limitations of existing 16S and WGS studies as well as their collected 
metadata, we did not find many consistent changes in the gut microbiota or their associated 
metabolic pathways. Despite the limitations outlined in Section 3.15, there is still potential 
for rigorous, well-designed human studies to uncover the potential roles of these metabolites. 
Figure 2 briefly outlines the potential pathways and known interactions of SCFAs, 
tryptophan metabolism and deconjugated bile acids in brain function and health. Although 
none of these pathways have been directly linked to changes in the gut microbiota, we are 
hopeful that consensus guidelines for sequencing and downstream analysis of the human 
microbiota will contribute to uncover these changes. It is also difficult to compare studies 
within a human disease without the multiple publicly available datasets, detailed dietary 
information and medical information, effect sizes, confidence intervals or detailed 
bioinformatics procedures. The widespread use of relative abundance as opposed to methods 
incorporating the compositional nature of the microbiota (i.e. using the CLR transformation) 
is problematic within the microbiome field (Gloor et al., 2017, Gloor et al., 2016, Fernandes 
et al., 2014, Fernandes et al., 2013). Reporting effect sizes along with 95% confidence 
intervals when finding differentially abundant microbes or metabolites would increase the 
interpretability of these results. For example, if a differentially abundant microbe is increased 
in one group, but its effect size has a very small lower bound (i.e. a large negative value), this 
is indicative of a spurious finding. 
We provide some guidelines for scientists analyzing their microbiome data when building 
their pipeline and selecting their methodology (see Box 1).  
In conjunction with metabolomic and proteomic studies, consistent well-designed 
bioinformatics pipeline can identify the involvement of microbially-associated SCFA, 
tryptophan and bile acid metabolites. There are still important questions that must be 
addressed or considered when designing these studies (see Box 2).  
While we may  standardize protocols and adapt to new sequencing platforms in the future, 
some researchers suggest the development of microbiome standards to better quantify 
microbial abundance within a sample (Ji et al., 2019, Venkataraman et al., 2018, Tourlousse 
et al., 2018, Vandeputte et al., 2017, Stämmler et al., 2016, Tkacz et al., 2018). In addition, a 
biobank of standardized references could be shared as controls across multiple studies (see 
Box 3). 
This analysis provides a novel approach for understanding the mechanisms behind 
metabolite-mediated communication within the MGBA and reiterates many technical and 
bioinformatics considerations that must be acknowledged when interpreting results. Despite 
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 Figure Captions 
Graphical Abstract. Dietary fibres, proteins and fats that are ingested by the host contain 
components which are metabolized by the host microbiota. Short-chain fatty acids (SCFAs) 
are produced from the fermentation of fibres and tryptophan-kynurenine (TRP-KYN) 
metabolites from dietary proteins. Primary bile acids derived from liver metabolism of aid in 
lipid digestion but can be deconjugated and bio-transformed into secondary bile acids. 
Though it’s is unclear how these metabolites impact brain health and disease, we can look 
towards existing studies of faecal microbiota composition in humans for evidence. Inter-
individual physiological variance as well as many technical and bioinformatics limitations 
hindered the replication of results across studies. However, by reanalyzing 35 studies with a 
consistent pipeline and comparing these results to other existing studies we found mild-to-
moderate evidence of the involvement of these metabolic pathways in Alzheimer’s disease, 
schizophrenia and anxiety/depression.  
Figure 1. Microbial metabolic pathways. A summary of pathways used by different 
microbes to generate SCFA, tryptophan-kynurenine or bile acid related metabolites. Due to 
the amount of different microbial genera known to generate these metabolites, only a subset 
of these microbes is referred to in this figure. Many different genera use multiple metabolic 
pathways; it is yet unclear if all human enzymes in the kynurenine/tryptophan pathway are 
found in the microbiome. 5-HTP: 5-hydroxytryptophan; 5-HT: serotonin; AADC: aromatic 
amino acid decarboxylase; IDO1: indoleamine-2,3-dioxygenase; TDO1: tryptophan-2,3-
dioxygenase; TH: tryptophan hydroxylase; K3H: kynurenine-3-hydroxylase; KAT: 
kynurenine amino-transferase; BSH: bile salt hydroxylase. 
Figure 2. Potential pathways for microbiota-gut-brain axis communication. While it’s is 
unclear exactly how microbial-derived metabolites impact the brain, there are several 
potential pathways. Non-digestible fibres are broken down into SCFAs which act as histone 
deacetylase inhibitors on FOXP3+ TReg cells in the gut, leading to clonal expansion. SCFAs 
many also influence the enteric dendritic and marcrophage cell population by increasing 
acetylation at specific gene targets. This leads to a decreased release of interleukin-6, 
interleukin-10 and interleukin-12. SCFAs may also affect enterochromaffin cells in the gut, 
stimulating the release of serotonin into the lumen. Travelling through the blood, the SCFA 
butyrate may increase occludin expression at the blood-brain barrier as well as decrease its 
permeability to different molecules. If present in a sufficient concentration, SCFAs may 
impact microglial maturation through free-fatty acid receptor-mediated mechanisms. Bile 
acids used to aid in lipid digestion are deconjugated and biotransformed into secondary bile 
acids. These act on myenteric neurons to inhibit gut motility. In the brain, there is evidence 
that the secondary bile acid, deoxycholic acid (DCA) is associated with cognition. 
Tryptophan derived from dietary protein sources impacts both the enteric and central nervous 
system environments. Briefly, bacteria may generate indole molecules which can act on 
myenteric neurons to increase gut motility. Tryptophan (TRP) or 5-Hydroxytryptophan (5-
HTP) are also generated from dietary protein sources. TRP and 5-HTP can be converted into 
5-HT in enterochromaffin cells. In the brain, indoles impact immunity through activation of 
the Aryl-Hydrocarbon receptor in astrocytes. Alternatively, TRP or 5-HTP can be transported 
across the blood-brain barrier and converted into the neurotransmitters 5-HT, quinolinic acid 
or kynurenic acid. It is unclear what role the vagal nerve pathway plays in mediating 







Box 1: Guidelines for metadata and bioinformatics analysis of human-microbiome-
brain studies 
1. If at all possible, ensure that extensive metadata is collected, including dietary intake, 
medication, supplement use, etc. 
2. Make sure all software is up-to-date. 
3. Use SILVA or other curated taxonomy databases instead of Greengenes. 
4. Use compositional data method to transform the counts tables (ex. CLR). 
5. Use compositional analysis methods to check for significance and employ a strict 
effect size cut-off. 
6. Use compositional alternatives to standard correlational statistics. 
7. Report effect sizes and confidence intervals along with p-values and p-adjusted 
values. 
8. When possible, provide open access to datasets, scripts and pipelines to reproduce the 
results. 
 
Box 2: Questions crucial for understanding the interactions between microbial 
metabolic pathways and the brain 
1. How ubiquitous is the expression of any specific GBM across the same 
genera/species? 
2. How explanatory are GBMs compared to metabolomic and proteomic faecal analysis? 
3. Can we accurately develop a GBM framework for bile-acid metabolism? 
4. How do we address causality when many microbes possess enzymes for multiple gut-
brain modules? 
5. How do we design studies to avoid the pitfalls of interindividual variation within the 
microbiome, metabolism and disease subtype/severity? 
Box 3: Methods to improve cross-study replicability and provide more accurate 
microbial quantification 
1. Decomposition of Variance Using Replicate Sampling: A combination of using 
technical replicates and spike-in controls to estimate absolute abundance. 
2. Spike-In: Adding a known amount of synthetic 16S rRNA sequences to samples for  
estimation of absolute abundance. 
3. Reference Materials and Biobank: Collecting and storing faecal samples from  
different cohorts of healthy individuals. This material would provide controls for 
multiple studies. It would allow for accurate quantification of variability between 





































Table 1. Microbiome-brain studies of healthy human cohorts.  
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; *: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are highlighted; 95% CI reported between square brackets [lower 
95% CI; upper 95% CI] 
 


















WGS (no) N = 63 Infants Negative Emotionality (High vs 
Low Scoring Group) 
↑ Bifidobacterium 
pseudocatenulatum (LFC: 4.085) 
↓ Streptococcus vestibularis (LFC – 
3.12) 
Regulation/Orienting (High vs Low 
Scoring Group) 
↑ Bifidobacterium 
pseudocatenulatum (LFC: 4.085) 
↑ Bifidobacterium catenulatum (LFC: 
4.177) 
Functional Connectivity: Left 
Default Network  (High vs Low 
Scoring Group) 
↓ Clostridium perfingens (LFC: 
3.559) 
Functional Connectivity: Left 
Fronto-Parietal Network (High vs 
Low Scoring Group) 
↑ Enterococcus fragilis (LFC: 3.765) 
↑ Collinsella  (LFC: 3.665) 
↑ Clostridium disporicum (LFC: 
3.415) 
↑ Prevotella copri(LFC: 3.415) 
Negative 
Emotionality (High 
















Default Network  







None  (Kelsey et 
al., 2021) 
↑ Clostridium perfingens (LFC: 
3.415) 
↑ Clostridium tertium (LFC: 3.367) 
↑ Clostridium (LFC: 3.167) 
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↓ Streptococcus salivarius (LFC : 
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16S (no) N = 34 Infants None None None  (Rosin 
et al., 
2020) 
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16S (no) N = 51 Infants 
(42 taking 
probiotics) 
Bifidobacterium** associated with 
soothability 
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2020b) 
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i et al., 
2019) 
16S (no) N = 39 None None None No genus-level 
associations with 
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16S via 454 
Pyrosequenc
ing (no) 
N = 77 Infants None None None  (Christi















16S (no) N = 15 
Probiotics 
N = 15 Placebo 
Probiotics vs Placebo 
↑ Bacteroides sp.; 
associated with response accuracy neutral stimuli scores*, 
general depression scale*  
 
Probiotics vs Placebo 
↑ Bacteroides sp.; 
associated with response accuracy neutral stimuli scores*, 
general depression scale*  
None Rarefaction (Bagga 
et al., 
2018) 
16S (no) N = 135 Healthy 
Individuals 
When accounting for fibre intake 
In males, DASS-42 anxiety scores 
negatively correlated with Blautia 
abundance 
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al., 
2018) 
16S (no) N = 655 Sociability (combination of 
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16S via 454 
Pyrosequenc
ing (no) 
N = 40 Healthy 
Women 
(N = 33 in 
Prevotella 
cluster, N = 7 in 
Bacteroides 
cluster) 
High Prevotella abundance 
associated with negative affect after 
negative valence picture block  
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Sleep 16S (yes) N = 10 
Insomnia 











 (Liu et 
al., 
2019a) 
16S (no) N = 113  
Focus on sleep 
Disruptions in sleep across stages in 
Prevotella enterotype 
None None  (Ko et 
al., 
2019) 
16S (no) N = 22 None None None  (Liu et 
al., 
2020c) 
16S (no) N = 8 Control 





Eubacterium* (rho = 0.785) 
Wake After Sleep Onset 
Escherichia** (rho = 0.915) 
Klebsiella* (rho = 0.768) 
Arousals Index 
Clostridium* (rho = 0.852) 
Ruminococcus* (rho = 0.738) 
Oscillospira* (rho = 0.842) 
None None  (Valenti
ni et al., 
2020) 
16S (no) N = 20 Acute 
Insomnia 
Disorder (AID) 
N = 38 Chronic 
Insomnia 
Disorder (CID) 
N = 38 Control 
 
AID vs Control 
↑ Bacteroides* 
↓ Lachnospira* 





CID vs Control 
↑ Bacteroides* 
 
  (Li et 
al., 
2020c) 




on et al., 
2017) 
16S (no) N = 35 
Narcolepsy 
Type 1 (NT1) 
N = 41 Control 








e et al., 
2020) 
16S (no) N = 24 Negative Associations 
Sleep efficiency and total sleep time: 
Blautia 




Number of awakenings: 
Coprococcus, Neisseria 










16S (no) N = 11 MCI 
with Risk of AD 
















↑ Bifidobacterium after 
Mediterranean Ketogenic Diet in 
MCI but not in Controls 
↑ Bifidobacterium 
after Mediterranean 
Ketogenic Diet in 
MCI but not in 
Controls 
 








16S (no) N = 26 PBO 





bifidum BGN4 and 
Bifidobacterium 
Probiotic vs PBO 
↓ Eubacterium 
 
In probiotic group 
Eubacterium negatively correlated 
with serum BDNF 
None None  (Kim et 
al., 
2020) 
longum BORI (1 × 
109 CFU/d)  
 
2 week washout 
16S via 454 
Pyrosequenc
ing (no) 
N = 37 Aged N 
= 39 Aged with 
Cirrhosis 





None None  (Bajaj et 
al., 
2016) 
T-RFLP (no) N = 34 
Dementia 
N = 94 Controls 
Dementia vs Control  
↓ Bacteroides 
 






Table 2. Microbiome-brain studies involving neurodevelopmental disorders. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; *: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are highlighted; 95% CI reported 



















16S (yes) N = 19 ADHD 
N = 77 Control 





WGS (no) N = 17 ADHD 
N = 17 HC 
ADHD vs Control 
↓ Faecalibacterium*  
↓ Ruminococcus gnavus*  
ADHD vs Control 







↑ Bacteroides caccae* 
 ↑ Odoribacter* 
 ↑ Enterococcus* 
 
↓ in KO terms 
for dopamine 
pathways** 
16S (no) N = 10 ADHD + 
nutrient 
intervention 
N = 7 ADHD 
(placebo) 
ADHD Associations with Symptomology 
↑ Bifidobacterium associated with lower ADHD-IV-RS score 
(t = −2.3, df = 15, p = 0.04); possibly due to 3 outliers 
 
 










16S (no) N = 14 ADHD 
N = 17 Control 
















16S (no) N = 42 ADHD 
N = 15 
Subthreshold 
ADHD 
N = 50 HC 
ADHD vs Control 
↑ Ruminoclostridium 9*, 
Ruminococcus 2*  
 
ADHD Medicated vs ADHD 
Unmedicated 
Ruminococcus 2 (B = 1.525, P = 
0.001) associated with inattention 
score 





16S (no) N = 30 ADHD 
N = 30 Control 






ADHD vs Control (Species-Level) 
↑ Bacteroides uniformis 
↑ Bacteroides ovatus 
↑ Sutterella stercoricanis 
↓ Bacteroides coprocola 
 





















N = 51 ADHD N 
= 32 Controls 






associated with total CPRS Score 
(Pearson Correlation: p < 0.001, R2 = 
-0.564) and hyperactivity index score 
(Pearson Correlation: p < 0.037, R2 = 
-0.294)  
 




qPCR (no) N = 35 Placebo 
N = 40 Probiotic 
↓ Bifidobacterium spp. at 6 weeks of life in children that 
developed ASD/ADHD 
None  (Pärtty 
et al., 
2015) 





N = 36 ASD 
N = 21 Control 




16S (yes) N = 51 ASD 
N = 40 Control 
None None None  (Son 
et al., 
2015) 
16S (yes) N = 20 ASD 
N = 20 Control 
ASD vs Control 
↑ Roseburia*** (effect = 0.9 [-1.9; 
10.38] 
 




16S (yes) N = 20 ASD 
N = 19 Control 
None 
 
None None  (Kang 
et al., 
2019) 
16S (yes) N = 20 ASD 
N = 19 Control 
ASD with ATEC score below 
median (62) vs ASD with score 
above median 
↓ Ruminoclostridium 9* (effect = 




None  (Kong 
et al., 
2019) 
16S (yes) N = 20 ASD 
Faecal samples 
taken before and 
after Vitamin A 
supplementation 











N = 40 ASD 
N = 40 Controls 
None None None  (Strati 
et al., 
2017) 
















WGS (no) N = 39 ASD 
N = 40 Control 
ASD vs Control 
↑ Veillonella parvula 
↑ Butyrivibrio unclassified 
↑ Streptococcus pasteurianus 
↑ Lactobacillus rhamnosus 
↑ Megasphera micronuciformis 
↑ Lachnospiraceae bacterium 
6163FAA 
↑ Haemophilus haemolyticus 
↓ Bifidobacterium longum 
↓ Prevotella copri 
↓ Bacteroides stercoris 
↓ Dorea unclassified 
↓ Lachnospiraceae bacterium 
1456FAA 
↓ Eubacterium limosum 
 













WGS (no) N = 30 ASD 
N = 14 Controls 




WGS (no) N = 166 Infants 
aged 6 weeks 
N = 158 Infants 
aged 1 year 
N = 129 Infants 
aged 2 years 
N = 140 Infants 








At One Year 
Blautia producta + association with 
SRS-2 
At Two Years 
Coprococcus + association with SRS-
2  
Ruminococcus gnavus + association 
with SRS-2  
Bifidobacterium + association with 
SRS-2 
Sutterella + association with SRS-2 
At Three Years  
Bytyricoccus pulliacaerum  
– association with SRS-2 
  
 





None  (Laue 
et al., 
2020) 







N = 92 ASD 
N = 42 Control 
ASD vs Control 
↑ Eggerthella lenta*  
↑ Eggerthella lenta DSM2243* 






















N = 143 ASD 
N = 143 Controls 
WGS: 
N = 30 ASD with 
Constipation (C-
ASD) 
N = 30 Non-
Constipated ASD 
(NC-ASD) 
N = 30 Controls 




↓ Prevotella 9 
↓ Megamonas 
↓ Ruminococcus 2 
 
C-ASD vs NC-ASD 
↑ Alistipes** 
↑ Anaerotruncus** 
↑ Ruminoclostridium 6** 
↑ Ruminococcus 2** 
ASD vs Control  
↑ Bifidobacterium 
 
























16S (no) N = 77 ASD 
N = 50 Control 
ASD vs Control 
↓ Bacteroides* 
↓ Faecalibacterium* 
Negative association between 
Faecalibacterium and ASD severity 
Multiple other genera associated with 
ASD severity 
ASD vs Control 
↓ Bacteroides* 
None  (Ding 
et al., 
2020) 
16S (no) N = 60 ASD + 
Sleep disorder 
(ASD-S) 
N = 60 ASD 
without Sleep 
disorder 
ASD-S vs ASD 
↓ Faecalibacterium (also correlated 
to 3-hydroxybutyric acid abundance 
in feces) 
None None Rarefaction (Hua 
et al., 
2020) 
16S (no) N = 78 ASD 
N = 58 Controls 








ASD vs Controls 
↑ Bacteroides** 
 
None Qiime v1.9.1 
(outdated 






16S (no) N = 30 ASD 
N = 20 Control 
ASD vs Controls 
↑ Megamonas 
↓ Eubacterium 
↑ Faecal valerate 
ASD vs Controls 
↓ Eubacterium 
 




↓ Faecal butyrate 
16S (no) N = 21 ASD  
N = 23 Control    
ASD vs Control  
↓ Faecalibacterium***  










16S (no) N = 9 ASD 
N = 6 Control 




16S (no) N = 37 ASD + 
Probiotic (4 
weeks) 
N = 77 ASD (no 
Probiotic) 
N = 40 Control 
 
Faecal samples 
not analysed after 
intervention  













None  (Niu 
et al., 
2019) 
16S (no) N = 25 ASD 
N = 35 Control 






↑ Ruminococcus (different OTU 
assigned to the same genera) 








16S (no) N = 24 ASD 













Day 80 vs Baseline ASD 




Day 80 vs Baseline 
ASD 
↑ Bifidobacteriun 












↓ Acetate, butyrate, propionate; 
increases over 80 days of intervention 
↑ B. longum to control levels 
↓ Clostridium 
 
Most short term measures were not 
sustained after the end of the study 
16S (no) N = 63 ASD 
N = 27 Control 
ASD vs Control 
↑ Aenerococcus 
↑ Burkholderia,  
↑ Desulfovibrio 
↑ Oxalobacter  
↓ Bilophila 









16S (no) N = 46 ASD 
N = 16 Control 









16S (no) N = 76 ASD 
N = 47 Control 
ASD vs Control 
Focus on co-abundance groups 
finding correlations with co-abundant 
Bacteroides ASVs and various ASD 
behaviours 




16S (no) N = 14 
Unrestricted Diet 
ASD (split into 
PBO and B-GOS) 
N = 12 exclusion 
diet (split into 
PBO and B-GOS) 













16S (no) N = 48 ASD 
30 with no mental 
regression 
(ANMR) 
18 with mental 
regression (AMR) 













N = 57 Controls ↑ Clostridium boltae 
↑ Clostridium difficile 












N = 59 ASD 
N = 30 Control 






None None Greengenes, 
Qiime v1.9.1 
(outdated 







16S (no) N = 11 ASD 
N = 14 Control 
ASD vs Control 























16S (no) N = 45 ASD 
N = 45 Control 
ASD vs Control 
↓ Flavonifractor** 
 




16S (no) N = 26 ASD 
N = 32 Control  
 
Faecal butyrate associated with diet 
quality within ASD 
No butyrate producing bacteria 
reported to correlate with butyrate 










16S (no) N = 26 ASD 
N = 32 Control 
ASD + Temporally Unstable 










16S (no) N = 6 ASD 
N = 6 Control 
ASD vs Control 
↓ Blautia 
↓ Faecalibacterium 
None None  (Inoue 
et al., 
2016) 
16S (no) N = 6 ASD 
Probiotic then 
PBO 











16S (no) N = 35 ASD 
N = 6 Control 









16S (no) N = 21 
ASD+GI 
problems (ASDGI) 
N = 29 
ASDnoGI 
N = 34 
ControlnoGI 
N = 7 ControlGI 
None 
 








N = 51 ASD 




Controlled for GI 
Dysfunction 








N = 10 ASD 




N = 10 Control 
Bacteria assessed at species-level; 
impossible to do reliably with 16S 












N =23 ASD 
without GI 
dysfunction 
N = 28 ASD with 
GI dysfunction 
N = 53 
neurotypical 
siblings 
No significant microbiome 
differences found 




qPCR (no) N = 41 ASD 
N = 45 Non-ASD 
Siblings 
N = 45 Control  








ASD vs Control 
↑ Bacteroides* 
 


























qPCR (no) N = 30 ASD 
N = 30 Control 
ASD vs Control 
↑ Clostridium difficile*** 
↑ C. paraputrificum* 
↑ C. clostridioforme*** 
↑ C. bolteae*** 
↑ C. clostridioforme*** 




qPCR (no) N = 23 ASD 
N = 22 Non-ASD 
Siblings 
N = 9 Control 
ASD vs Control 
↑ Sutterella spp.* 
 
Non-ASD Siblings vs Control 
↑ Sutterella spp.* 
None None  (Wang 
et al., 
2013) 
qPCR (no) N = 10 ASD 
N = 10 Control 
Siblings 
N = 9 Unrelated 
Controls 
Desulfvibrio correlated to autism 
intensity with ADI RRB 
 
ASD vs Unrelated Control Baseline 
↑ Lactobacillus spp.*** ( no 
difference with siblings) 
 
ASD After Probiotic vs Before 
Probiotic 
↓ Bifidobacterium spp.*** 
↓ Desulfvibrio spp.*** 
ASD vs Unrelated 
Control Baseline 
↑ Lactobacillus 




ASD After Probiotic 








Schizophrenia 16S (yes) N = 64 SZ 
N= 53 Control 
SZ vs Control 
↑ Fusicatenibacter*** (effect = 
0.67[-1.48; 7.56]) 
None None  (Shen 
et al., 
2018) 
16S (yes) N = 40 SZ 
N = 40 Control 
SZ vs Control 
↓ Lactobacillus*** (effect = -1.28 [-
12.85; 0.11]) 
↑Fusicatenibacter*** (effect =1.06 [-
1.05; 7.60]) 
↑ Ruminococcus 1***(effect = 0.80 [-
2.23; 7.33] 
Butyrate Synthesis II*** (effect = 
0.61 [-1.83; 5.41]) 
↑ Kynurenine synthesis*** (effect = 
0.68 [-2.10; 6.12]), Inositol 
Degradation*** 
SZ vs Control 
↓ Lactobacillus*** 
(effect = -1.28 [-12.85; 
0.11]) 
 
SZ vs Control: 
↓ Histamine 
Synthesis* 
(effect = -0.48 
[-5.41; 1.89]) 
 (Xu et 
al., 
2019) 
(effect = 0.83 [-1.58; 6.96]), 
 
 
16S (yes) N = 21 taking 
atypical 
antipsychotics 
N = 16 taking 
Lithium or 
Lamotragine 




16S (yes) N = 25 SZ 
N = 25 Controls 






WGS (no) N = 84 SZ 
N = 84 Control 
SZ vs Control: 
↑ Bifidobacterium adolescentis***  
↑ Clostridium perfringens*** 
↑ Lactobacillus gasseri*** 
 






None  (Xu et 
al., 
2019) 
WGS (no) N = 90 drug-naïve 
SZ 
N = 81 Control 
SZ vs Control 
↑ Eubacterium siraeum*  
↑Bacteroides plebius*  
↑ Bifidobacterium adolescentis* 
↑ Bifidobacteriun bifidum* 
↑ Bifidobacteriun dentium* 
↑ Bifidobacteriun longum* 
↑ Clostridium bolteae* 
↑ Clostridium ramosum* 
↑ Clostridium symbiosum* 
↑ Enterococcus faecium* 
↑ Lactobacillus crispatus*, 
↑ Limosilactobacillus fermentum* 
 
 
↓ Clostridium perfogens* 
↓ Bacteroides intestinales* 
↓ Bacteroides finegoldii* 
↓ Lactococcus lactis* 


























↓ Lactobacillus acidophilus* 









WGS (no) N = 28 First 
Episode Psychosis 
(FEP) 
N = 16 Matched 
Controls 
FEP vs Controls 
↑ Lactobacillus 
 







16S (no) N = 40 Drug 
Naive SZ (DSZ) 
N= 85 Treated SZ 
(TSZ) 
N = 69 Control 
TSZ vs DSZ 
↑ Escherichia (LFC = 1.65)*** 
↑ Fusobacterium (LFC = 2.43)** 
↑ Megasphaera (LFC = 5.76)*** 
↑ Enterococcus (LFC = 3.69)*** 
↑ Lactobacillus (LFC = 5.02)*** 
↑ Streptococcus (LFC = 2.67)*** 
↑ Shigellia (LFC = 1.18)** 
↑ Veillonella (LFC = 2.81)*** 
↑ Clostridium (LFC = 1.26)** 
↑ Enterobacter (LFC = 1.93)** 
↑ Ruminococcus (LFC = 0.95)*** 
↑ Sutterella (LFC = 1.06) 
 
DSZ vs Control 
↑ Escherichia (LFC = 1.86)*** 
↓ Fusobacterium (LFC = -2.99)*** 
↓ Megasphaera (LFC = -4.60)*** 
 
TSZ vs Control 
↓ Bacteroides (LFC = -0.73)** 
↑ Enterococcus (LFC = 2.82)*** 
↑ Lactobacillus (LFC = 3,74)*** 
↑ Parabacteroides (LFC = -0.76)** 
↑ Shigella (LFC = 1.66)*** 
↑ Streptococcus (LFC = 1.29) 
TSZ vs Control 
↑ Enterococcus (LFC 
= 3.69)*** 
↑ Lactobacillus (LFC 
= 5.02)***5.02)*** 
 
TSZ vs Control 
↓ Bacteroides (LFC = 
-0.73)** 
↑ Enterococcus (LFC 
= 2.82)*** 








↓ Turcibacter (LFC = -2.04)*** 
↑ Veilonella (LFC = 2.31)*** 
↑ Clostridium (LFC = 1.67)** 
16S (no) N = 82 SZ 
N = 80 Control 





↑ Corynebacterium (negatively 
assocaited with negative SZ 
symptoms) 
↑ Succinovibrio(correlated to severity 





SZ vs Control 
↑ Lactobacillus 
 




16S (no) N = 48 SZ 
N = 48 Control 
SZ vs Control 
No genera-level differences identified 




16S (no) N = 26 SZ with 
no history of 
violence 
N = 16 SZ with 
violent behaviours 
(SZV) 
SZV vs SZ 
↓ Delftia  
↓ Allobaculum 
 
None None  (Chen 
et al., 
2021) 
16S (no) N = 29 SZ in 
remission 






Remission vs Acute SZ 
↑ Clostridium sensu stricto 
None None  (Pan 
et al., 
2020) 
16S (no) N = 81 High Risk 
of Psychosis 
N = 69 Control 
Ultra High Risk vs High Risk 
↑ Lactobacillus 
↑ Prevotella 
None None Rarefaction (He et 
al., 
2018) 
N = 19 Ultra High 
Risk of Psychosis 
 
16S (no) N = 30 patients 
B. breve A1 
probiotic given 
daily for 4 weeks, 
washout for 4 
weeks 
1*1011 CFU daily 
Responders vs Non-Responders (4 
weeks vs Baseline) 
↑ Parabacteroides*  
Improved HADS and PANSS 








16S (no) N = 20 
Sampled before 
olanzapine and 
after 7 day 
washout 6 weeks 
later 

















16S (no) N = 16 Controls 





Schizophrenia vs Control 
↓ Faecalibacterium 
↓ Fusicatenobacter 
↓ Coprococcus 1 
↓ Coprococcus 2 
↓ Butyricoccus 
↑ Actinomyces 






↑ Ruminoccocus gnavus 












16S (no) N = 63 
Schizophrenia 
N = 69 Controls 























Post- vs Pre- Prebiotic Intake 
↑ Bifidobacteirum** 
↓ Clostridium XIVa* 
 








qPCR (no) N = 41 SZ 
N = 41 Control 
 
SZ vs Control 
↑ Clostridium coccoides*** 
↓ Bifidobacterium spp.*** 
↓ Escherichia coli*** 
↓ Lactobacillus spp.*** 
 
Ameliorated after 24 weeks of 
risperidone 













16S (yes) N = 30 with 
PANS/PANDAS 
N = 70 Controls 







16S (yes) N = 8 RTT 
N = 10 Control 
RTT vs Control 
↑ Faecal iso-butyrate** 
↑ Faecal iso-valerate** 
 








N = 50 RTT 
N = 29 Control 
RTT vs Control 
↑ Faecal propionate* 
↑ Faecal iso-butyrate*** 
↑ Faecal iso-valerate** 
No differences even when 
accounting for constipation and 
severity 




Table 3. Microbiome-brain studies involving epilepsy. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; *: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are highlighted; 95% CI reported 
between square brackets [lower 95% CI; upper 95% CI] 














Epilepsy WGS N = 12 Patients 
with epilepsy – 
before and after 
ketogenic diet 
After diet vs Before 
↑ L-tryptophan biosynthesis* (effect 
= 0.9 [-1.07; 10.67]) 
 



















16S (yes) N = 25 Cerebral 
Palsy with 
Epilepsy (CPE) 
N = 21 Control 
CPE vs Control 
↓ Acidaminococcus (effect = -1.14 [-
9.60; 1.17])*** 
↓ Akkermansia (effect = -1.52 [-
11.32; 0.40])*** 
↓ Alistipes (effect = -1.33 [-10.13; 
0.48]) 
CPE vs Control 
↓ Bacteroides (effect = 
-0.72 [-7.75; 2.23])*** 
↓ Bifidobacterium 








↓ Bacteroides (effect = -0.72 [-7.75; 
2.23])*** 
↓ Bifidobacterium (effect = -2.97 [-
24.09; 0.35]) *** 
↓ Blautia (effect = -1.83 [-14.30; 
0.41]) 
↓ Catenibacterium (effect = -1.67 [-
11.67; 0.60]) *** 
↓ Clostridium sensu stricto 1 (effect 
= -0.96 [-11.22, 0.81]) *** 
↓ Collinsella (effect = -1.88 [-12.63; 
0.41]) *** 
↓ Desulfovibrio (effect = -1.40 [-
11.91; 0.53]) *** 
↓ Enterococcus (effect = -1.56 [-
13.23; 0.46]) *** 
↓ Escherichia/Shigella (effect = -1.73 
[-14.91; 0.43]) *** 
↓ Eubacterium (effect = 1-.09 [-
10.91; 0.61]) *** 
↓ Faecalibacterium (effect = -1.70 [-
12.12; 0.37])*** 
↓ Flavonifractor (effect = -0.98 [-
9.93; 1.26])*** 
↓ Gemella (effect = -0.97 [-9.03; 
1.85])*** 
↓ Haemophilus (effect = -0.95 [-8.94; 
1.39])*** 
↓ Klebsiella (effect = -1.27 (-10.67; 
0.93])*** 
↓ Lactobacillus (effect = -0.70 [-8.59; 
2.31])** 
↓ Methanobrevibacter (effect = -0.89 
[-8.59; 0.78])*** 
↓ Neisseria (effect = -0.70 [-8.07; 
2.44])** 
↓ Oscillibacter (effect = -1.10 [-
10.04; 1.18])*** 
↓ Eubacterium (effect 
= 1-.09 [-10.91; 0.61]) 
*** 
↓ Lactobacillus (effect 




↓ Parabacteroides (effect = -1.95 [-
13.85; 0.39])*** 
↓ Prevotella_2 (effect = -0.67 [-8.09; 
2.23])** 
↓ Prevotella_9 (effect = -1.08 [-9.34; 
0.90])*** 
↓ Ruminiclostridium_5 (effect = -1.06 
[-9.16; 1.20])*** 
↓ Ruminiclostridium_9 (effect = -0.79 
[-9.80; 1.25])*** 
↓ Streptococcus (effect = -2.20 [-
19.31; 0.38])*** 
↓ Sutterella (effect = -0.79 [-12.31; 
0.56])*** 
↓ Veillonella (effect = -1.32 [-10.60; 
0.45])*** 
16S (no) N = 30 
Idiopathic Focal 
Epilepsy 
N = 10 Control 
None None None  (Safak 
et al., 
2020) 
16S (no) N = 55 Epilepsy 
N = 46 Control 
For validation 
cohort: 
N = 13 Epilepsy 
N = 10 Control 
Epilepsy vs Control 
↓ Stutterella 
↓ Klebsiella 
↓ Lachnospiraceae NK4A613 





↑ Ruminococcaceae UCG 014 
↑ Ruminococcus gnavus 
↑ Megamonas 
↑ Akkermansia 
↑ Eubacteirum hallili 




Epilepsy vs Control 
↑ Bifidobacterium 





























and 6 mo. after 
diet 





↓ Lachnospiracea incertae sedis 
↑ Bacteroides  
 
Non-Responders vs Responders 
↑ Alistipes 
↑ Clostridium i 
↑ Oscillibacter 
↑ Gordonibacter 









After Diet vs Before 
↑ Bacteroides 
 
None Unclear if 
comparisons 










16S (no) N = 42 drug-
responsive 
N = 49 drug-
resistant 






































16S (no) N = 30 healthy 
infants 
N = 14 epileptic 
infants 
Difficult to interpret  
 
 








Table 4. Microbiome-brain studies involving neurodegenerative disorders. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; AD: Alzheimer’s Disease, PD: Parkinson’s Disease; MCI: mild-cognitive impairment; MSA: multiple-
systems atrophy; ALS: amyotrophic lateral sclerosis*: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are highlighted; 95% CI reported between square 

















AD and MCI 
 






N = 33 AD 
















16S (yes) N = 30 AD 
N = 30 MCI 
N = 30 Controls 
AD vs Control 
↓ Ruminoclostridium 5** (effect = -
0.67[-8.52; 1.59]) 
↑ Isovaleric-Acid Synthesis II* 
(effect = 0.42 [-2.11, 5.62]) 
↑ Acetate Synthesis III* (effect = 
0.50 [-2.04, 5.92]) 
↑ Butyrate Synthesis I* (effect = 0.44 
[-2.33, 6.25]) 
↑ Butyrate Synthesis II* (effect = 
0.52 [-3.60, 4.79] ) 
 
MCI vs Control 
↑ Isovaleric-Acid Synthesis II** 
(effect = 0.43 [-2.48; 5.98]) 
↑ Acetate Synthesis I** (effect = 0.58 
[-1.93; 5.86]) 
↑ Acetate Synthesis II* (effect = 0.47 
[-1.81; 5.33]) 
↑ Acetate Synthesis III** (effect = 
0.64 [-1.52; 6.26]) 
↑ Tryptophan synthesis* (effect = 
0.48 [-1.94, 6.71] 
↑Quinolinic Acid Synthesis** (effect 
= 0.49 [-2.02; 6.43]) 
↑Quinolinic Acid Degradation ** 
(effect = 0.56 [-1.93; 6.43]) 
 
None MCI vs Control 
↑ Glutamate 
synthesis I** 












= 0.64 [-1.61; 
7.26]) 
↑ClpB** (effect = 












(effect = -0.50 [-
7.02, 2.42] ) 




↓ Vitamin K2 
Pathway 
Synthesis II** 
(effect = -0.42 [-
1.52; 6.3]) 
 
AD vs Control 
↑ Glutamate 
Synthesis II* 
(effect = 0.45 [-
2.03; 5.63])  
↑ Histamine 
Degradation* 




= 0.54 [-2.26, 
5.82]) 
 
↓ Vitamin K2 
Pathway 
Synthesis II* 








(effect = -0.48 [-
5.90, 1.57]) 
↓ Vitamin K2 
Pathway 
Synthesis I (effect 
= -0.46 [-5.79, 
2.03]) 
WGS (no) N = 24 AD 
N = 33 Other 
Dementia  
N = 51 Controls 
AD vs Control 
↑ Bacteroides*  
↑ Alistipes***  
↑ Odoribacter***  
AD vs Other Dementia 
↑ Odoribacter* 
↓ Eubacterium***  
↓ Roseburia*  







16S (no) N = 43 AD 
N = 43 age and 
gender-matched 
controls 











16S (no) N = 25 AD 
N = 25 Control 














None Greengenes (Vogt 
et al., 
2017) 









N = 10 Control 
(Age and sex-
matched) 
AMY+ vs AMY- 
↑ Escherichia/Shigella*** 
↓ Eubacterium rectale*** 
 
AMY+ vs Control 
↑ Escherichia/Shigella*** 
↓ Bacteroides fragilis* 
↓ Eubacterium rectale*** 
 
AMY- vs Control 
↑ Escherichia/Shigella** 
↓ Eubacterium rectale** 
 



























AD after Probiotic vs Baseline 
↑ Faecalibacterium prausnitzii*** 







MSA 16S (no) N = 40 MSA 
N = 40 Control 
(spouses) 
 










Rarefaction (Du et 
al., 
2019) 
16S (no) N = 6 MSA 
N = 11 Control  




16S (no) N = 17 MSA 
N = 17 Control 
MSA vs Control 
↑ Bacteroides** 
↓ Prevotella clara* 
↓ Paraprevotella*** 
↓ Faecal acetate, propionate and 
butyrate 
 








ALS WGS  (no) N = 37 ALS 
 
N = 29 age and 
BMI-matched 
controls 
ALS vs Control 
↓ Tryptophan metabolism genes 
 
 







N = 20 ALS  
N = 20 Control 
WGS 
N = 10 ALS 
N = 10 Control 
ALS vs Control 
↑ Enterococcus columbae 





N = 66 ALS 
N = 12 
Neurodegenerativ
e Control (ND) 
ALS vs Control 
↑ Prevotella copri 











↑ Bacteroides clarus 
↑ Dorea 
↑ Escherichia 
↓ Aldercreutzia equolifaciens 
↓ Lachnospiraceae bacterium 5 1 
63FAA 
↓ Coprobacter fastidious 
↓ Ruminococcus lactaris 
↓ Eubacterium eligens 
↓ Ruminococcus sp 5 1 39BFAA 
↓ Bifidobacterium longum 
↓ Roseburia intestinalis 
↓ Eubacterium rectale 
Decrease in butyrate producers 
ALS vs ND 
↑ Ruminoccous gnavus 
↑ Veillonella parvula 
↓ Lachnospiraceae bacterium 3 1 
57FAA CT1 
↓ Lachnospiraceae bacterium 1 1 
57FAA  
↓ Lachnospiraceae bacterium 5 1 
63FAA 
↓ Parasutterella excrementihominis 
↓ Roseburia hominis 







16S (no) N = 8 ALS 
N = 8 Control 








16S (no) N = 49 Motor 
Neuron Disease 
N = 51 Control 







N = 25 ALS 
N = 32 Control 




qPCR (no) N = 50 ALS 
N = 50 Control 
ALS vs Control 
↑ Enterobacter 
↑ Escherichia coli 
↓ Clostridium 






WGS (yes) N = 31 PD 
N = 28 Controls 










N = 76 PD  





N =78 Controls 










16S (yes) N = 64 PD 
N = 64 Controls 




(effect = 0.45 [-





16S (yes) N = 80 PD 
N = 72 Controls 




16S (yes) N = 34 PD 
N = 25 Control 
PD with Low L-DOPA (<300mg/day) dose vs Control 
↓ Lactobacillus (effect = 0.83 [-2.10; 8.07] 







N = 45 PD 
N = 45 Controls 
(spouses) 







WGS (no) N = 40 PD 
N = 40 Controls 
(spouses) 







Streptococcus salivarius negatively 
correlated to L-DOPA dose 
equivalency 
Enterobacter cloacae positively 
correlated with unified Parkinson’s 







PD vs Control 
↑ Lactobacillus 
 
None  (Qian 
et al., 
2020) 
16S (no) N = 197 PD 
N = 130 Controls 
PD vs Control (significant via 
Kruskal-Wallis and ANCOM after 
adjusting for covariates and 
COMT/AC) 
↑ Bifidobacterium*** (Abundance: 
0.0089 vs 0.0076) 
↑ Lactobacillus*** (Abundance: 
0.0017 vs 0.0004) 
↑ Akkermansia*** (Abundance: 
0.0476 vs 0.0185)  
↓ Roseburia (OTU1)* (Abundance: 
0.0073 vs 0.0125)  
 
PD vs Control 
(significant via 
Kruskal-Wallis 







0.0089 vs 0.0076) 
↑ Lactobacillus*** 
(Abundance: 
















16S (no)  
     
  
     
N = 13 PD-MCI  
  
N = 13 PD with 
no MCI (PD-NC) 
  
N = 13 Control 
Spouses 
 
GLMs incorporated sex, age, bMI, 
education 
 
























16S (no) N = 666 Aged 
individuals 
Motor deficits indicating 
subthreshold parkinsonism associated 
with   
↓ Odoribacter 












16S (no) N = 80 PD 
N = 77 Controls 
PD vs Control after accounting for 
age, sex, diet 
↑ Parabcteroides 
↓ Prevotella (reduced by 46.6%) 
 
PD Tremor-Subtype vs PD Non-
Tremor Subtype accounting for 
age, sex, diet 










Bacteroides abundance and TNFα 
16S (no) N = 89 PD 
N = 66 Control 














16S (no) N = 29 PD 
N = 29 Controls 







16S (no) N = 104 PD 
N = 96 Control 
PD vs Control 
↑ Bacteroides fragilis 




↑ Akkermansia muciniphilia 
↑ Bifidobacterium bifidum BGN4 
↑ Bacteroides fragilis NCTC 9343 
↑ Clostridium saccharolyticum WM1 
Reduction in all fecal acetate, 
butyrate and propionate in low 
cognitive scoring patients 








fragilis NCTC 9343 
↓ Bile acid 
degradation 
pathways 
  (Tan 
et al., 
2020) 
16S (no) N = 25 PD 
Sequenced at 
baseline, 1 year, 2 
year and 3 year 
follow-up 
↓ Roseburia linked to development of 
non-motor, severity of mnesic-
attention disorders 
↓ Roseburia and Faecalibacterium at 
baseline linked to faster cognitive 
decline 






↑ Oscillospira at baseline linked to 
faster cognitive decline 
Results not significant after post-hoc 
correction 
16S (no) N = 63 PD 
N = 63 Healthy 
spouses (HS) 
N = 74 Control 








Genera positively associated with 
disease stage and duration: 
Parabacteroides, Akkermansia, 









16S (no) N = 64 PD 
N = 51 Control 
PD vs Control 
↑ Veillonella*** (mean difference = 
1.556) 
↓ Blautia* (mean difference =             
-0.596) 
↓ Butyrivibrio** (mean difference =    
-0.951) 
↓ Coprococcus* (mean difference =    
-0.873) 




16S (no) N = 24 PD 
N = 14 Controls 
PD vs Controls 
↑ Enterococcus** 
↑ Escherichia-Shigella* 
↑ Streptococcus**  
↑ Proteus* 
↓ Blautia*  
↓ Faecalibacterium*  
↓ Ruminococcus* 














16S (no) N = 75 PD 
N = 45 Controls 





16S (no) N = 10 PD 
N = 10 Controls 
PD vs Controls 
↑ Akkermansia,*  
↑ Parasutterella *  
↑ Subdoligranulum*  
↑ Butyricimonas*  
↓ Clostridium*  
↓ Collinsella*  
↓ Bacteroides* 
PD vs Controls 
↓ Bacteroides* 
None QIIME v1.8 
(outdated 







16S (no) N = 193 PD 
(de novo – 39, 
early – 57, mid-
stage – 53, 
advanced – 44) 
N = 113 Controls 
 
PD vs Control 
↑ Bifidobacterium* 
↓ Roseburia* 
↓ Ruminococcus**  




























16S (no) N = 197 PD 
N = 103 Controls 
PD vs Control 
↑ Bifidobacterium*** (4.02 fold 
change) 
↓ Roseburia*** (0.71 fold change) 
↓ Faecalibacterium prasunitzii*** 
(0.75 fold change) 
 
PD vs Control 
↑ 
Bifidobacterium*** 
(4.02 fold change) 
 
 







16S (no) N = 9 PD 
N = 13 Controls 












16S (no) N = 34 PD 
N = 31 Controls 
PD vs Control 
↑ Bacteroides* 













 raw # of 
sequences 
compared 





16S (no) N = 54 PD 






















N = 74 PD 
N = 75 Controls 
PD (IBS+) vs PD (IBS-) 
↓ Bacteroides (LFC = -4.929) * 
↓ Prevotella (LFC = -5.675) *** 
PD (IBS+) vs PD 
(IBS-) 
↓ Bacteroides (LFC 










N = 72 PD 
N = 72 Controls 








qPCR (no) N = 45 PD 
N = 35 Controls 
PD vs Control 
↑ Lactobacillus 
↓ Clostridium coccoides** 
↓ Clostridium leptum* 















qPCR (no) N = 28 PD  
 
N = 17 Stable 
N=11 
Deteriorated  
Follow-up vs Baseline (All PD) 
↓ Bifidobacterium 
↓ Clostridium leptum subgroup  
↓ Bacteroides fragilis group  
↓ Atopobium cluster  
↓ Enterococcus 
↓ L. gasseri subgroup 
Follow-up vs 












↓ Lactobacillus reuteri subgroup 
↓ Prevotella 
 
Follow-up vs Baseline (Stable) 
↓ Bifidobacterium 
↓ Clostridium leptum subgroup  
↓ Bacteroides fragilis group  
↓ Atopobium cluster  
↓ Enterococcus 
↓ Lactobacillus. gasseri subgroup 
↓ Lactobacillus reuteri subgroup 
Follow-up vs Baseline 
(Deteriorated) 





















qPCR (no) N = 19 PD with 
COMT inhibitor 




COMT inhibitor (Entacapone) vs 
No COMT Inhibitor 
↓ Faecalibacterium prausnitzii 
 
COMT inhibitor (Entacapone) vs 
Other COMT Inhibitors 











N = 34 PD 
N = 34 Control 
PD vs Age-Matched Control 
↑ Bifidobacterium*** 




















Table 5. Microbiome-brain studies involving alcohol, nicotine and recreational drug use/addiction. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; AD: Alzheimer’s Disease, PD: Parkinson’s Disease; MCI: mild-cognitive impairment; MSA: multiple-
systems atrophy; ALS: amyotrophic lateral sclerosis*: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are highlighted; 95% CI reported between square 




















16S (yes) N = 15 Healthy 
participants, 
compared before 
and after acute 
binge 
None None None Binge is 






16S (yes) N = 15 Alcohol-
Dependent 
N = 15 Control 
Alcohol-Dependent vs Control 
↑ Ruminoccocus 2* (effect = 0.72 [-
2.91; 6.75]) 
↓ Ruminoclostridium 9*** (effect =  -
0.99 [-7.99; 1.00]) 
 
↓ Tryptophan degradation* (effect = -











c acid (GHB) 
degradation** 















N = 72 Alcohol 
dependence 
syndrome (ADS) 
ADS vs Control 
↑ Lactococcus 
↑ Lactobacillus salivarius  
↑ Lactococcus lactis subsp. Cremoris 
↓ Prevotella 
ADS vs Control 
↑ Lactobacillus 
salivarius  





N = 27 Alcoholic 
liver cirrhosis 
(ALC) 
N = 60 Controls 
ALC vs Control 
↑ Bifidobacterium (B. longum, 
dentium, and breve)  
↑ Streptococcus (S. thermophilus and 
mutans)  
↑ Lactobacillus species (L. salivarius, 
antri, and crispatus)  
↓ Coprococcus 
↑ Bifidobacterium (B. 
longum, dentium, and 
breve)  
↑ Lactobacillus 
species (L. salivarius, 
antri, and crispatus)  
 
16S (no) N = 14 Non-
Smoking, Non-
Drinking 
N = 31 Smoking 
only 
N = 28 Drinking 
only 
N = 43 Smoking 
and drinking 














None  (Lin et 
al., 
2020) 
16S (no) N = 212 twins 
pairs 
AUDIT score III (high alcohol 
consumption) vs Medium and Low 
Alcohol Consumption Groups 
↑ Prevotella copri* 
↑ Megamonas*** (4 OTUS) 
↓ Blautia obeum* 
↓ Roseburia* 
 














N = 13 Alcohol 
Dependent  




N = 15 Controls 
High IP vs Low IP 
↓ Ruminococcus  
↓ Faecalibacterium 
↓ Clostridium  
↓ Bifidobacterium spp.  
 
Bifidobacterium spp. and Blautia 
negatively correlated to IP 
After 3 Weeks of Detoxification 
High IP vs Low IP 
↓ Bifidobacterium  
After 3 Weeks of 
Detoxification 
↑ Bifidobacteria spp. 













N = 16 Alcohol 
Dependent 
N = 48 Control 
Alcoholic vs Control 




Alcoholic+Smoker vs Control Non-
Smoker 








































N = 28 Alcohol 
Overconsumption 






















16S (yes) N = 10 Electronic 
Cigarette 
N = 10 Tobacco 
N = 10 Control 
Tobbacco Smoker vs Non-Smoker  
↑ Tryptophan Degradation* (effect = 
0.84 [-0.97; 8.52])   
↑ Propionate Synthesis III* (effect =  









↓ Propionate Synthesis II* (effect = - 









N = 21 Smokers 
with Crohn’s 
Disease 
N = 21 Smoker’s 
without Crohn’s 
Disease 










N = 5 Continuing 
Smokers 
N = 5 Non-
Smokers 



















qPCR (no) N = 14 Smokers 
N = 6 Non-
Smokers 
Smokers vs Non-Smokers 
↓ Bifidobacterium* 
 







N = 101 with 
Crohn’s (29 
smokers) 
N = 58 Controls 
(8 smokers) 









16S (no) N = 37 at two 
timepoints (HIV+ 
cohort) 
↓ Ruminococcus2  with 
methamphetamines, prescription drug 
use 
↑ Ruminoccus2  with synthetic drugs, 
‘poppers’ use 
 




16S (no) N = 48 Users 
N = 45 Controls 
No significance after controlling for 
sex and age 
   (Xu 
et al., 
2017) 
16S (no) N = 20 Marijuana 
users 
N = 19 Controls 
Prevotella abundance associated 
positively with cognitive function in 
users 





Table 6. Microbiome-brain studies involving demyelinating disease. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; AD: Alzheimer’s Disease, PD: Parkinson’s Disease; MCI: mild-cognitive impairment; MSA: multiple-
systems atrophy; ALS: amyotrophic lateral sclerosis; NMOSD: neuromyelitis optica spectrum disorder*: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are 






















16S (yes) N = 60 MS 
N = 43 Control 
None None None  (Jangi 
et al., 
2016) 
16S (yes) N = 84 NMOSD 
N = 54 Control 
NMOSD vs Control 
↑ Streptococcus (effect = -0.74 [-
6.40; 1.63])*** 
↓ Faecal SCFAs 
Acetate and butyrate negatively 
associated with severity 







N = 40 Controls 
N = 40 MS 
None None MS vs Control 
↓ GABA 
Degradation* 








(effect = -0.54 
[-2.07, 8.10]) 
WGS (no) N = 26 MS 
N = 77 Control 
MS vs Control 
↑ Sutterella sp.** (effect = 2.73) 
↓ Gemella morbillorum** (effect =  
-0.95) 
 







N = 34 
Discordant twin 
pairs 






N = 15 MS 
N = 15 Control 
 
Hispanic 
N = 16 MS 
N = 15 Control 
 
African American 
N = 14 MS 
N = 14 Control 












African American: MS vs Control 
↑ Clostridium 




16S (no) N = 22 MS 
N = 33 Control 
MS vs Control 
↑ Blautia 
↑ Flavonifractor 







↓ Clostridium XIVb 




16S (no) N = 26 Relapse-
Remitting MS 
(RRMS) 
N = 12 Secondary 
Progressive MS 
(SPMS) 
N = 38 Control 


































16S (no) N = 98 MS 
N = 120 Control 
MS vs Control 
↓ Alistipes (Effect = -0.18)* 
↓ Anaerotruncus (Effect = -0.16)* 
↓ Butyricoccus (Effect = -0.24)** 
↓ Clostridium cluster IV (Effect = -
0.35)*** 
↓ Gemmiger (Effect = -0.30)*** 
↓ Lactobacillus cluster IV (Effect = -
0.18)* 
↓ Methanobrevibacter (Effect = -
0.20)* 
↓ Olsonella (Effect = -0.19)* 
↓ Parabacteroides (Effect = -0.15)* 
↓ Roseburia (Effect = -0.17)* 
↓ Ruminococcus (Effect = -0.17)* 
MS vs Control 
↓ Lactobacillus cluster 






↓ Sporobacter (Effect = -0.39)*** 
 
Many differences within clinical 
subtypes : 
Butyricoccus, Clostridium cluster IV 




16S (no) N = 17 paediatric 
MS 











16S (no) N = 18 
Pediatric MS  
N = 17 Control 
MS vs Control 
↑ Bilophila*** (FC = 3 [2.9; 3.2]) 
↑ Bifidobacterium*** (FC = 4.2 [3.9; 
4.5]) 
↑ Desulfovibrio***(FC = 5.1 [4.7; 
5.7]) 
↑ Prevotella copri***(FC = 5 [4.4; 
5.6]) 





16S (no) N = 15 Pediatric 
Relapse-
Remitting MS 
N = 9 Control 










16S (no) N = 15 Primary 
Progressive MS 
N = 15 Control 
MS vs Control 
↑ Gemmiger 




16S (no) N = 17 Pediatric 
MS 










16S (no) N = 9 relapsing-
remitting MS 










16S (no) N = 8 MS no 
fasting 




fasting (IF) pilot  




16S (no) N = 34 relapsing-
remitting MS 





N = 34 Control 
MS vs Control 
↑ Streptococcus 
↓ Faecalibacterium 
↓ Prevotella 9 
↓ Faecal acetate*** 
↓ Faecal butyrate* 
↓ Faecal propionate*** 
 
 
NMOSD vs MS 
↑ Prevotella 9 
↓ Faecal acetate*** 
↓ Faecal butyrate*** 
 
NMOSD vs Control 
↓ Faecal acetate*** 
↓ Faecal propionate*** 
↓ Faecal butyrate*** 
 
None None  (Zeng 
et al., 
2019) 
16S (no) N = 27 MS 
treated with 
dimethyl fumarate 
N = 9 MS treated 
with other therapy 
 
12 week treatment 
 





















baseline and after 
12 months 













N = 13 MS 
N = 13 neuro-
Behçet Disease 
(NBD) 
N = 14 Control 
MS vs Control 
↑ Coproccocus*** (LFC = 9.3) 
↑ Ruminococcus 2** 
(LFC = 11.79) 
↑ Butyricoccus** (LFC = 8.41) 
↑ Clostridium XVIII** (LFC = 
12.07) 
↑ Dorea* (LFC = 3.60) 
↑ Escherichia/Shigella* (LFC = 5.85) 
↑ Parabacteroides* (LFC = 7.05) 
↑ Gemmiger* (LFC = 4.43) 
↓ Succinivibrio* (LFC = 0.03) 
↓ Prevotella* (LFC = 0.12) 
 




NBD vs HC 
↑ Parabacteroides** (LFC = 11.4) 
↓ Vampirovibrio* (LFC = 0.03) 
 
NBD vs MS 
↑ Butyricomonasi** (LFC = 32.29) 
↓ Erysipelotichaceae incertae sedis* 
(LFC = 0.09) 
Phylochip 
(no) 
N = 8 Controls 




in RA after 
Vitamin D 
supplementation 
MS Untreated vs Control 
↑ Akkermansia  
↑ Faecalibacterium 
↑ Coproccus 








N = 16 NMOSD 
N = 16 MS 
N = 16 Control 
NMOSD vs Control 






↑ Blautia producta*** 
↓ Prevotella*** 
 
NMOSD vs Control 
↑ Bacteroides*** 
 
None  (Cree 
et al., 
2016) 
FISH (no) N = 25 MS (10 on 
ketogenic diet for 
6 months) 
N = 14 Control 





Table 7. Microbiome-brain studies involving pain-related disorders. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; AD: Alzheimer’s Disease, PD: Parkinson’s Disease; MCI: mild-cognitive impairment; MSA: multiple-
systems atrophy; ALS: amyotrophic lateral sclerosis; NMOSD: neuromyelitis optica spectrum disorder*: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are 

















Fibromyalgia 16S (yes) N = 77 
Fibromyalgia 
N = 79 Total 
Controls 
N = 11 first-
degree relatives 
(controls) 




N = 48 unrelated 
controls 
Fibromyalgia vs Same Household 
Address as Patient  
↑Sutterella (effect = 0.66 [-0.43; 
0.92])* 
Fibromyalgia vs Unrelated 
Control 
↑ Serum butyrate 
↓ Serum propionate 
↓ Serum isobutyrate 
 




16S (yes) N = 105 
Fibromyalgia 
N = 54 Controls 
 




WGS (no) N = 77 
Fibromyalgia 
N = 79 Total 
Controls 
N = 11 first-
degree relatives 
(controls) 




N = 48 unrelated 
controls 
Fibromyalgia vs Unrelated 
Control 
↑ Parabacteroides merdae 
↑ Clostridium scindens 
↑ Blautia hydrogentrophica 
↑ Eisenbergella massiliensis 
↑ Hungatella hathewayi 
↑ Alistipes oderdonkii 
↑ Blautia massilensis 
↑ Butyricoccus desmolans 
↑ Flavonifractor plautii 
↓ Faecalibacterium prausnitzii 
↓ Blautia faecis 
↓ Haemophilus parainfluenzae 
↓ Prevotella copri 
↓ Bacteroides uniformis 
↑ Serum butyrate 
↓ Serum propionate 
↓ Serum isobutyrate 
 
 







16S (no) N = 48 with IBS ↑ Bacteroides with higher perceived stress 
None 







16S (no) N = 38 IBS;  
Samples taken 
before and after 
gut-directed 
hypnotherapy 












B. infantis M-63 
 
N = 20 Control 
Probiotic vs Control 
Improved anxiety score, mental 
component of QoL  
















Subset of 72 
consented to 
faecal samples 





IBS vs No IBS 
↑ Paraprevotella 
 
No genus-levelenus-level differences 
for anxiety found 
 




16S (no) N = 10 IBS, 
sampled at 0, 4, 
12 weeks after 
FMT 
Donor for Responder vs Non-Responder 
↑ Bifidobacterium 
No community change detected in responders or non-
responders  
 








16S (no) N = 37 IBS 
N = 20 age and 
sex matched 
controls 
IBS vs Control 











No genera level associations with 
anxiety or depression 









16S (no) N = 17 IBS, 
sampled at 0, 1, 2, 
4 weeks after 
FMT 
Baseline: HAM-D >=8 vs HAM-D 
<8 
↓ Eubacterium  
Week 4 vs Baseline HAM-D >=8 
↑  Eubacterium  
HAM-D Responders vs Non-
Responders : 
↑  Streptococcus 
Baseline: HAM-D 
>=8 vs HAM-D <8 
↓ Eubacterium  
Week 4 vs Baseline 
HAM-D >=8 












N = 44 IBS with 
moderate anxiety 
and/or depression 
N = 22 PBO 
N = 22 B. longum 
NCC3001 
Improvement in HAD-D subscale for 
B. longum  group 







16S (no) N = 30 with 
refractory IBS; 
sequenced stool 
before FMT and 1 
mo. after 
1 Month vs Baseline in Responders 
↑ Methanobrevibacter 
↑ Akkermansia 
 ↑ Quality of 
life 1 mo. and 3 
mo. after FMT 













N = 65 IBS 
N = 21 Control 
Clostridium XIVa, Coprococcus 
associated with differences in 
connectivity of cortical and 
subcortical networks between IBS 
and Control 






N = 13 post-
infectious IBS 
N = 19 general 
IBS 
N = 16 Control 












or PBO (0g, 3.5g, 
7g daily) 
PBO vs trans-GOS 3.5g 
↑ Bifidobacterium spp.* 
↑ E. rectale/C. coccoides***  
  
PBO vs trans-GOS 7g 
↑ Bifidobacterium spp.***  
↓ Clostridium perfingensr* 
↓ Bacteroides/Prevotella*** 
↓ HADS-A Score* 
↑ QOL Score* 




↑ E. rectale/C. 
coccoides***  
  


















N = 16 IBS, 
Sampled at 0, 1, 
3, 12, 20/28 
weeks after FMT 
Responders vs Non-Responders 
↑ Bacteroides*** before FMT  
↑ Megasphera/Dialister* at week 1, 
12,  20/28 
 
 





















N = 37 PBO 
 
4 week trial 
scFOS vs PBO 
↓ HAD-D score 
 
scFOS at D28 vs Baseline 
↑ Bifidobacterium* 
 
PBO at D28 vs Baseline 










N = 54 older 
women with 
migraines 
N = 54 Controls 
Migraine vs Control 
↓ Faecalibacterium prausnitzii** 
↓ Bifidobacteirum adolescentis*  
↑ Kynurenine synthesis* GBMs 
↓ Quinolinic Acid Degradation* 
 
Migraine vs Control 



















N = 48 Control 







Negative correlation between 
Faecalinacterium and total sleep 
awakenings 
 




16S (no) N = 113 Chronic 
Widespread Pain 
(CWP) 
N = 1623 Control 
CWP vs Control 
↓ Coprococcus comes *** 
 







Table 8. Microbiome-brain studies involving eating-related disorders. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; AD: Alzheimer’s Disease, PD: Parkinson’s Disease; MCI: mild-cognitive impairment; MSA: multiple-
systems atrophy; ALS: amyotrophic lateral sclerosis; NMOSD: neuromyelitis optica spectrum disorder*: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are 

















Obesity  WGS (no) N = 14 Obese 
N = 13 Non-obese 




WGS (no) N = 35 Obese 
N = 35 Non-obese 
No genus-level differences or 
associations identified 






WGS (no) N = 65 Obese 
N = 51 Control 
Bacterial genera positively associated 
with memory: 
Bacteroides, Citrobacter, 
Enterobacter, Salmonella, Klebsiella 
Specifically associated with verbal 











Roseburia CAG357, Veillonella 
magna 
Negatively associated with memory 
scores: Eubacterium, Clostridium, 
Proteobacteria 
Roseburia and Bacteroidetes 
associated with volume in left 
hippocampus 
Altered tryptophan metabolism in 
obesity associated with reductions in 
short term and working memory, as 
well as volume of frontal interior 
orbital right gyrus and left 
hippocampus  
16S (no) N = 86 Women 
with no food 
addiction (FA) 
N = 19 Women 
with FA 
OTUs enriched in FA: 
Megamonas 
OTUs depleted in FA: 
Bacteroides, Akkermansia, 
Eubacterium biforme. 
Reduction is associated with 
decreased plasma indolepropionate in 
the brain reward system 
OTUs depleted in FA: 
Bacteroides 


















and food addiction symptoms 
























N = 20 Obese 
N = 19 Non-obese 














N = 102 Morbid 
Obesity 
N = 15 Control 
Associations in Obese Group: 
WHO-5 Wellbeing Index 
Negatively associated with 
Bacteroides spp. and Prevotella 
Negatively associated with faecal 
acetate, butyrate and propionate 
Positively associated with 
Faecalibacterium prausnitzii, Dorea 
spp. 
Associations in Obese Group: 
Hopkin Symptom Checklist 10 
Negatively associated with 
Faecalibacterium prausnitzii 
Positively associated with 
Bacteroides stercoris 







16S (yes) N = 15 Anorexia 
N = 15 Controls 




16S (yes) N = 55 Anorexia 
baseline (AN-1) 
N = 44 Anorexia 
after weight gain 
(AN-2) 
N = 55 Control 
AN-1 vs Control 
↑ Isovaleric acid synthesis I   (effect 
= 0.44 [-2.80, 5.07])* 
↑ Quinolinic acid synthesis (effect = 
0.48[-2.13; 5.35])* 
↑ Quinolinic acid degradation (effect 
= 0.42 [-2.33; 4.80])** 
 
AN-2 vs Control 





































(effect = -0.43 
[-5.09; 2.32]) * 
 
16S (no) N = 18 Anorexia 
N = 20 Athletes 
N = 26 Normal 
Weight 
N = 22 
Overweight 
N = 20 Obese 
 
All women 
None None None Storage at -
20C 
(Mork
l et al., 
2017) 
16S (no) N = 21 Anorexia 
at enrollment 
N = 16 Anorexia 
at discharge 
N = 29 Healthy 
women 













16S (no) N = 19 Anorexia 
N = 20 Healthy 
Control 
Anorexia at Admission vs Control 
↑ Anaerostipes* 
Anorexia at Discharge vs Control 
↑ Unclassified Lachnospiraceae** 
↑ Fusicatenibacter* 
Anorexia at Admission vs 
Discharge 
↓ Bacteroides* 
↑ Unclassified Ruminococcaceae* 





























qPCR (no) N = 25 Anorexia 
(11 binge eating, 
14 restrictive) 
N = 21 Control 
Anorexia vs Control 
↓ Total bacteria*** 
↓ Clostridium coccoides*** 
↓ Clostridium leptum*** 














qPCR (no) N = 20 Obese 
N = 9 Anorexia 
N = 20 Control 
Obese vs Control 
↑ Lactobacillus* 
 
Obese vs Anorexia 
↑ Lactobacillus* 
 
Anorexia vs Control 
↑  Methanobrevibacter smithii* 
Obese vs Control 
↑ Lactobacillus* 
 





















Table 9. Microbiome-brain studies involving neurovascular disease. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; AD: Alzheimer’s Disease, PD: Parkinson’s Disease; MCI: mild-cognitive impairment; MSA: multiple-
systems atrophy; ALS: amyotrophic lateral sclerosis; NMOSD: neuromyelitis optica spectrum disorder*: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are 






























CA vs Control 
↑ Bacteroides thetaomicron*** 
↑ Odoribacter sphlancus***  
↓ Bifidobacterium adolescentis***  
↓ Faecalibacterium prausntzii*** 
 
Aggressive vs Non-Aggressive CA  
↑ Bifidobacterium adolescentis*** 
↓ Bacteroides eggerthii* 
 
CA with Symptomatic Hemmorhage 
vs CA No Hemmorhage 
↑ Faecalibacterium prausnitzii 
↑ Oscillobacter 







Aggressive CA  








16S (no) N = 8 Cerebral 
Infarction (CI) 
N = 2 Ischemic 
Stroke (IS) 
N = 10 Controls 
CI vs Control 
↓ Bacteroides  
↓ Parabacteroides  
↓ Akkermansia  
↓ Prevotella  
↓ Faecalibacterium 
IS vs Control 
↑ Escherichia  
CI vs Control 
↓ Bacteroides 
 
IS vs Control 
↓ Bacteroides 
 
CI vs IS 
↑ Bacteroides 






↑ Dialister  
↑ Bifidobacterium 
↓ Bacteroides  
↓ Megamonas  
↓ Parabacteroides  
↓ Akkermansia  
↓ Prevotella  
↓ Faecalibacterium  
↓ Ruminococcus 
CI vs IS 
↑ Escherichia  
↑ Bacteroides 
↑ Megamonas 
↑ Prevotella  
↑ Ruminococcus 
↓ Parabacteroides  
↓ Akkermansia 
↓ Faecalibacterium 




16S (no) N = 30 Ischemic 
Stroke 
N = 30 Control 





↓ Ruminoclostridium 5 















N = 35 non-PSCI 
 
PSCI vs non-PSCI 
↑ Fusobacterium 
↑ Bacteroides 





























N = 25 non-PSCI 
 
PSCI vs non PSCI 
↓ Fusicatenibacter 
↑ Veilonella 




16S (no) N = 10 Cerebral 
Infarction patients 
N = 10 Control 














treated with  
hypothermia  
N = 9 Control 



















Table 10. Microbiome-brain studies involving stress-related and psychiatric disorders. 
Legend: LFC: log-2 fold change; LC: log change; RA: relative abundance; DASS-42: Depression Anxiety Stress Scales; ADHD: Attention-Deficit Hyperactivity Disorder; 
HE: hepatic encephalopathy; FOS: Fructo-oligosaccharide; HADS-A: Hamilton Anxiety and Depression Scales – Anxiety Subscale; HADS-A: Hamilton Anxiety and 
Depression Scales – Depression Subscale; RTT: Rett’s Syndrome; AD: Alzheimer’s Disease, PD: Parkinson’s Disease; MCI: mild-cognitive impairment; MSA: multiple-
systems atrophy; ALS: amyotrophic lateral sclerosis; NMOSD: neuromyelitis optica spectrum disorder*: padj < 0.1; **: padj < 0.01; ***: padj < 0.001; Reanalyzed studies are 

















Stress 16S (no) N = 50 Healthy 
subject in double-
blind PBO RCT 
None None None  (Soldi 
et al., 
2019) 
16S (no) N = 47 Black ♀ 
N = 33 white ♀ 
↑ Fusobacterium* with stress in 
Black participants, but not in white 
participants 








High ACE vs Low ACE Score 
↑ Prevotella*** 
 








pregnant at time 
of study 
16S (no) N = 75 
Pregnancy-related 
anxiety associated 


























at birth, 4-12 
weeks and 20-28 
weeks 
Mothers with Exposure to Intimate 
Partner Violence vs Control 
↑ Weisella*** at 4-12 weeks 









16S (no) N = 31 Probiotic 
(Lactobacillus 
gasseri CP2305) 
N = 29 Placebo 
Probiotic vs Placebo after stressor 
Smaller decrease in Bifidobacteria 
after stressor 
Increased faecal Valeric acid with 
probiotic 
 








N = 16 PBO 
N = 16 Probiotic 
 
L. gasseri CP2305 
Probiotic 
administration 
Probiotic vs PBO after Stressor 
Differences in Corynebacterium  
 
Improved sleep quality 


































composition at 5 















16S (no) N = 29 PTSD 
N = 64 Controls 
PTSD without Hepatic 







↓ Colstridium XIVAa 
↓ Pseudoflavonibacter 
 











16S (no) N = 18 PTSD 
N = 12 Trauma-
exposed controls 







WGS (no) N = 31 BD 
N = 31 MDD 
N = 31 Control 





















species and strains 
differed between BD 
and Control 
  (Rong 
et al., 
2019) 
Various Prevotella and 
Bifidobacterium species and strains 
differed between BD and Control 
WGS (no) N = 25 BD 
N = 28 Controls 










Dysregulation in tryptophan 
metabolism pathway in BD 




  (Lai et 
al., 
2021) 
16S (no) N = 115 BD 
N = 64 Control 




Faecalibacterium associated with 
higher PCS, lower PSQI and PHQ9  
Anaerostipes associated with 









16S (no) N = 23 BD 
N = 23 Control 




16S (no) N = 217 BD 
N = 165 MDD 
N = 217 Control 
BD vs Control (From top 5 LDA) 
↑ Ruminococcus gnavus (2 OTUs) 
↑ Clostridium sensu stricto 
↑ Bacteroides 
↑ Pseudomonas (2 OTUs) 
↓ Prevotella 9 (2 OTUs) 
↓ Bacteroides  
↓ Ruminococcus 2 
↓ Klebsiella 
 
MDD vs Control (From top 5 LDA) 
BD vs Control (From 
top 5 LDA) 
↑ Bacteroides (OTU) 
↓ Bacteroides (OTU) 
 
MDD vs Control 
(From top 5 LDA) 
↑ Bacteroides 












↑ Ruminococcus gnavus 
↑ Bacteroides  
↑ Ruminococcus 2 
↓ Bacteroides (5 OTUs) 
 





↓ Eubacterium rectale 




BD vs MDD (From 
top 5 LDA) 
↑ Bacteroides 
↓ Eubacterium rectale 
↓ Eubacterium hallii 
↓ Bacteroides 
 




16S (no) N = 113 BD 
N = 113 Control 
(37 unaffected 
relatives) 










16S (no) N = 52 BD 
(N = 12 BD-1 
N = 38 BD-II) 
 
N = 20 After 
treatment with 
quietiapene 
N = 45 Control 












BD vs Controls 
↑ Bacteroides 
 
















16S (no) N = 32 Bipolar 
disorder (BD) 
N = 10 Control 




↑ Lactobacillus** associated with 
high IL-6 
↑ Prevotella* with low LDL 
cholesterol 
↑ Roseburia** with less depressive 
symptoms 
↑ Lactobacillus** associated with 
high serum tryptophan 
↑ Prevotella* with low LDL 
cholesterol 
↑ Roseburia** with less depressive 
symptoms 
 





16S (no) N = 117 BD 





AAP vs Non-AAP 
























qPCR (no) N = 36 BD 
(before treatment) 
N = 27 Control 
BD vs Control 
↑ Faecalibacterium prausnitzii* 
↑ Atopobium*** 
BD vs Control 
↓ Bifidobacteria* 
 




↑ Clostridium cluster IV*** 
↓ Bifidobacteria* 
 
qPCR (no) N = 13 BD I 
N = 26 BD II 
N = 58 Control 









N = 111 
Psychiatric 
inpatients 
Coprococcus catus and Clostridium 
symbiosum associated with moderate 
anxiety at admission 
↓ Coprococcus catus associated with 
lower remission from anxiety and 
depression 







N = 1054 Faecalibacterium, Coprococcus 
associated with higher quality of life 
indicators  
Dialister, Coprococcus spp. depleted 
in depression  
 














WGS (no) N = 156 MDD 
N = 155 Control 
MDD vs Control 
↑ Multiple Bacteroides ASVs 
↓ Multiple Blautia ASVs 
Many upregulated and downregulated 
ASVs assigned to Eubacterium 
 
MDD vs Control 
↑ Multiple Bacteroides 
ASVs 
 
None  (Yang 
et al., 
2020) 
16S (no) N = 37 MDD 












16S (no) N = 15 MDD, 11 
Responders and 4 
Non-Responders 







16S (no) N = 22 
Depression/Anxie
ty 
N = 28 Control 














16S (no) N = 23 MDD Functional connectivity in lDLPFC inversely correlated with 
relative abundance of Bacteroides 
None Controls not 
in the scope 







16S (no) N = 24 Current 
depressive 
episode (CDE) 
N = 16 Control 
CDE vs Control 
↑ Akkermansia 
↑ Veillonella 





None None  (Jiang 
et al., 
2020) 
16S (no) N = 12 breast 
cancer survivors 
sampled at 






No significant microbiota differences 
after FDR adjustment  




16S (no) N = 27 Control 
N = 27 MDD 
MDD vs Control 
↑ Coprococcus*  
↑ Pseudomonas* 
↑ Blautia* 




16S (no) N = 34 depressed 
+ probiotic 
N = 37 + PBO 
N = 20 Non-
depressed 
No differences between groups 
Ruminococcus gnavus associated 
with DASS depression score* 






























16S (no)  N = 16 Inpatients 
at admission and 
6 weeks later 
Paraprevotella positively associated 
with Hamilton Depression Scale-24 
Item score* (r=0.8) 











No genera-level associations with 
specific psychotropic medication 
within the cohort 




16S (no) N = 10 MDD 
N = 10 Control 
MDD vs Control 
↑ Prevotella* (D1, D10 and D29) 
↑ Streptococcus* (D1, D10) 
↑ Clostridium XI* (D29) 
 
 







N = 58 MDD 
N = 63 Control 
MDD vs Control 
↑ Collinsella (RA = 4.2% vs 1.7%)* 
↑ Olsenella (RA = 0.003% vs 0%)* 
↑ Blautia (2 OTUs)** 
↑ Anaerostipes (RA = 1.491% vs 
0.303%)*** 
↓ Alistipes (RA = 0.249% vs 
0.761%)* 








N = 38 Co-
morbid anxiety 
and depression 
N = 8 Anxiety 
N = 14 
Depression 
N = 10 Control 









N = 29 MDD 
responded 
N = 17 MDD 
active 
N = 30 Control 
Active MDD vs Control 
↑ Blautia 
↑ Oscillibacter  
↑ Roseburia  
↓ Bacteroides  
↓ Dialister 
↓ Faecalibacterium 
↓ Prevotella  
↓ Ruminococcus  
Responded MDD vs Control 
↑ Bacteroides 
↑ Roseburia 
↓ Oscillibacter  
↓ Prevotella  
↓ Ruminococcus  
↓ Faecalibacterium 
 
Negative correlation between 
Faecalibacterium and depressive 
symptoms 
Active MDD vs 
Control 
↓ Bacteroides 





















N = 36 Controls 
N = 12 anti-
depressant naïve 
patients 
N = 22 Control 
GAD vs Control 
↓ Faecalibacterium* 
↓ Eubacterium rectale* 
↓ Sutterella* 
↓ Butyricoccus  
↑ Bacteroides* 
↑ Ruminococcus gnavus* 
↑ Fusobacterium* 
Treatment Naïve vs Control 
↑ Lactobacillus* 





↓ Eubacteirum recetale 
↓ Roseburia 
↓ Subdoligranulum 
GAD vs Control 
↑ Bacteroides* 















N = 40 with 
diarrhea-
predominant IBS 
(IBS-D) N = 15 
with Depression, 




All Depression vs Control 
↑ Bacteroides***  
↑ Prevotella*** 
↓ Coprococcus*** 
All Depression vs 
Control 
↑ Bacteroides***  
 













(n = 8), 
duloxetine (n=6) 
Post vs Pre Bifico 
↓ Bifidobacterium 
Post vs Pre Duloxetine 
↑  Faecalibacterium 
Post vs Pre Bifico 
↓ Bifidobacterium 

















N = 43 MDD 
N = 57 Control 









RFLP (no) N = 56 OI 
N = 9 Control 
OI vs Control 
↑ Clostridium subcluster XIVa* 
OI Depressed vs OI Non-Depressed 
↓ Bifidobacterium 










Table 11. Common limitations of human microbiome studies 
 




Many studies use operational 
taxonomic units which are less 
precise and more prone to error. 
ASVs are a more precise 
alternative which can be 
implemented through DADA2 
Non-compositional 
data analysis 
Counts data must be properly 
transformed to account for its 
relational data structure 
• Normalization with rarefaction or 
DESeq2 
• Measuring distance between 
groups using Bray-Curtis, 
UniFrac, Jenson-Shannon; often 
used with Principal Co-ordinate 
Analysis 
• Pearson or Spearman 
Correlations (compositional data 
is prone to spurious correlation) 
• Differential abundance with 
LEfSe, DESeq, metagenomSeq 
 
• Compositional normalization 
with ALDEx2 (i.e. CLR, IQR, 
ALR) 
• Measure distance between 
groups with the Aitchison 
metric in conjunction with 
Principal Component Analysis 
• SparCC, SpiecEasi, Φ for 
Correlations 




Often confounding variables are not 
measured or included in studies. 
There are several confounds that 
must be accounted for during 
analysis. 
Participant data: 
• Food-frequency questionnaire 
• Alcohol-use 
• Smoking status 
• Prescription and recreational 
drug-use 





While adjusted p-values are often 
reported, studies seldom mention 
effect sizes or confidence intervals. 
Report effect sizes and 95% 
confidence intervals. Sparse 
microbiome datasets are prone to 
uncertainty. If the confidence 
interval does not overlap with 0, 
then there is more certainty in the 
direction of the effect. 
 
Use gut-brain module analysis to 
provide more insight into your 
data. 
 
Deposit your data and code 
publicly if possible. 
Updating tools for 
data analysis 
Occasionally, studies use databases 
or tools that are no longer updated or 
supported i.e. QIIME version 1 or 
Greengenes database from 2013 
Ensure that your bioinformatics 
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Recent investigations in neuroscience implicate the role of microbial-derived 
metabolites in brain health and disease. Short-chain fatty acids are neuroactive 
metabolites produced by the gut microbiota. Short-chain fatty acid metabolites like 
acetate, propionate and butyrate have pleiotropic effects within the immune and 
enteric systems. They are crucial for the maturation of the brain’s innate immune 
cells, the microglia and modulate other glial cells through the aryl-hydrocarbon 
receptor. In vivo these metabolites show neuroprotective and antidepressant 
properties. In humans, they even modulate the acute stress response and satiety. 
Together, these findings present a potential role for SCFA-astrocyte interactions. Our 
novel investigation tested the impact of physiologically relevant doses of SCFAs on 
male and female primary cortical astrocytes. We find that butyrate (0 – 25µM) 
positively correlates with Bdnf and Pgc1-α expression, implicating histone-
deacetylase inhibitor pathways. Intriguingly, this effect is only seen in females. We 
also find that acetate (0 – 1500 µM) dosage positively correlates with Ahr and Gfap 
expression in males only, suggesting immune modulatory pathways. These findings 
show a novel sex-dependent impact of acetate and butyrate, but not propionate on 
astrocyte gene expression. 
Keywords: 





The microbiota-gut-brain axis emerged in recent years as a contributor or mediator 
of many neurophysiological and behavioural processes. The trillions of 
microorganisms within the mammalian gut, collectively called the microbiota, 
communicate with the brain through neuroendocrine, immune or vagal signalling 
(Cryan et al., 2019). In addition, they generate a cornucopia of neuroactive 
metabolites, absorbed into peripheral circulation, however it is still unclear if these 
metabolites act on brain cells directly. Recent work brought these metabolites into 
the spotlight, showing they were associated with host quality of life and depression 
in humans (Valles-Colomer et al., 2019).  
Among the most promising candidates for modulating brain function are the short-
chain fatty acids (SCFAs). SCFAs are fermented by-products, produced by specific 
colonic bacterial genera from dietary fibre. They consist of an aliphatic chain of 
carbon molecules with a carboxylic acid group. The most common types of SCFAs 
produced within the gut are acetate, butyrate and propionate, typically found in a 
60:20:20 molar ratio (Dalile et al., 2019). SCFAs are also substrates easily used by 
colonocytes and other cell types to generate energy within the Krebs cycle.  
SCFAs exert their action by acting as histone-deacetylase inhibitor (HDACi) 
intracellularly or by binding to G-coupled protein receptors (Dalile et al., 2019). In 
rodents, SCFA administration has shown to be neuroprotective against stroke (Sadler 
et al., 2020, Lee et al., 2020a), stress (van de Wouw et al., 2018), oligodendrocyte 
function (Chen et al., 2019b), and depressive-like behaviour (Yamawaki et al., 
2018). These results are confounded by the broad influence of SCFAs on peripheral 
immune cells involved in both innate and adaptive immunity (Correa-Oliveira et al., 
2016). However, SCFAs modulate blood-brain barrier permeability in vitro (Hoyles 
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et al., 2018) and are shown to cross the blood-brain barrier in rodent and primate 
studies (Dalile et al., 2019).  
In humans, 13C radiolabelled carbohydrate substrates are converted to acetate within 
the gut, reaching the hypothalamus through peripheral circulation leading to appetite 
suppression (Frost et al., 2014). Additionally, researchers observed elevations in the 
glutamate-glutamine cycle substrates within the hypothalamus (Frost et al., 2014). 
Another study provided healthy men with different doses of dietary-fibre that is 
converted into SCFAs or a placebo (Dalile et al., 2020). In a psychosocial stress 
paradigm, colon-derived SCFAs reduced the cortisol response with peripheral SCFA 
levels covarying with cortisol levels (Dalile et al., 2020). Interestingly, it did not 
alter the subjective response to the acute stressor, fear learning or extinction (Dalile 
et al., 2020).   
The combination of preclinical and clinical data suggests that SCFAs exert both 
immune and metabolic effects within the central nervous system. Astrocytes within 
the brain are responsible for both metabolic regulation (Belanger et al., 2011) within 
the brain as well as neuroimmune functioning (Jensen et al., 2013).  Recent work 
also implicates the metabolic functioning of cortical and subcortical astrocytes in 
learning and memory (Alberini et al., 2018). Additionally, dietary-derived 
tryptophan metabolites influence astrocytic immunity through the intracellular 
activation of the aryl-hydrocarbon receptor pathway (Rothhammer et al., 2016). To 
address whether SCFAs interact with cortical astrocytes, we used an enriched 
primary astrocyte culture. 
Previous cell culture studies characterized the effects of supraphysiological levels on 
neuroimmune inflammation. While this provides insight into potential 
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neuroprotective functions, which could be induced by increasing the dietary-fibre 
intake, the question of what role SCFAs play in the homeostatic environment remain 
(Chen et al., 2007, Suh et al., 2010, Soliman et al., 2012, Singh et al., 2014, Wang et 
al., 2018a). These studies did not focus on identifying sex or region-specific effects 
as they were out of the scope of those respective studies. However, it’s clear that sex 
may play a role in determining the physiological effects of SCFAs (Jaggar et al., 
2020). Additionally, we aim to characterize the impact on primary astrocyte cultures, 
which have been seldom used in such studies. We also explored the potential of 
SCFAs to impact glutamate/glutamine metabolism, the aryl-hydrocarbon receptor 
pathway as well as genes related to HDACi. 
Experimental Procedures 
Animals 
Experiments are authorised under a Euthanasia Only Project (2019-009). 
Experiments were conducted in accordance with guidelines established by 
University College Cork’s Animal Welfare Body. 
Seeding Primary Glial Culture 
Litters of C57BL/6 mice were sexed and euthanized at postnatal day 1-3 (PND1-3). 
The mouse brains were removed from the skulls and the cortices were dissected out. 
The meninges and hippocampus were also removed. Cortices were pooled by sex 
into collection tubes, filled with DMEM-F12 (Gibco: 11320033), stored on ice. 
Pooled brains were washed with PBS 10mM, then incubated with 1.5mL of 
Trypsin/EDTA (0.25%) (Thermofisher: 25200072) at 37°C, 5% CO2 for 20 minutes. 
Trypsin/EDTA (0.25%) was inactivated with 9mL of DMEM/F12 with 10% heat 
inactivated Fetal Bovine Serum (Thermofisher: 16140071). This mixture was 
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mechanically dissociated, transferred to a 15mL Falcon Tube and centrifuged at 
200g, 21°C for 10 minutes. Supernatant was removed and resuspended in media. 
Media was composed of DMEM (Gibco: 16219961) with 10% heat inactivated Fetal 
Bovine Serum, 1% Penicillin/Streptomycin (Gibco: 15070063) and 2mM L-
Glutamine (Thermofisher: 25030149) Cells were then seeded into T75 flasks with 
filtered caps, coated overnight with Poly-D-Lysine (Sigma-Aldrich: P6407-5MG). 
Half of the cell media was removed every 3-4 days and replenished with new media. 
Cells were grown at 37°C, 5% CO2.  
Primary Astrocyte Enrichment 
After 14 days, cells were placed on an orbital shaker for 24 hours at 150rpm, 37°C, 
5% CO2. This process removed contaminating microglia from the culture. Media 
was aspirated, cells were washed with PBS 10mM and media was replenished. Cells 
were than shaken for 24 hours at 230rpm, 37°C, 5% CO2 to remove oligodendrocyte 
precursor cells. Cells were washed with PBS 10mM and left for 1-2 days. 
Afterwards, astrocytes were dissociated using 3.0 mL Trypsin/EDTA (0.25%) before 
being seeded at a density of ~150 000 cells into a 6-well cell culture plate. Each well 
contained 1.5mL of media and 150 000 cells.  
Primary Astrocyte Purity 
To confirm enrichment, cells from three different litters were grown of coverslips 
and fixed with 4% PFA (Sigma-Aldrich: 158127) in triplicate. Briefly cells were first 
blocked for an hour with a solution of PBS 10mM with 0.1% Triton-X (Sigma-
Aldrich X100) and 5% Donkey Serum (Sigma-Aldrich D9663). The primary 
antibodies, Rat anti-GFAP (1:250) (Thermofisher:13-0300) and Rabbit-anti IBA1 
(1:1000) (Wako: 019-19741).  was added in a PBS/0.1% Triton-X/2% Donkey 
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Serum solution and left at 4°C for 12 hours. After three washes, a secondary 
antibody, anti-Rat AlexaFluor 488 (Thermofisher: A-21028) and anti-Rabbit 
AlexaFluor  594 (Thermofisher: A-11012) were both  added  in a 1:500 dilution of 
PBS/0.1% Triton-X/2% Donkey Serum for two hours in a humid chamber. Cells 
were washed three times and DAPI (Thermofisher: D1306) was added at a 
concentration of 1:1000 in a PBS solution with 2% Donkey Serum. Finally, cells 
were mounted onto slides and GFAP/DAPI double positive cells were counted as 
astrocytes while DAPI positive cells or IBA1/DAPI double positive cells were 
counted as non-astrocytes. We found our enriched culture was >95% pure. In 
addition, T75 flasks were viewed under a microscope to ensure no microglia (small 
rounded cells adherent to the surface layer of attached cells) were present before 
further experiments.  
Cell Culture Treatments 
Once the cells adhered (after ~5 days), 150mL of media was removed, and new 
media with different concentrations of the short-chain fatty acids acetate (Sigma‐
Aldrich: S7545), propionate (Sigma-Aldrich: P1880) or butyrate (Sigma‐Aldrich, 
303410) diluted in culture media were added. Physiologically relevant 
concentrations were estimated based on the study by (Guardia-Escote et al., 2019). 
For acetate we tested concentrations at 0µM, 150 µM, 750 µM and 1500µM. For 
propionate we tested concentrations at 0µM, 3.5 µM, 17.5 µM and 35µM. For 
butyrate we tested concentrations at 0µM, 2.5 µM, 12.5 µM and 25µM.  
Quantitative PCR 
24 hours after treatment, cells were lysed and isolated according to the TRIzol 
protocol (Thermofisher: 15596026). RNA concentrations were then measured using 
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a Nanodrop-1000 (Thermofisher) followed by the generation of cDNA using the 
High-Capacity cDNA Reverse Transcription Kit (Thermofisher: 4368814). Using the 
primers listed in Table 1 (Eurofins) along with the SYBR™ Green PCR Master Mix 
kit (Thermofisher: 4309155), we conducted a quantitative PCR.  
Table 1. PCR Primers 
Pathway Gene Sequence 
Forward (5’ -> 
3’) 
Sequence Reverse 











(Zeisel et al., 
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Garcia et al., 
2020, 
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Each sample was analysed in duplicate for both target gene and reference gene (β-
actin), and the relative mRNA expressions were calculated using the 2−ΔΔCt method 
Linear regression was used to test for SCFA-dose responses (Livak and Schmittgen, 
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2001). Results in bar plots are presented as mean ± SEM. For presentation in heat 
maps, the means for gene expression were scaled. For linear regression, the SCFA 
dose was treated as a continuous independent variable while gene expression was 
treated as a continuous dependent variable. Graphs were made using ggplot2 in R 
4.0.0. Linear regression was performed using the lm function in R 4.0.0. The code 





Low levels of butyrate (2.5 - 25µM) did not significantly impact gene expression in 
males (see Fig 1). However, in females Bdnf expression positively associated with 
butyrate dose (df = 10, residual standard error = 0.9446, R2= 0.4419, Adjusted R2= 
0.3861, F-Statistic = 7.918, p = 0.01835). Similarly, the expression of Pgc1-α was 
positively associated with butyrate dose in female astrocytes (df = 10, residual 
standard error = 0.9229, R2= 0.3447, Adjusted R2= 0.2792, F-Statistic = 5.26, p = 




Fig 1. Impact of butyrate on cortical astrocyte gene expression. A-C. The impact of different 
concentrations of butyrate on immune-related, glutamine/GABA metabolism and histone deacetylase 
inhibitory pathways in male and female cortical astrocytes (N = 3 litters). Raw data was analyzed 
using the 2-∆∆CT method. Plots show the means within each group normalized to the vehicle (0µM) 
with bars representing the standard error of the mean.  D. A heatmap visualizing mean changes in 
gene expression across different genes.  E. Using linear regression, there is a significant association 
between butyrate dose and Bdnf expression in female cortical astrocytes (df = 10, residual standard 
error = 0.9446, R2= 0.4419, Adjusted R2= 0.3861, F-Statistic = 7.918, p = 0.01835) but not in males 
(df = 10, residual standard error = 1.386, R2= 0.01261, Adjusted R2= -0.08612, F-Statistic = 0.1278, p 
= 0.7282). There is a significant association between butyrate dose and Pgc1-α in female cortical 
astrocytes (df = 10, residual standard error = 0.9229, R2= 0.3447, Adjusted R2= 0.2792, F-Statistic = 
5.26, p = 0.04475) but not in males (df = 10, residual standard error = 0.6803, R2= 0.1897, Adjusted 
R2= -0.07913, F-Statistic = 0.1934, p = 0.6995).  
Table 2. Linear regression results in male cultures treated with butyrate. 
             
                























































































































































































           
                      
           
                      
           
                      
           
                      
            
           
                      
           
                      
           
                      
           
                      
           
                      
           
                      
           
                      
           
                      
           
                      
           
                      
           
                      
           
                    
           
                    
     
              
            













Low levels of acetate (2.5 - 25µM) did not significantly impact gene expression in 
females (see Fig 2). However, in males Ahr expression positively associated with 
acetate dose (df = 10, residual standard error = 0.5271, R2= 0.5457, Adjusted R2= 
0.5003, F-Statistic = 12.01, p = 0.00606). The expression of Gfap was positively 
associated with acetate dose in male astrocytes (df = 10, residual standard error = 
0.8891, R2= 0.4414, Adjusted R2= 0.3855, F-Statistic = 7.902, p = 0.01844) but not 





Fig 2. Impact of acetate on cortical astrocyte gene expression. A-C. The impact of different 
concentrations of butyrate on immune-related, glutamine/GABA metabolism and histone deacetylase 
inhibitory pathways in male and female cortical astrocytes (N = 3 litters). Raw data was analyzed 
using the 2-∆∆CT method. Plots show the means within each group normalized to the vehicle (0µM) 
with bars representing the standard error of the mean.  D. A heatmap visualizing mean changes in 
gene expression across different genes.  E. Using linear regression, there is a significant association 
between acetate dose and Ahr expression in male cortical astrocytes (df = 10, residual standard error = 
0.5271, R2= 0.5457, Adjusted R2= 0.5003, F-Statistic = 12.01, p = 0.00606) but not in females (df = 
10, residual standard error = 0.6358, R2= 0.0243, Adjusted R2= -0.07327, F-Statistic = 0.2491, p = 
0.6285). There is a significant association between butyrate dose and Gfap in male cortical astrocytes 
(df = 10, residual standard error = 0.8891, R2= 0.4414, Adjusted R2= 0.3855, F-Statistic = 7.902, p = 
0.01844) but not in females (df = 10, residual standard error = 0.5173, R2= 0.008557, Adjusted R2= -
0.09059, F-Statistic = 0.0863, p = 0.7749).  
  
 

















Propionate treatment (3.5 – 35µM) did not impact gene expression significantly (see 
Fig. 3 and Table 6-7). 
 
Fig 3. Impact of acetate on cortical astrocyte gene expression. A-C. The impact of different concentrations of 
butyrate on immune-related, glutamine/GABA metabolism and histone deacetylase inhibitory pathways in male 
and female cortical astrocytes (N = 3 litters). Raw data was analyzed using the 2-∆∆CT method. Plots show the 
means within each group normalized to the vehicle (0µM) with bars representing the standard error of the 
mean.  D. A heatmap visualizing mean changes in gene expression across different genes.  
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To our knowledge, this is the first in vitro study which assessed a physiologically 
relevant gradient of SCFAs in cortical astrocytes. Most in vitro studies of SCFA 
function pre-treated neuroimmune cells to induce inflammation before the addition 
of SCFAs and did not assess sex-differences (Yang et al., 2019, Yamawaki et al., 
2018, Wang et al., 2018a, Singh et al., 2014, Chen et al., 2007, Hoyles et al., 2018). 
Thus, we used primary enriched male and female cortical astrocyte culture to 
investigate the potential impacts of butyrate, acetate and propionate on gene 
expression. We investigated the impact of SCFAs in aryl-hydrocarbon 
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receptor/immune signalling, glutamate/glutamine metabolism and histone-
deacetylase inhibitor (HDACi) pathways. 
When treating cells with butyrate, we did not see any impact on immune-related or 
glutamate-glutamine metabolism genes. However, in females we found that butyrate 
concentrations positively correlated with Bdnf and Pgc1-α expression. These genes 
may be activated downstream of HDACi activity. Intriguingly, these effects were 
only found in female cortical astrocytes.  
Surprisingly, acetate treatment did not alter glutamate-glutamine related gene 
expression in the astrocytes. A previous human study found 13C radiolabelled 
carbohydrate substrates are converted to acetate within the gut, reaching the 
hypothalamus through peripheral circulation leading to appetite suppression as well 
as changes to hypothalamic glutamate-glutamine metabolism (Frost et al., 2014). 
Acetate treatment did not impact any HDACi pathway-related genes but did alter 
immune gene expression in male cortical astrocytes. In male, but not female cortical 
astrocytes, acetate treatment positively correlated with Ahr and Gfap expression. 
Previous studies identified dietary-derived tryptophan metabolites as mediators of 
astrocytic immunity through the intracellular activation of the aryl-hydrocarbon 
receptor pathway (Rothhammer et al., 2016). Additional studies suggested that this 
receptor is also activated by SCFAs (Marinelli et al., 2019, Jin et al., 2017). These 
results suggest that acetate may also play a role in this astrocytic immune pathway. 
Meanwhile, propionate did not induce any dose-dependent or sex-specific responses 
in astrocyte gene expression.  
There are practical limitations within the study. Prior to this investigation, there was 
a lack of insight into which pathways would be impacted by small concentrations of 
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SCFAs. There may be other pathways with larger undetected effects. Additionally, 
our study did not investigate the supernatants or metabolic responses within cell 
culture to these stimuli. Nonetheless, it is valuable insight for future mechanistic 
studies.  
These results add to a growing collection of studies suggesting the importance of 
SCFAs for neuroprotection and behavior. In rodents, SCFA administration has 
shown to be neuroprotective against stroke (Sadler et al., 2020, Lee et al., 2020a), 
stress (van de Wouw et al., 2018), oligodendrocyte function (Chen et al., 2019b), and 
depressive-like behaviour (Yamawaki et al., 2018). SCFAs modulate blood-brain 
barrier permeability in vitro (Hoyles et al., 2018) and are shown to cross the blood-
brain barrier in rodent and primate studies (Dalile et al., 2019). Now, we present 
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Chapter 4: Discussion 
4.1 Overview of Findings in Chapter 2 
In Chapter 2, I reanalyzed 249 studies involving some measures of human brain 
health, psychiatric disorders, mood/behaviour and which sequenced the gut 
microbiome of participants. Where data was publicly accessible, studies were 
reanalyzing used a consistent pipeline which included assessing the abundance of 
neuroactive gut-brain modules. 
Very few datasets involving healthy humans had publicly accessible data. Across six 
studies of infant temperament and microbiome, (Carlson et al., 2018, Gao et al., 2019, 
Christian et al., 2015, Wang et al., 2020d, Aatsinki et al., 2019, Loughman et al., 2020), only 
two found the same genus-level association of Bifidoacterium with positive behaviors 
(Wang et al., 2020d, Aatsinki et al., 2019). Four studies looked to correlate the abundance of 
gut microbes with aspects of personality and emotion (Tillisch et al., 2017, Taylor et al., 
2019, Kim et al., 2018, Johnson, 2020). While each study found specific genus level 
associations with personality, emotion or anxiety, these were not consistent across studies. 
Next, the (Liu et al., 2019a) dataset was reanalysed finding that Alloprevotella abundance 
was significantly reduced in individuals with insomnia, compared to controls. However, 
there were no differences in gut-brain module abundance. Across four other studies that 
were not reanalyzed, two did not find any genera-level associations with sleep metrics (Liu 
et al., 2020c, Anderson et al., 2017). A 16S sequencing study associated sleep disturbance 
with the Prevotella enterotype (Ko et al., 2019). Another intriguing study found associations 
between multiple aspects of sleep quality with bacterial genera (Smith et al., 2019b). 
However, this study may be limited by its use of fecal swabs for sample collection. Five 
studies of healthy ageing and cognition all compared different subsets of unhealthy cognitive 
aging thus, no genus-level differences were found in common amongst them (Nagpal et al., 
2019, Kim et al., 2020, Bajaj et al., 2016, Saji et al., 2019). 
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Many studies assessed the microbiome composition of people with 
neurodevelopmental disorders. Several of these datasets were reanalyzed. In 
attention-deficit hyperactivity disorder (ADHD), one reanalyzed study did not find 
any differences in microbial composition or GBMs (Aarts et al., 2017). Wan et al. 
(2020) used a WGS approach, finding a reduction in dopaminergic pathways in the 
ADHD microbiome, as well as a reduction in Faecalibacterium. Jiang et al. (2018b) 
also observed this reduction, correlating it to scores assessing behavioural difficulties 
and hyperactivity. Five other studies did not report similar findings (Stevens et al., 
2019, Prehn-Kristensen et al., 2018, Szopinska-Tokov et al., 2020, Pärtty et al., 
2015, Wang et al., 2020b).  
Seven studies assessing the microbiome of children with autism spectrum disorders 
(Averina et al., 2020, Son et al., 2015, Pulikkan et al., 2018, Kang et al., 2019, Kong 
et al., 2019, Liu et al., 2019d, Strati et al., 2017). Only two studies showed 
significant differences in microbial abundance but none showed any changes in gut-
brain modules. Thirty other studies were summarized and compared (see Table 1), 
finding very few consistent microbiome changes across the studies. One of the four 
studies which used a WGS approach reported a reduction in glutamate/glutamine 
metabolism in ASD (Wang et al., 2019a). A study by (Liu et al., 2019d). reported 
increased valerate and decreased butyrate in ASD faecal samples. Berding and 
Donovan (2019) reported that fecal SCFAs correlated strongly with diet. These 
results suggest that dietary preferences play a strong role in shaping the ASD 
microbiome.   
Four studies assessing the schizophrenia microbiome were reanalyzed (Xu et al., 
2020, Shen et al., 2018, Flowers et al., 2019, Nguyen et al., 2019). Across two of 
these studies, the schizophrenia microbiome was enriched with the acetate-producing 
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Fusicatenibacter (Shen et al., 2018, Xu et al., 2020). When looking for gut-brain 
modules, one of the datasets also found an increased abundance of butyrate 
synthesis, kynurenine synthesis and inositol degradation in the schizophrenia 
microbiome (Xu et al., 2020). Additionally, this dataset showed a reduction in 
Lactobacillus (Xu et al., 2020).  However, across three WGS studies which were not 
reanalyzed (Zhu et al., 2020, Xu et al., 2020, Schwarz et al., 2018), the reported 
findings were not consistent.  
A few studies analysed the microbiome in other neurodevelopmental disorders but 
were too few in number to draw any conclusions or comparisons (Borghi and 
Vignoli, 2019, Strati et al., 2016, Quagliariello et al., 2018). 
One WGS epilepsy study was reanalyzed finding that the ketogenic diet increased 
the L-Tryptophan biosynthesis pathway in children with epilepsy (Lindefeldt et al., 
2019). Another reanalyzed study compared children with cerebral palsy co-morbid 
with epilepsy to controls, finding over 20 differentially abundant microbes but no 
changes in gut-brain module abundance (Huang et al., 2019a). There were four 16S 
studies that could not be reanalyzed, however they each used different subsets of 
patients for comparisons (Zhang et al., 2018b, Peng et al., 2018, Xie et al., 2017, 
Safak et al., 2020). 
Analyzing a dataset comparing Alzheimer’s disease, mild-cognitive impairment and 
controls, we found multiple changes across microbial composition and gut-brain 
modules (Li et al., 2019a). In individuals with Alzheimer’s disease, the microbiome showed 
a reduction in Ruminoclostridium-5 and an enrichment in gut-brain modules involved in 
isovaleric acid synthesis, butyrate synthesis and acetate synthesis. Intriguingly, more gut-
brain modules were found dysregulated when comparing the mild-cognitive impairment 
group to controls. This includes enrichment in isovaleric acid synthesis, butyrate synthesis, 
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acetate synthesis, tryptophan synthesis, quinolinic acid synthesis, quinolinic acid 
degradation. Three other studies (two 16S and one WGS) could not be reanalyzed; 
Bacteroides abundance was found increased in two of these studies (Haran et al., 2019, Vogt 
et al., 2017), but decreased in the third (Zhuang et al., 2018). Two of these studies also found 
Alistipes enrichment in individuals with AD (Haran et al., 2019, Vogt et al., 2017). 
However, none of these studies inferred the abundance of gut-brain modules nor did they 
measure fecal SCFAs. These findings provide moderate evidence for an increased SCFA 
production in Alzheimer’s disease and mild cognitive impairment. This warrants further 
studies with more extensive metadata collection to untangle these interactions. 
Three studies analysed the gut microbiome of individuals with Multiple Systems 
Atrophy, however the studies did not show consistent differences in the abundance 
of bacterial genera (Du et al., 2019, Engen et al., 2017, Tan et al., 2018). None of 
these studies were publicly accessible and thus were not reanalyzed. (Tan et al., 
2018) found reductions in fecal SCFAs, suggesting they may be dysregulated in this 
disorder.  
Three studies assessed the microbiome in Amyotrophic Lateral Sclerosis, however 
they all reported different results (Zhai et al., 2019a, Brenner et al., 2018, Mazzini et 
al., 2018). Using a WGS approach, (Blacher et al., 2019) found a reduction in 
tryptophan metabolism-related genes in ALS corresponding to alterations in serum 
tryptophan and nicotinamide metabolites.  
Although Parkinson’s Disease is among the most studied disorders in the context of 
the microbiota-gut-brain axis, our reanalysis did not find many differences in 
publicly accessible datasets (Bedarf et al., 2017, Heintz-Buschart et al., 2018, Aho et al., 
2019, Pietrucci et al., 2019, Qian et al., 2018, Weis et al., 2019). However, after stratifying 
individuals by L-DOPA dose, we found one differentially abundant ASV of Lactobacillus 
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which was reduced compared to controls (Weis et al., 2019). Across ten studies that could 
not be reanalyzed, all of them found significant microbial community changes in 
Parkinson’s disease even after accounting for covariates (Petrov et al., 2017, Barichella et 
al., 2019, Cirstea et al., 2020, Hill-Burns et al., 2017) (Keshavarzian et al., 2015, Vidal-
Martinez et al., 2020, Li et al., 2019b, Unger et al., 2016, Ren et al., 2020, Lin et al., 2019). 
Perhaps information about pharmacological treatments, diet and lifestyle are required to 
uncover more consistent microbiome differences. 
Two studies involving alcohol were reanalyzed (Stadlbauer et al., 2019, Bjorkhaug et 
al., 2019). In one study, the alcohol dependent cohort had an increased abundance of 
Ruminococcus 2 and a reduction in Ruminoclostridium 9, as well as reduction in the 
tryptophan degradation gut-brain module (Bjorkhaug et al., 2019). Other studies that could 
not be reanalyzed all used different sequencing methods, cohorts and comparisons making it 
difficult to assess similarities across these studies (Dubinkina et al., 2017, Seo et al., 2020, 
Tsuruya et al., 2016). 
One study involving smokers found that tobacco but not electronic cigarette users 
had a reduction in tryptophan degradation and propionate synthesis (Stewart et al., 
2018). No other smoking studies which used next-generations sequencing were 
found. One datasets of recreational drug-use was reanalysed but no differentially 
abundant microbes or gut-brain modules were found (Barengolts et al., 2018). An 
additional three studies could not be reanalyzed. Among them, Fulcher et al. (2018) 
reported specific changes in microbial abundance associated with recreational drugs. 
(Xu et al., 2017) controlled for age and sex, finding no microbial changes associated 
with drug use. Finally, (Panee et al., 2018) reported a positive association between 
Prevotella abundance in recreational marijuana users and cognition.  
Across two multiple sclerosis datasets, we did not find any differences in gut-brain 
modules or microbial abundance (Miyake et al., 2015, Jangi et al., 2016).. However, 
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when reanalyzing a dataset comparing individuals with neuromyelitis optica spectrum 
disorder to controls, we found reductions in Streptococcus in the disease group (Gong et al., 
2019). The researchers also reported an overall reduction in fecal SCFAs also associating 
acetate and butyrate with disease severity (Gong et al., 2019). Across four studies that could 
not be reanalyzed, no differences were consistently reported (Ventura et al., 2019, Berer et 
al., 2017, Reynders et al., 2020, Zeng et al., 2019). (Zeng et al., 2019) reported reductions in 
fecal SCFAs when comparing either the multiple sclerosis or the neuromyelitis optic 
spectrum disorder to controls. The involvement of SCFAs in multiple sclerosis warrants 
further investigation.  
While few studies looked specifically at the associations between pain-related 
disorders, the brain and the microbiome, there is nonetheless some evidence that 
warrants further investigations. There is some evidence from a WGS study that the 
gut microbiome influences fibromyalgia and serum SCFAs (Minerbi et al., 2019). 
Meanwhile, across several different irritable-bowel syndrome studies different 
microbes are associated with pain (Peter et al., 2018b, Peter et al., 2018a, Labus et 
al., 2019, Jeffery et al., 2012). These studies provide some evidence that the 
microbiome may be involved with the psychological aspects of irritable bowel 
syndrome. Meanwhile, a recent study found enrichment of the kynurening synthesis 
and quinolinic acid degradation gut-brain modules in elderly women with migraines 
(Chen et al., 2019). 
Two anorexia nervosa datasets were reanalyzed (Borgo et al., 2017, Mack et al., 
2016). We found significant differences only in the latter dataset which had a larger 
sample size. We saw enrichment in isovaleric acid synthesis, quinolinic acid 
synthesis, quinolinic acid degradation pathways in patients with anorexia (Mack et 
al., 2016). Notably, the alpha-melanocortinin stimulating hormone mimetic, known 
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to reduce appetite in mice (Tennoune et al., 2014) is restored to control level after 
weight gain and renourishment (Mack et al., 2016). While these changes were not 
reported in four other studies (Morkl et al., 2017, Morita et al., 2015, Kleiman et al., 
2015, Armougom et al., 2009), authors did not measure the abundance of gut-brain modules. 
Future studies focusing on SCFAs and ClpB in anorexia nervosa are needed to better 
understand its role in satiety signalling. 
While butyrate has been characterized as a neuroprotective agent for ischemia in 
preclinical studies (Akhoundzadeh et al., 2018, Lee et al., 2020a, Sadler et al., 2020, Singh 
et al., 2018, Sun et al., 2016a), few human studies have been conducted. None of these 
datasets were publicly accessible. (Wang et al., 2018b) did not find any changes in the gut 
microbiota after a cerebral infarction. In contrast, another study found that bacteria involved 
in butyrate and tryptophan metabolism (Bacteroides, Parabacteroides, Akkermansia, 
Prevotella and Faecalibacterium) were reduced following the cerebral infarction (Ji et al., 
2017). When stratifying patients by type of stroke and severity, other researchers uncovered 
more microbial perturbations. For example, Liu et al. (2020a) found many genera associated 
with individuals showing post-stroke cognitive impairment. Two other studies reported 
conflicting differences in the abundance of Akkermansia in patients with ischemic stroke, 
with one study reporting an increased abundance while another reporting a reduction (Ji et 
al., 2017, Li et al., 2019c). (Polster et al., 2020) found robust differences and correlations 
within a large sample (N = 122) of cavernous angioma using 16S and WGS techniques.  The 
abundance of several species was enriched in the cavernous angioma group including 
Bacteroides thetaomicron and Odoribacter sphlancus while the abundance of other species 
was reduced Bifidobacterium adolescentis and Faecalibacterium prausnitzii (Polster et al., 
2020). They even reported differentially abundant species by cavernous angioma subtype 
and severity (Polster et al., 2020). However, they did not assess differentially abundant gut-
brain modules. Nonetheless, similar large scale studies are crucial for understanding whether 
a certain microbiome composition is protective against stroke or neurovascular disease. 
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None of the studies involving stress or psychiatric disorders had publicly accessible 
datasets. Thus, none of this data could be reanalyzed. Across three studies of 
different types of stressors, the microbiome appears to play a role. One study found 
that adverse childhood events increased the abundance of Prevotella during 
pregnancy  (Hantsoo et al., 2019). Other studies found that maternal stress influenced infant 
microbial composition (Hu et al., 2019a, Naude et al., 2020, Carson et al., 2018). These 
results suggest that stress should be closely monitored during pregnancy and that early-life 
insults may influence the microbiome composition in later life.  
Two further studies analysed the impact of post-traumatic stress disorder on the gut 
microbial composition (Hemmings et al., 2017, Bajaj et al., 2019). While (Bajaj et al., 
2019) reported many differences in microbial abundance in veterans suffering from this 
disorder, more studies are needed to confirm these findings in a broader population. Across 
ten studies of bipolar disorder, no consistent microbial changes were reported across studies 
(Rong et al., 2019, Vinberg et al., 2019, Schwarz et al., 2018, Painold et al., 2019, McIntyre 
et al., 2019, Evans et al., 2017, Coello et al., 2019, Hu et al., 2019b, Zheng et al., 2020b). 
A total of 18 studies of depression and anxiety were reanalyzed and summarized. 
Across multiple studies of depression, Faecalibacterium shows a positive impact on 
quality of life/anxiety/depression (Jiang et al., 2015, Jiang et al., 2018a, Stevens et 
al., 2018, Valles-Colomer et al., 2019). Similarly, Dialister is depleted in depression 
across several other studies (Jiang et al., 2015, Jiang et al., 2020, Valles-Colomer et 
al., 2019). Indeed, other studies also found negative correlations between 
Faecalibacterium and anxiety or depression (Jiang et al., 2015, Jiang et al., 2018a, 
Stevens et al., 2018). These findings are especially interesting since they replicated 
in non-compositionally analysed data sets. 
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Together this data provides strong evidence that SCFA and tryptophan metabolism may be 
altered in Alzheimer’s disease, depression, anxiety and schizophrenia.  
4.2 Overview of Findings in Chapter 3 
In Chapter 2, SCFAs were identified as important neuroactive metabolites. Despite 
these findings, the mechanisms behind these effects are unclear. Human studies 
suggested that SCFAs reach the brain and impact glutamate metabolism, stress, and 
satiety (Frost et al., 2014, Dalile et al., 2020). Preclinical and in vitro studies 
identified several potential pathways by which they impact neuroimmune cells: 
histone-deacetylase inhibition, glutamate-glutamine metabolism and aryl-
hydrocarbon receptor/immune pathways (Erny et al., 2015, Yang et al., 2019, 
Yamawaki et al., 2018, Wang et al., 2018a, Singh et al., 2014, Chen et al., 2019b, 
Marinelli et al., 2019, Jin et al., 2017). These experiments often pre-treated cells to 
induce inflammation. Then supraphysiological levels of SCFAs, mainly butyrate, to 
observe any of its effects.  
Recent investigations identified the important roles of astrocytes in brain and 
behavior, as well as in mediating the impact of microbial metabolites (Rothhammer 
et al., 2016, De Luca et al., 2020, Tomova et al., 2019, Khakh and Deneen, 2019, 
Alberini et al., 2018, Jensen et al., 2013, Cao et al., 2013). To address the potential 
role of SCFAs on naïve astrocytes, we generated enriched primary cultures and 
treated the cells with low, physiological doses of SCFAs. Addressing sex-differences 
across brain disorders and the microbiota-gut brain axis (Jaggar et al., 2020), we 
tested three different concentrations of butyrate, acetate and propionate on male and 
female murine cortical astrocytes separately. Using qPCR, the expression of a panel 
of genes was assessed after treatment. 
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When treated with butyrate, genes implicated in neuroimmune and glutamate 
metabolic pathways were not affected in males or females. However, in females but 
not in males, two genes (Bdnf and Pgc1- involved in the histone deacetylase 
inhibition pathway increased in a dose-dependent manner in response to butyrate. 
Meanwhile, only the neuroimmune pathway was altered by acetate treatment. We 
noticed a dose-dependent increase of Ahr and Gfap expression only in males in 
response to acetate. Finally, we did not find any dose-dependent or sex-specific 
effects of propionate on astrocyte gene expression. 
4.3 Limitations of Human Data 
Despite advances in sequencing and bioinformatics, it is still difficult to replicate 
findings across multiple studies. This is in part due to confounders emerging from 
the collection of metadata (medications, food-frequency questionnaires, 
symptoms/pathology), sequencing methods and the nature of the microbiome itself. 
When attempting to reanalyse studies with an up-to date bioinformatic pipeline, we 
demonstrated the wide confidence intervals of many differentially expressed 
microbes. Further, we found similar statistical uncertainties when inferring 
metabolites with neuroactive potential.  
However, it remains clear even with these limitations that there are striking 
similarities across many microbiome cohorts involving schizophrenia, anxiety, 
depression and Alzheimer’s disease. While we can infer metabolism from 16S or 
WGS sequencing, it does not provide more exact information about the metabolites, 
proteins, lipids and signals produced by gut microbes. While we used inferred 
neuroactive gut-brain modules, this database will likely be expanded in future studies 
as some neuroactive pathways, like bile metabolism, remain unannotated (Valles-
Colomer et al., 2019).  It will be important  to further identify the metabolites 
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involved in these altered pathways to confirm these findings. Perhaps it might help 
us better understand the pathophysiology of these diseases or their symptoms. 
4.4 Glia and the Microbiome: Where to Next? 
As more researchers focus in on the gut microbiome, the glial cells of the brain have 
become an intriguing target. In the last decade, the importance of astrocytes and 
microglia in synaptic pruning and neurodevelopment has started to become 
unravelled (Paolicelli et al., 2011, Bilimoria and Stevens, 2015, Tremblay et al., 
2011, Stephan et al., 2012, Sheridan and Murphy, 2013). Recent research looks to 
expand the role of microglia, oligodendrocytes and astrocytes beyond 
neurodevelopment and neuroinflammation including neuronal activity through 
negative feedback (Badimon et al., 2020), motor function and social interaction 
(Kana et al., 2019) and memory (De Luca et al., 2020, Drulis-Fajdasz et al., 2018, 
Alberini et al., 2018) amongst other functions. More microbiome studies are 
beginning to recognize the importance of glia within the brain (van der Lugt et al., 
2018, Tse, 2017, Thion et al., 2018, Singh et al., 2018, Schmidtner et al., 2019, 
Sampson et al., 2016, Sadler et al., 2020, Rothhammer et al., 2016, Radulescu et al., 
2019, Minter et al., 2016, McMurran et al., 2019, Matt et al., 2018, Leyrolle et al., 
2019). Combined with new insights from single-cell RNA-sequencing technology 
(Zeisel et al., 2018, Van Hove et al., 2019, Sankowski et al., 2019, Prinz et al., 2019, 
Masuda et al., 2019), we may soon discover how specific microbial metabolites 
influence the brain, behavior and development. 
4.5 SCFAs and the Microbiome: A Therapeutic Target Emerges 
Several studies are already beginning to unravel the impacts of SCFAs on the brain 
and behaviour. SCFA supplementation attenuates the cortisol response in adult men 
after an acute psychosocial stressor in a dose-dependent manner (Dalile et al., 2020). 
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Another human study finds that acetate is able to reach the brain to influence satiety 
and glutamate/glutamine cycling in the hypothalamus (Frost et al., 2014). Recent 
advances in our understanding of prebiotic fibres pave the way for new personalized 
interventions to boost the levels of circulating SCFAs as an adjuvant for stress and 
eating disorders (Gill et al., 2020, Dalile et al., 2019, Fatahi et al., 2020, Deehan et 
al., 2020, Berding and Donovan, 2018). While one systematic review did not find 
that prebiotic intake impacted anxiety or depression measures (Liu et al., 2019c) 
while another found it associated with a lower odds-ratio for depression (Fatahi et 
al., 2020).  Future studies are poised to identify specific effects of SCFAs on our 
cortisol response as well as determine whether they alleviate anxiety or depression. 
Since different fibres impact the microbiome in different ways (Gill et al., 2020, 
Deehan et al., 2020),  this must be considered when suggesting appropriate prebiotic 
interventions. 
4.6 Tryptophan Metabolism and Microbiota: Diet to 
Neuroimmunity 
Tryptophan and indole metabolites are a source of intrigue, as more and more 
research focused on neuroinflammation and psychiatry suggest they play key roles. 
Dietary tryptophan metabolites were found to active the astrocyte aryl-hydrocarbon 
receptor (Rothhammer et al., 2018, Rothhammer et al., 2016). A systematic review 
of tryptophan/kynurenine metabolites suggests that perturbation of this delicate 
balance may contribute to schizophrenia, however more large-scale studies are 
needed (Pedraz-Petrozzi et al., 2020). Another meta-analysis finds that metabolism 
shifts towards the kynurenine pathway, away from serotonin production across many 
psychiatric disorders (Marx et al., 2020a).  In schizophrenia, kynurenine metabolism 
then shifts towards the production of kynurenic acid while in mood disorders it shifts 
towards the production of excitotoxic quinolinic acid (Marx et al., 2020a). Future 
216 
 
studies may look to use diet as a means of influencing tryptophan or indole 
metabolism.  
4.7 Bile Acids and the Brain: More than a Gut Feeling? 
Several studies suggest that bile acids play intriguing roles beyond digestion, 
signalling through the microbiota-gut-brain axis. Several studies of neuronal and 
glial cells have identified the presence of bile acid receptors (Cani et al., 2013, 
Dempsey et al., 2018, Keitel et al., 2010, Mertens et al., 2017, Poole et al., 2010, 
Silva et al., 2012, Yanguas-Casás et al., 2017). Bile acid metabolism by the 
microbiota is implicated in social behaviour, gastrointestinal distress, 
neuroinflammation, depressive-like behaviors and the HPA axis across preclinical 
and in vitro models (Choudhuri et al., 2003, Golubeva et al., 2017, Hoffman et al., 
2019, Jena et al., 2018, Klaassen and Aleksunes, 2010, McMillin et al., 2015, 
Mertens et al., 2017, Nizamutdinov et al., 2017, Yanguas-Casás et al., 2017, 
Yanguas-Casas et al., 2017, Wang et al., 2020a). A recent study found alterations in 
bile acid profiles in individuals with Alzheimer’s and mild-cognitive impairments 
(MahmoudianDehkordi et al., 2019). A double-blind randomized clinical trial found 
that supplementation with the bile acid taurursodiol combined with sodium 
phenylbutyrate slowed motor decline in individuals with amyotrophic lateral 
sclerosis while another study found it increased survival (Paganoni et al., 2020a, 
Paganoni et al., 2020b). It is clear that bile acids may play important neuroprotective 
and anti-inflammatory roles in brain health, however more studies are needed to 
assess their effects across different brain disorders. 
4.8 Future Directions 
Many current human microbiome studies now focus on identifying gut-microbial 
metabolites derived from aromatic amino acids in the faeces and serum, to 
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understand their role in brain health (Arnoriaga-Rodríguez et al., 2020, Molinaro et 
al., 2020, Bar et al., 2020). There remain a multitude of unidentified microbial by-
products that subtly impact our metabolism, serum metabolites and brain-signalling. 
Future bioinformatics studies will focus on identifying the range of metabolites and 
functional molecules produced by different genera or species of bacteria. In addition, 
different bacterial proteins might also contribute to cross-kingdom signalling. No 
example is as striking as ClpB, a bacterial protein was a mimetic of alpha-
Melanacortonin Stimulating Hormone (Breton et al., 2016, Dominique et al., 2019, 
Tennoune et al., 2014). Moreover, quorum signalling molecules released by 
Staphylococcus aureus act as excitatory or inhibitory modulators of enteric nerves 
(Uhlig et al., 2020). Screening the supernatant proteins and secreted metabolites 
from a host of potential gut-bacteria could help identify new neuroactive molecules. 
Additionally, open metabolomic, proteomic and lipidomic datasets could also be 
reanalysed. This could potentially identify new candidate signalling molecules 
altered due to gut microbiome disruptions. 
However, we still don’t know which metabolites may cross the blood-brain barrier 
and in what amount. Additionally, we do not understand the flux of these metabolites 
over the course of the day. Studies are only able to provide a snapshot of one 
moment in time. Studying the levels of these metabolites in the faeces and serum in 
conjunction with functional brain-imaging is the next step in understanding the 
impact of microbial metabolism on the brain. These studies would lead into the 
development of postbiotics or biologics mimicking beneficial microbial signals. 
Candidates could then be tested in preclinical disease models and later translated into 
humans. Microbial-derived metabolites will be key for understanding the 
mechanisms underlying the microbiota-gut-brain axis. 
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The next step would involve determining their potential mechanism of action. In  
vitro high-throughput studies could identify potentially neuroactive metabolites in 
Caenorhabditis elegans or Danio rerio. Alternatively, primary cultures or co-
cultures of neurons and glia may be used to identify which cell types can respond to 
these metabolites. Metabolites with potential impacts on early neurodevelopment or 
neurobehavioral pathways would continue into in vivo rodent studies. Different 
doses are assessed on their microbiome modulatory properties as well as their impact 
on the brain. Once validated within a rodent model, these metabolites may be 
regulated either through dietary interventions or through oral supplementation. 
Potentially, some of these metabolites could even be delivered at supraphysiological 
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